








Ras	 proteins	 are	 GTPases	 that	 are	molecular	 central	 hubs	 for	 propagation	 of	intracellular	 signals	 that	 are	 involved	 in	 diverse	 processes,	 including	 cell	differentiation	and	proliferation.	The	 four	main	Ras	 isoforms,	HRas,	NRas	and	the	 two	 KRas	 splice	 variants,	 KRasA	 and	 KRasB,	 are	 highly	 homologous		and	 conserved	 proto-oncogenes	 that	 constitute	 a	 paradigm	 of	 cellular	transformation.	While	all	RAS	genes	are	commonly	mutated	in	human	cancers,	different	 isoforms	 couple	 to	 distinct	 tumours	 and	 the	 mutations	 in	 KRAS	constitute	the	majority	(~86%)	of	all	RAS	mutations.	Intriguingly,	KRasB	is	the	only	Ras	isoform	essential	for	normal	embryonic	growth	in	the	mouse.		
Such	 discrepancy	 of	 Ras	 isoform	 contribution	 to	 different	 cancers	 and	 the	uniquely	 essential	 role	 of	 KRasB	 in	 normal	 development	 may	 stem	 from	 the	distinct	 spatiotemporal	 expression	 of	 Ras	 isoforms	 and	 their	 differential	coupling	 to	 downstream	 effectors.	 However,	 to	 date	 there	 has	 been	 no	comprehensive	 quantitative	 comparison	 of	 Ras	 isoform	 expression	 across	various	 tissues	 throughout	 development.	 Moreover,	 there	 are	 no	 studies	 that	compared	Ras	isoform-specific	signalling	in	an	endogenous	context.	Therefore,	this	 thesis	 aims	 to	 provide	 the	 first	 complete	map	 of	 Ras	 isoform	 expression	during	 development	 and	 the	 first	 comparison	 of	 endogenous	 Ras	 isoform-specific	signalling.	
In	 the	 first	 part	 of	 this	 work,	 quantitative	 real-time	 RT-PCR	 was	 used	 to	measure	 Ras	 isoform	 transcript	 levels	 in	mouse	 embryonic	 stem	 cells	 (ESCs)	and	 in	 a	 panel	 of	 embryonic,	 postnatal	 and	 adult	 mouse	 tissues.	 KRasB	 was	found	to	be	the	most	highly	expressed	isoform,	whereas	KRasA	was	shown	to	be	the	most	dynamically	 regulated.	Transcript	 copy	number	does	not	necessarily	
	 III	
correlate	 with	 protein	 copy	 number;	 therefore,	 protein	 standard	 absolute	quantitation	 mass	 spectrometry	 was	 used	 to	 accurately	 measure	 tissue	 Ras	protein	 levels.	 In	 contrast	 to	 the	 qRT-PCR	 data	 where	 KRasB	 was	 5-10-fold	higher	expressed	than	any	of	the	other	isoforms,	protein	abundance	levels	were	found	to	be	similar	for	the	Ras	isoforms.	The	mechanistic	basis	for	this	and	the	implications	for	models	of	isoform-specific	Ras	association	with	specific	cancers	are	discussed.	
In	 the	 second	 part	 of	 this	 thesis,	 isogenic	 SW48	 human	 colorectal	 cancer	 cell	lines	identical	except	for	the	presence	of	an	activating	G12V	mutation	in	each	of	the	 three	RAS	 gene	 loci	were	utilised	 to	 study	endogenous	Ras	 signalling.	The	results	 revealed	 isoform-specific	 coupling	 to	 canonical	 Ras	 effector	 pathways	for	 example,	 HRas	 was	 the	 most	 potent	 activator	 of	 downstream	 MAPK	 and	PI3K	 pathways.	 These	 data	 represent	 the	 basis	 for	 planned	 network	 biology	studies	to	model	Ras	isoform-specific	signalling.	
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1.1.1		 	 	 Ras	superfamily	of	GTPases		Ras	proteins	are	part	of	a	 superfamily	of	 small	GTPases,	which	comprise	over	100	 molecules,	 sized	 20	 to	 25	 kDa	 (Colicelli,	 2004,	 Karnoub	 and	 Weinberg,	2008,	Rojas	et	al.,	2012).	The	superfamily	is	divided,	among	the	others,	into	Ras,	Rab,	Ran,	Rho	and	Arf	 families,	which	all	 share	a	 common	 intrinsic	 guanosine	triphosphate	 (GTP)	 hydrolysis	mechanism	 (Fig	 1.1)	 and	 are	 highly	 conserved	across	different	species.				
	
	














Fig.	 1.2	 Phylogenetic	 tree	 of	 the	 extended	 Ras	 family	 members	 in	Mus	









































Activated	Ras	oncogenes	have	since	been	found	in	numerous	human	cancer	cell	lines	 and	 human	 tumours	 (Der	 et	 al.,	 1982,	 Parada	 et	 al.,	 1982,	 Santos	 et	 al.,	1984,	Santos	et	al.,	1982,	Cox	et	al.,	2014,	Feig	et	al.,	1984,	Prior	et	al.,	2012).	The	 genes	 were	 labelled	 HRAS	 and	 KRAS,	 and	 the	 corresponding	 protein	products	 HRas	 and	 KRas.	 The	 third	 ras	 gene	 was	 discovered	 in	 human	neuroblastoma	 and	 leukaemia	 cell	 lines	 and	 was	 termed	 NRAS,	 for	





conserved	aspartate	 residue	 situated	 in	 the	DxxG	motif	 and	 the	main	 chain	of	the	alanine	(Ala146)	residue	from	the	SAK	motif.		The	 G	 domain	 also	 contains	 two	 so-called	 “switch	 regions”	 that	 change	conformation	 upon	 GTP	 binding	 and	 take	 part	 in	 interactions	 of	 Ras	with	 its	upstream	regulators,	such	as	GAPs	and	GEFs,	as	well	as	downstream	targets	by	exposing	effector	binding	domain	(Milburn	et	al.,	1990,	Schlichting	et	al.,	1990,	Vetter	and	Wittinghofer,	2001).	In	the	GTP-bound	state,	the	γ-phosphate	forms	two	hydrogen	bonds	with	the	threonine	(Thr35,	which	also	binds	Mg2+)	residue	in	 switch	 I	 (amino	 acids	 30-38)	 and	with	 glycine	 (Gly60)	 residue	 in	 switch	 II	region	(amino	acids	60-76)	(Cox	and	Der,	2010).	Following	GTP	hydrolysis,	the	two	switch	regions	go	back	to	the	relaxed	GDP-bound	conformation.		Ras	 proteins	 are	 highly	 conserved	 across	 different	 species,	 as	 depicted	 in	 Fig.	1.5,	which	 compares	 all	 three	main	Ras	 protein	 sequences	 and	 their	 isoforms	based	 on	 protein	 sequences	 from	 model	 organisms	 representing	 major	eukaryotic	kingdoms	and	phyla.	Although	there	are	no	direct	homologs	of	Ras	in	plant	genomes,	the	flowering	plant	Arabidopsis	thaliana,	as	shown	in	the	figure,	expresses	a	Ras-related	RABD2A	protein,	which	 is	related	more	to	RAB	family	member	RAB1A	(part	of	Ras	superfamily).	However,	homologous	Ras	proteins	have	 been	 studied	 in	 species	 such	 as	 amoeba	 Dictyostelium	 discoideum	(Reymond	 et	 al.,	 1984),	 yeast	 Saccharomyces	 cerevisiae	 (Dhar	 et	 al.,	 1984,	Powers	et	al.,	1984),	nematode	Caenorhabditis	elegans	 (Beitel	et	al.,	1990,	Han	and	 Sternberg,	 1990),	 arthropods,	 such	 as	 common	 fruit	 fly	 Drosophila	





Fig.	1.5	Ras	 isoform	conservation	across	species.	Phylogenetic	tree	of	main	Ras	 subfamily	 members	 and	 their	 isoforms	 in	 model	 organisms	 and	 human	(Saccharomyces	 cerevisiae,	 Dictyostelium	 discoideum,	 Caenorhabditis	 elegans,	
Drosophila	melanogaster,	 Xenopus	 laevis,	 Danio	 rerio,	Mus	musculus	 and	Homo	
































Ras	isoforms	Although	 highly	 conserved	 in	 mRNA	 and	 protein	 sequence,	 Ras	 isoforms	 are	non-redundant	 in	 their	 cellular	 functions.	 Table	 1.1	 summarises	 the	 main	functional	differences	between	the	four	main	Ras	isoforms	that	are	discussed	in	the	next	sections.		
	
1.1.3.1		 	 	 Ras	signalling	pathways	
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(EGFR)	 was	 the	 first	 receptor	 discovered	 responsible	 for	 conveying	 signals	upstream	of	Ras	(Kamata	and	Feramisco,	1984).	Stimulation	of	EGFR,	as	well	as	another	 receptor	 tyrosine	kinase	 (RTK)	platelet-derived	growth	 factor	 (PDGF)	receptor	(PDGFR)	by	receptor-specific	ligands	was	shown	to	augment	activated	Ras	 (GTP-bound)	 (Gibbs	 et	 al.,	 1990,	 Satoh	 et	 al.,	 1990a,	 Satoh	 et	 al.,	 1990b).	Further	work	determined	 that	Grb2	 is	an	adaptor	protein	 that	 links	upstream	RTKs	with	Ras	(Lowenstein	et	al.,	1992)	through	its	association	with	GEF	Sos1	(Buday	and	Downward,	1993,	Chardin	et	al.,	1993,	Egan	et	al.,	1993,	Gale	et	al.,	1993,	Li	et	al.,	1993,	Olivier	et	al.,	1993,	Quilliam	et	al.,	1994,	Rozakis-Adcock	et	al.,	 1993,	 Simon	 et	 al.,	 1993).	 Further	 research	 demonstrated	 that	Grb2	 could	connect	Ras	with	other	adaptors,	such	as	Shc,	leading	to	association	of	Ras	with	many	 different	 RTKs	 (Giubellino	 et	 al.,	 2008,	 Margolis	 and	 Skolnik,	 1994,	Yonezawa	et	al.,	1994).		Subsequent	work	 showed	 that	 Ras	 proteins	 can	 be	 stimulated	 by	 a	 variety	 of	upstream	 receptors,	 including	 G	 protein-coupled	 receptors	 (GPCR),	 such	 as	bradykinin	 B2	 or	 adrenergic	 receptors	 via	 activation	 of	 phospholipase	 C	 β	(PLCβ)	(Blaukat	et	al.,	2000,	Della	Rocca	et	al.,	1997,	Dikic	et	al.,	1996,	Dorsam	and	Gutkind,	2007),	and	integrin	receptors	(Schlaepfer	et	al.,	1994,	Yoon	et	al.,	2006).	Nonetheless,	the	level	of	activation	by	upstream	signalling	is	not	uniform	among	Ras	 isoforms.	Ras-GRF1,	a	GEF,	activates	 in	vivo	HRas,	but	not	KRas	or	NRas	(Jones	and	Jackson,	1998,	Matallanas	et	al.,	2003).	In	contrast,	RasGRP2,	a	GEF	that	is	stimulated	by	calcium	and	diacylgrycerol	(DAG),	activates	only	NRas	and	KRas	(Clyde-Smith	et	al.,	2000).	Sos1,	 in	 turn,	activates	Ras	 isoforms	with	the	 following	 efficiency:	 HRas	 >	 NRas	 >	 KRas	 (Jaumot	 et	 al.,	 2002).	 Further	differences	 between	 Ras	 isoform	 coupling	 and	 activation	 include	 preferential	binding	of	calmodulin	to	KRas,	which	inhibits	downstream	ERK1/2	(Villalonga	et	 al.,	 2001),	 covalent	 binding	 of	 the	 cyclopentenone	 15-deoxy-delta	 12,14-prostaglandin	 J2	 to	HRas,	which	 leads	 to	 cell	 proliferation	 (Oliva	 et	 al.,	 2003)	and	 preferential	 activation	 of	 KRasB	 by	 the	 growth	 factors	 interleukin-3,	colony-stimulating	factor	1	and	epidermal	growth	factor	(EGF)	(Ehrhardt	et	al.,	2004).		
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1.1.3.1.2	 	 Downstream	Ras	effectors		The	canonical	signalling	pathways	that	diverge	from	activated	Ras	are	mitogen-activated	 protein	 kinase	 (MAPK)	 and	 phosphoinositide	 3-kinase	 (PI3K)	pathways	 (Fig.	 1.7).	 The	 first	 identified	 mammalian	 Ras	 effector	 was	 the	serine/threonine	protein	kinase	Raf	(Van	Aelst	et	al.,	1993,	Warne	et	al.,	1993,	Zhang	et	al.,	1993),	which	was	known	to	activate	downstream	MAPK	kinase	1	and	2	(MEK1	and	MEK2),	as	well	as	MAPK,	also	known	as	extracellular	signal-regulated	kinase	1	and	2	(ERK1	and	ERK2)	(Dent	et	al.,	1992,	Howe	et	al.,	1992,	Kyriakis	et	al.,	1992,	Moodie	et	al.,	1993).	In	this	way,	the	prototypical	Ras-Raf-MEK-ERK	pathway	(MAPK	cascade)	was	delineated	and	it	was	ascertained	that	homologous	pathways	 are	 present	 in	 a	 range	 of	 species	 (Dickson	 et	 al.,	 1992,	Masuda	et	al.,	1995,	Han	et	al.,	1993).	To	propagate	signals	down	the	pathway,	the	 effectors	 utilise	 activating	 phosphorylation	 events	 on	 their	 downstream	targets.	In	mammals,	the	pathway	is	essential	for	a	myriad	of	cellular	functions,	including	 proliferation,	 differentiation	 and	 gene	 expression	 (Chang	 and	Karin,	2001,	Imajo	et	al.,	2006,	Nishida	and	Gotoh,	1993,	Pearson	et	al.,	2001).			The	second	Ras	effector	to	be	discovered	was	PI3K,	a	lipid	kinase	that	consists	of	 the	 p110	 catalytic	 and	 p85	 regulatory	 subunits	 (Rodriguez-Viciana	 et	 al.,	1994,	 Rodriguez-Viciana	 et	 al.,	 1996,	 Sjolander	 et	 al.,	 1991).	 Activated	 PI3K	generates	 phosphatidylinositol-3,4,5-triphosphate	 (PIP3),	 which	 acts	 as	 a	second	messenger	 and	 translocates	protein	 kinase	B	 (PKB,	 also	 called	Akt)	 to	the	 PM	 (Scheid	 and	 Woodgett,	 2001).	 Akt,	 in	 turn,	 is	 phosphorylated	 and	activated	 by	 phosphoinositide	 dependent	 kinase	 1	 (PDK1).	 Akt	 regulates	 a	range	of	downstream	effectors,	such	as	mammalian	target	of	rapamycin	(mTOR)	and	glycogen	synthase	kinase-3	(GSK-3),	which	are	key	for	regulating	cell	cycle,	cell	proliferation	and	survival	(Cross	et	al.,	1995,	Nave	et	al.,	1999,	Osaki	et	al.,	2004,	Sekulic	et	al.,	2000).		Importantly,	 each	 Ras	 effector	 possesses	 a	 Ras	 binding	 domain	 (RBD),	 which	allows	them	to	specifically	associate	with	activated	GTP-bound	Ras	through	its	effector	domain	(Spaargaren	and	Bischoff,	1994,	Vojtek	et	al.,	1993).	Apart	from	
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Raf	 and	 PI3K,	 Ras	 propagates	 signals	 to	 a	 plethora	 of	 other	 downstream	effectors.	 RalGDS	 (ral	 GDP	 dissociation	 stimulator),	 a	 GEF	 for	 Ras-related	proteins	(RalA	and	RalB),	is	the	third	main	downstream	target	of	Ras	(Hinoi	et	al.,	1996,	Kikuchi	and	Williams,	1996,	Urano	et	al.,	1996).	 It	 interacts	with	Ras	via	 its	 Ras	 association	 (RA)	 domain	 (Hofer	 et	 al.,	 1994,	 Kikuchi	 et	 al.,	 1994,	Spaargaren	 and	 Bischoff,	 1994)	 and	 transmits	 signals	 to	 downstream	phospholipase	D	(PLD)	and	Ral-interacting	protein	1(RIP1),	to	name	a	few,	that	are	 responsible	 for	 cell	migration,	 actin	 organisation,	 as	well	 as	 regulation	 of	endocytosis	and	exocytosis	(Cantor	et	al.,	1995,	Feig,	2003,	Jullien-Flores	et	al.,	1995,	Luo	et	al.,	1998,	Rosse	et	al.,	2006).		The	 remaining	 Ras	 effectors	 include	 Rac-specific	 GEF	 –	 T	 lymphoma	 invasion	and	metastasis	protein	1	(Tiam1)	(Lambert	et	al.,	2002),	which	takes	part	in	cell	migration	(Yamauchi	et	al.,	2005a,	Yamauchi	et	al.,	2005b),	PLCε	(Kelley	et	al.,	2001,	Lopez	et	al.,	2001,	Song	et	al.,	2002),	which	is	involved	in	cell	growth	and	differentiation	 (Wu	et	 al.,	 2003,	Yun	et	 al.,	 2008)	and	RAS	association	domain	family	 proteins	 (e.g.	 Rassf1)	 (Tommasi	 et	 al.,	 2002,	 Vos	 et	 al.,	 2003b)	 that	control	 apoptosis	 (Allen	 et	 al.,	 2007,	 Eckfeld	 et	 al.,	 2004,	 Khokhlatchev	 et	 al.,	2002,	Vos	et	al.,	2000,	Vos	et	al.,	2003a).	Nonetheless,	different	Ras	isoforms	differ	in	their	quantitative	ability	to	activate	downstream	 effectors.	 KRas	 recruits	 Raf-1	 more	 efficiently	 to	 the	 plasma	membrane	and	is	its	more	potent	activator	than	HRas,	which,	in	turn,	is	a	better	activator	of	PI3K	(Yan	et	al.,	1998).	Yet,	recent	work	has	shown	that	Ras	alone	cannot	activate	PI3K,	but	for	this	it	requires	stimulation	by	GFs	(Mendoza	et	al.,	2011,	 Toettcher	 et	 al.,	 2013).	 Moreover,	 all	 four	 Ras	 isoforms	 differ	 in	 their	abilities	to	activate	Raf-1,	with	the	following	order:	KRasB	>	KRasA	>>>	NRas	>	HRas	(Voice	et	al.,	1999).	The	extent	of	G	domain	reorientation	towards	the	PM	is	 thought	 to	 affect	 such	 preferential	 coupling	 of	 isoforms	 to	 downstream	effectors	(Abankwa	et	al.,	2010,	Abankwa	et	al.,	2008).		The	activation	of	the	Rac	pathway	by	oncogenic	KRasG12V	is	2-fold	greater	than	that	by	HRasG12V,	which	is	demonstrated	by	higher	surface	area	of	membrane	
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Fig.	 1.7	 Ras	 signalling	 pathways.	 A	 growth	 factor	 (GF)	 binds	 and	 activates	receptor	 tyrosine	 kinase	 (RTK),	 which	 then	 propagates	 the	 signal	 through	adapter	 proteins	 and	 guanosine	 exchange	 factors	 (GEFs)	 (not	 shown)	 to	 a	membrane-bound	Ras.	As	a	central	signalling	hub,	Ras	disseminates	activating	signals	 to	 a	 plethora	 of	 downstream	 effectors,	 which	 stimulate	 signalling	cascades	 involved	 in	 all	 major	 cellular	 processes,	 including	 cell	 cycle	 and	survival.	
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1.1.3.2	 	 	 Ras	trafficking	and	posttranslational	modifications	









1.1.4		 	 	 Ras	function	in	development	
	
1.1.4.1	 	 	 Functions	of	Ras	isoforms	in	self-renewal	and	
differentiation	





	Mouse	models	are	often	utilised	to	study	cellular	signalling	at	different	stages	of	development	by	gene	knock-in	(KI)	or	knock	out	(KO)	techniques.	However,	to	appreciate	the	phenotypic	outcomes	of	such	models,	 it	 is	 imperative	to	clearly	understand	 the	 physiological	 changes	 that	 take	 place	 during	 normal	 mouse	development.	The	following	paragraphs	describe	prenatal	and	postnatal	mouse	development	with	particular	emphasis	on	the	major	organs	that	were	examined	in	this	study	–	brain,	intestine,	stomach,	liver,	skeletal	muscle,	heart,	kidney	and	lung.	
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Around	 4	 days	 post-conception	 (E4.5),	 the	mouse	 embryo	 is	 a	 blastocyst	 and	begins	 implantation,	 i.e.	 adhering	 to	 the	 uterine	 wall	 (Theiler,	 1989).	 At	embryonic	 day	 6	 (E6),	 differentiation	 of	 embryonic	 and	 extraembryonic	endoderm	and	ectoderm	begins,	while	mesoderm	starts	to	form	around	E7.	At	E7.5	 the	neural	 plate	 is	more	distinct	 and	 the	head	process	 starts	 to	 develop.	Mouse	 organogenesis	 begins	 at	 E8,	 during	 which	 the	 gut	 pocket,	 pronephric	duct	and	cardiac	crescent	appear	and	the	brain	plate	rapidly	develops	(Theiler,	1989,	Davidson,	2008,	Mitiku	and	Baker,	2007,	Kaufman,	1992).	Also,	 the	 first	somite	 pairs	 appear,	 which	 are	 lumps	 of	 mesenchymal	 cells	 derived	 from	paraxial	mesoderm	 of	 segmented	 animals	 and	 subsequently	 differentiate	 into	vertebrae,	 ribs,	 skeletal	 muscle	 and	 the	 dermis	 (Tam,	 1981,	 Gilbert,	 2010).	Mouse	 embryos	 reach	 over	 60	 pairs	 of	 somites	 at	 E15	 (up	 to	 65	 pairs)	(Kaufman,	1992,	Tam,	1981).		At	E8.5	the	mouse	embryo	rotates	resulting	in	a	major	change	in	shape	(Theiler,	1989).	The	first	organ	buds	start	to	form	from	the	foregut	and	hindgut	around	E9–10.5	and	give	rise	to	lung,	liver,	stomach,	pancreas	and	intestine	(Crawford	et	 al.,	 2010,	 Maeda	 et	 al.,	 2007,	 Wells	 and	 Melton,	 1999).	 By	 E9,	 the	 heart	sustains	primitive	circulation	with	regular	heartbeat,	while	both	the	ventricular	and	 atrial	 chambers	 are	 being	 developed	 (Savolainen	 et	 al.,	 2009,	 Theiler,	1989).	 Proper	 kidney	 development	 starts	 at	 E10.5	 with	 the	 formation	 of	 the	uretic	bud	from	the	pronephric	duct	(Davidson,	2008).	By	the	same	time,	brain	development	has	substantially	advanced	(Gilbert,	2010,	Kaufman,	1992,	Theiler,	1989).	 The	 neural	 tube	 closed	 completely	 as	 the	 neural	 folds	 joined	 together	and	 the	 cranial	 blood	 vessels	 rapidly	 developed.	 Differentiating	 neural	 crest	gave	 rise	 to	 peripheral	 nervous	 system	 ganglia.	 The	 hindbrain	 portion	 of	 the	brain,	which	 later	 develops	 into	 the	 pons,	medulla	 oblongata	 and	 cerebellum,	enlarged	substantially.	Cranial	motor	nuclei	and	inferior	olivary	nucleus,	which	are	 involved	 in	 motor	 control,	 show	 peak	 in	 neurogenesis	 at	 E9	 and	 E10,	respectively	 (Finlay	 et	 al.,	 1995).	 By	 E11	 mouse	 sex	 cannot	 be	 determined	(Theiler,	1989).		At	E11.5	 the	 limb	buds	 start	 to	differentiate,	while	 the	 arterial	 system	 is	now	more	mature	(Kaufman,	1992,	Theiler,	1989).	The	heart	is	still	developing	–	the	
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atrium	is	almost	partitioned,	but	the	ventricle	remains	unpaired	and	the	aorta	is	differentiating.	The	liver	shows	hematopoietic	foci	and,	together	with	stomach,	it	enlarged	substantially	as	compared	to	E10.5	(Theiler,	1989).	In	the	lung,	the	branching	 of	 the	major	 bronchi	 takes	 place	 (Metzger	 et	 al.,	 2008,	Warburton,	2008).	 At	 this	 stage,	 kidney	 development	 progresses	 with	 the	 formation	 of	metanephros	as	a	 result	of	branching	of	 the	uretic	bud	 (Davidson,	2008).	The	brain	has	grown	and	matured	 substantially	 and	 the	 forebrain	part,	which	will	form	 the	 thalamus	 and	hypothalamus,	 is	more	distinct	 (Gilbert,	 2010,	Theiler,	1989).	The	embryo	is	around	6-7	mm	long	and	has	now	43-48	pairs	of	somites	(Kaufman,	1992,	Theiler,	1989).			At	 E12	 the	 mouse	 embryo	 has	 the	 first	 signs	 of	 developing	 fingers	 (Theiler,	1989).	The	aorta	and	the	pulmonary	artery	are	formed	through	the	division	of	an	arterial	trunk	(Gilbert,	2010,	Theiler,	1989).	The	rudiments	of	the	tongue	and	teeth	 start	 to	 develop	 and	 the	 lung	 buds	 have	 now	 tertiary	 bronchi.	 The	epithelium	of	the	stomach	shows	regional	differentiation,	while	the	liver	starts	producing	 megakaryocytes,	 which	 are	 responsible	 for	 the	 production	 of	platelets.	At	this	stage	sexual	differentiation	may	be	apparent	(Theiler,	1989).	In	the	 brain,	 the	 pineal	 gland	 starts	 to	 form,	 while	 the	 lens	 of	 the	 eye	 is	differentiating.		By	E13	the	length	of	the	embryo	is	around	9-11	mm	and	the	outer	ear	is	rapidly	developing	 (Theiler,	 1989).	 In	 the	 heart,	 the	 valves	 have	 formed,	while	 in	 the	lungs,	 the	 branching	 of	 the	 bronchi	 has	 advanced.	 The	 liver	 development	progresses	 substantially	and	both	hepatocytes	and	biliary	epithelial	 cells	 start	to	differentiate	(Zorn,	2008).	By	E13.5	the	liver	is	divided	into	four	main	lobes	(Crawford	 et	 al.,	 2010).	 The	 kidneys	 also	 rapidly	 develop,	 while	 sexual	differentiation	begins	(Theiler,	1989).	In	the	brain,	the	development	of	choroid	plexus,	which	produces	cerebrospinal	fluid,	is	complete	(Gilbert,	2010,	Theiler,	1989).			By	E15	the	mouse	embryo	is	around	11.5-14	mm	and	the	toes	of	its	hindlimbs	are	well	separated	(Theiler,	1989).	The	final	prenatal	circulation,	as	well	as	the	
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shape	 of	 the	 heart	 are	 established.	 The	 four	main	 heart	 valves	 are	 developed	and	the	ventricles	are	separated	(Gilbert,	2010,	Theiler,	1989).	In	the	small	and	large	intestine,	the	villi	and	the	crypts	are	forming,	respectively	(Theiler,	1989).	The	 two	 parts	 of	 the	 stomach	 –	 the	 glandular	 and	 nonglandular	 –	 can	 be	distinguished.	 In	 the	 developing	 lung,	 the	 major	 bronchi	 subsequently	 form	secondary	and	tertiary	branches	that	proliferate	until	E16	(Metzger	et	al.,	2008,	Warburton,	 2008).	 This	 process	 is	 accompanied	 by	 innervation	 and	vasculogenesis	 (Maeda	 et	 al.,	 2007).	 In	 the	 forebrain,	 the	 primary	 cortex	 is	formed	and	the	cranial	nerves,	as	well	as	ganglia	are	more	distinct.		By	E16	the	embryo’s	heart	achieved	the	definitive	prenatal	configuration,	apart	form	 the	 coronary	 artery	 and	atrioventricular	 valve	 leaflets	 (Savolainen	et	 al.,	2009,	 Theiler,	 1989).	 The	 intestinal	 tract	 is	 still	 developing	 –	 the	 villi	 of	 the	small	 intestine,	 the	 crypts	 of	 the	 large	 intestine	 and	 the	 epithelium	 of	 the	stomach	are	forming	and	rapidly	growing	(Theiler,	1989).	The	liver	achieved	its	final	 external	 appearance	 and	 is	 increasing	 the	 production	 of	 blood	 cells.	 The	glomeruli	 of	 the	 kidney	 are	 being	 formed,	 but	 the	 nephrons	 are	 still	 not	developed	 (Theiler,	 1989).	 In	 the	 foetal	 brain,	 the	 pituitary	 and	 pineal	 glands	are	still	differentiating	and	the	primary	cerebral	cortex	is	expanding.		At	E17	mouse	foetus	is	around	16.5-20	mm,	its	eyelids	are	fused	and	the	skin	is	thickened	 (Theiler,	 1989).	 At	 this	 stage,	 the	 major	 changes	 include	 the	developing	 epithelium	 in	 the	 aveolar	 ducts	 of	 the	 lungs.	 By	 E17.5	 pulmonary	acinus	becomes	organised	and	the	respiratory	epithelium	starts	to	differentiate,	which	 will	 continue	 until	 around	 postnatal	 day	 5	 (P5)	 (Maeda	 et	 al.,	 2007).	Between	 E17	 and	 birth,	 the	 intrahepatic	 bile	 ducts	 are	 forming	 in	 the	 liver,	while	hepatocytes	become	more	epithelial	and	mature	(Zorn,	2008).			Around	E18	the	mouse	measures	between	18-23	mm	and	has	long	whiskers.	By	this	time,	 large	alveolar	ducts	and	primitive	alveoli	markedly	developed	in	the	lungs	(Theiler,	1989).	The	liver	is	still	the	site	of	haemopoiesis	and	the	stomach	is	subdivided	into	two	parts:	glandular,	which	contains	gastric	glands,	and	non-glandular,	which	 stores	 and	digests	 the	 food	 (Kararli,	 1995).	 In	 the	 brain,	 the	
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pineal	and	pituitary	glands	and	the	olfactory	 lobe	are	now	developed	(Theiler,	1989).		At	birth	(postnatal	day	0	–	P0),	the	newborn	mouse	measures	around	23-27	mm	and	 its	eyes	and	ears	are	closed.	By	 this	 time,	histological	development	 is	 still	ongoing	 and	 the	 neonates	 are	 considered	 histologically	 immature	 (Theiler,	1989).	 In	 the	 heart,	 the	 foramen	 ovale,	 which	 is	 a	 foetal	 cardiac	 shunt	 that	allows	the	blood	to	flow	from	the	right	to	the	left	atrium,	is	no	longer	functional	(Gilbert,	2010,	Theiler,	1989).	The	 liver	 is	 still	 the	 site	of	haemopoiesis,	while	the	stomach	starts	active	enzyme	secretion	to	aid	in	the	digestion	of	milk.	The	kidneys	 are	 growing	 in	 size	 and	more	 ossification	 centres	 are	 present	 in	 the	vertebral	column.		During	postnatal	period,	the	mouse	grows	in	size	and	fully	matures	at	least	until	P30	(Holder	and	Blaustein,	2014,	Theiler,	1989).	Postnatal	development	of	the	lungs	is	demonstrated	by	the	formation	and	growth	of	alveoli	and	maturation	of	the	 vasculature	 until	 P28	 (Maeda	 et	 al.,	 2007).	 For	 the	 liver,	 its	 size	 rapidly	increases	until	P21	and	the	final	remodelling	of	the	bile	duct	and	organisation	of	hepatocytes	 takes	 place	 (Crawford	 et	 al.,	 2010).	 In	 the	 brain,	 some	 major	changes	 in	 the	 formation	of	 layer	V	 in	 the	 cerebral	 cortex	 and	 in	 the	whisker	sensory	 area	 occur	 until	 P5.	 Also	 by	 the	 same	 time,	 the	 internal	 ear	 is	 still	differentiating,	but	the	ears	open	and	a	fine	fur	appears	(Theiler,	1989).		By	P10,	more	ossification	centres	are	present	in	the	bone	and	by	P15	both	ears	and	eyes	are	 open	 and	 fully	 developed.	Weaning	 starts	 around	 P20	 and	may	 continue	until	P30	(Curley	et	al.,	2009).	By	this	time,	mice	should	show	firs	signs	of	sexual	maturation	 –	 for	 CD1	 mice,	 vaginal	 opening	 occurs	 approximately	 at	 P30	(Holder	and	Blaustein,	2014).	The	 first	oestrus	cycle	occurs	around	7-20	days	after	 the	 vaginal	 opening	 (Holder	 and	 Blaustein,	 2014)	 and	 the	 first	 mating	when	the	mouse	is	around	2-3	months	old	(Theiler,	1989).					
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1.1.4.2.2	 Ras	mouse	models	
 Several	 mouse	 models	 demonstrated	 that	 only	 KRasB	 is	 essential	 for	 mouse	embryo	development	(discussed	in	section	5.1.1)	(Koera	et	al.,	1997,	Johnson	et	al.,	1997,	Plowman	et	al.,	2003,	Umanoff	et	al.,	1995,	Esteban	et	al.,	2001).	KRASB	KO	 mice	 had	 increased	 embryonic	 lethality	 due	 to	 anaemia,	 liver	 defects,	 thin	heart	 ventricular	 walls	 and	 increased	 motoneuron	 cell	 death.	 However,	subsequent	studies	demonstrated	that	replacement	of	KRas	with	HRas,	which	was	knocked	 into	 the	 KRAS	 locus,	 resulted	 in	 normal	 embryonic	 development,	 but	induced	 dilated	 cardiomyopathy	 during	 adulthood	 (Potenza	 et	 al.,	 2005).	 This	suggests	 that	 HRas	 could	 functionally	 replace	 KRas	 during	 early	 development,	when	its	expression	pattern	in	mouse	tissues	mimics	that	of	KRas.	However,	HRas	may	 not	 compensate	 for	 KRas-specific	 function	 in	 adult	 cardiovascular	homeostasis.	 Yet,	 the	 ability	 of	HRas	 to	 substitute	 KRas	 in	 certain	 physiological	context	 could	 mean	 that	 Ras	 isoforms	 share	 many	 cellular	 functions	 and	 the	isoform-specific	differences	in	signalling	are	the	result	of	disparity	in	timing	of	their	 gene	 expression	 and	 in	 tissue/lineage-specific	 expression	 pattern	(Castellano	and	Santos,	2011).		To	 date,	 only	 a	 few	 studies	 have	 provided	 semi-quantitative	 data	 on	 Ras	expression	across	different	tissues	and	developmental	stages	in	the	mouse	and	human	(further	discussed	in	section	5.1.2)	(Leon	et	al.,	1987,	Pells	et	al.,	1997,	Plowman	 et	 al.,	 2006,	 Plowman	 et	 al.,	 2003).	 More	 work	 is	 needed	 to	quantitatively	 measure	 Ras	 abundance,	 which	 will	 inform	 models	 of	 the	mechanistic	basis	of	Ras	isoform	functional	overlap.	
		
1.2		 	 	 Ras	in	pathogenesis		
	
1.2.1		 	 	 Ras	in	developmental	disorders	
	The	 role	 of	 isoform-specific	 function	 in	 early	 development	 could	 be	 better	understood	 by	 studying	 rasopathies	 –	 distinct	 congenital	 disorders	 caused	 by	germline	 mutations	 in	 RAS	 genes	 or	 in	 other	 components	 of	 Ras	 signalling	pathways	(Denayer	et	al.,	2008,	Schubbert	et	al.,	2006,	Tartaglia	and	Gelb,	2010,	
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Tidyman	and	Rauen,	2008,	Tidyman	and	Rauen,	2009).	Rasopathies	share	many	phenotypic	 features	 and	 are	 collectively	 referred	 to	 as	 neuro-cardio-faciocutaneous	 (NCFC)	 developmental	 syndromes,	 characterised	 by	 mental	retardation,	developmental	delay,	cardiomyopathies,	as	well	as	musculoskeletal	and	craniofacial	abnormalities.			Costello	 syndrome	 (CS)	 is	 a	 rare	 autosomal	 dominant	 disease	 predominantly	caused	by	germline	HRAS	mutations,	especially	G12S	(Aoki	et	al.,	2008,	Rauen,	2007,	 Tidyman	 and	 Rauen,	 2009).	 Patients	 with	 CS	 are	 predisposed	 to	developing	 tumours,	 such	 as	 bladder	 carcinoma	 or	 ganglioneuroblastoma	(Roberts	et	al.,	2006a).	Noonan	syndrome	(NS),	 in	 turn,	 is	a	common	disorder	(1/2000	births)	 caused	by	 various	 germline	mutations	 in	 the	MAPK	pathway,	where	 Ras	mutations,	 especially	 in	KRAS,	 constitute	 less	 than	 2%	 of	 all	 cases	(Cirstea	 et	 al.,	 2010,	 Roberts	 et	 al.,	 2007,	 Tartaglia	 and	 Gelb,	 2010).	 NS	 is	characterised	 by	 webbed	 neck	 and	 rotated	 ears	 and	 cancer	 is	 uncommon	 in	patients,	 but	 some	 can	 develop	 acute	 lymphoblastic	 leukaemia.	 Scarce	 RAS	mutations	 have	 also	 been	 reported	 in	 cardio-facio-cutaneous	 syndrome	 and	autoimmune	lymphoproliferative	syndrome	(Oliveira	et	al.,	2007,	Tidyman	and	Rauen,	2008). 	
RAS	 mutations	 involved	 in	 NCFC	 syndromes	 affect	 various	 codons	 and	 are	usually	 milder	 than	 those	 found	 in	 cancers	 (Fernandez-Medarde	 and	 Santos,	2011,	 Schubbert	 et	 al.,	 2006,	 Seeburg	 et	 al.,	 1984).	 Mouse	models	 have	 been	developed	 for	many	 of	 these	mutations,	which	 allows	 investigating	molecular	mechanisms	that	lead	to	distinct	phenotypic	changes	in	NCFC	syndromes.			
	
1.2.2		 	 	 Ras	in	cancer	
	Ras	proteins	constitute	a	paradigm	of	cellular	transformation	by	being	some	of	the	 most	 commonly	 mutated	 proto-oncogenes	 in	 human	 cancer	 (Cox	 et	 al.,	2014,	Forbes	et	al.,	2015,	Prior	et	al.,	2012).	Although	HRas,	NRas	and	both	KRas	splice	variants	share	high	sequence	homology	and	many	cellular	functions,	each	
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There	 has	 been	 little	 progress	 in	 the	 development	 of	 anti-Ras	 therapies.	Farnesyltransferase	 inhibitors	 (FTIs)	 that	 target	 post-translational	farnesylation	 of	 Ras	 proteins	 and	 therefore	 their	 membrane	 recruitment,	proved	 largely	unsuccessful	due	 to	alternative	geranylgeranylation	of	Ras	and	off-target	effects	 (Zhu	et	al.,	2003).	 So	 far	 little	advancement	 in	 targeting	Ras-driven	cancers	was	achieved	by	using	anti-Ras	ribozymes	(Kijima	et	al.,	2004)	and	small	interfering	RNA	(siRNA)	(Fleming	et	al.,	2005).	A	recently	developed	treatment	against	activated	Ras	shows	a	more	specific	and	promising	approach	by	 allosterically	 targeting	 KRas	 G12C	 mutation,	 often	 found	 in	 lung	 tumours	(non-small	cell	lung	carcinoma	–	NSCLC)	(Fiala	et	al.,	2013,	Ostrem	et	al.,	2013).	The	inhibitor	disrupts	the	conformational	state	of	Ras	and	blocks	the	interaction	with	downstream	Raf	 effector.	Nevertheless,	 this	 approach	 still	 awaits	 further	validation	 in	vitro	and	 future	clinical	 trials.	More	research	 into	key	differences	between	Ras	mutations,	as	well	as	Ras	isoform-dependent	signalling	is	needed	to	elucidate	specific	mechanisms	as	targets	for	possible	Ras-targeted	therapies.	
		
1.3		 	 Aims	of	this	study		While	 there	 has	 been	 substantial	 research	 into	 Ras	 function	 in	 pathological	context	 of	 cancer,	 still	 little	 is	 known	 about	 Ras	 isoform-specific	 biological	functions	 in	 normal	 non-cancerous	 tissues	 and	during	 development.	 Research	into	normal	physiological	processes	and	endogenous	levels	of	expression	of	Ras	isoforms	 could	 lead	 into	 clues	 in	 answering	 questions	 about	 KRasB	predominance	 in	 the	 regulation	 of	 normal	 mouse	 development	 and	 the	prevalence	 of	 KRas-driven	 tumours.	 Yet,	 there	 is	 no	 single	 study	 that	 would	provide	a	comprehensive	quantitative	method	for	measuring	expression	levels	across	 all	 Ras	 isoforms	 and	 across	 various	 tissue	 types	 throughout	development.	Based	on	this,	the	following	hypothesis	can	be	formulated:		Hypothesis	 1:	 The	 expression	 levels	 can	 explain	 Ras	 isoform	 functional	 non-redundancy	during	development.		
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2.1	 	 	 Materials	All	 tissue	 culture	 plasticware	 was	 from	 Corning	 (Corning	 B.V.	 Life	 Sciences,	Fogostraat	12,	1060	LJ	Amsterdam,	 the	Netherlands),	unless	otherwise	stated.	Mouse-specific	 Ras	 plasmids	 (pCR4-TOPO-ERas	 (IMAGE	 ID:	 8734026),	 pCR-Blunt	 II-TOPO-KRas-4A	 (IMAGE	 ID:	 40052024)	 and	 pCMV-SPORT6-KRas4B	(IMAGE	ID:	3158212))	were	purchased	from	Source	BioScience	(William	James	house,	Cowley	Road,	Cambridge,	CB4	0WU,	UK).		
All	chemicals	were	ordered	 from	Sigma	(Sigma-Aldrich	Company	Ltd.,	The	Old	Brickyard,	 New	 Road,	 Gillingham,	 Dorset,	 SP8	 4XT),	 unless	 otherwise	 stated.	Absolute	ethanol	and	methanol	were	obtained	from	the	Chemistry	Department,	University	of	Liverpool.	
In	 this	 work	 the	 following	 laboratory	 equipment	 was	 used:	 benchtop	microcentrifuges:	#022621807,	5417R,	Eppendorf	AG;	#13-100-676,	 accuSpin	Micro	17R,	Fisher	Scientific	and	#5453	000.011,	MiniSpin	plus,	Eppendorf	AG;	Jouan	CR4i	 centrifuge,	Thermo	Electron	Corporation;	 tissue	 culture	 centrifuge	#5804	 000.013,	 5804,	 Eppendorf	 AG;	 thermomixer	 compact,	 Eppendorf	 AG;	microplate	reader	Multiskan	Spectrum	no.	1500,	Thermo	Lab	Systems.	
	
2.2	 	 													Cell	lines	
2.2.1		 	 	 SW48	Ras	isogenic	cell	lines	
The	 SW48	 cell	 line	 was	 originally	 derived	 from	 Duke’s	 type	 C,	 grade	 IV,	colorectal	adenocarcinoma	from	an	82-year-old	female	by	A.	Leibovitz	at	Scott	and	 White	 Clinic,	 Temple,	 Texas,	 USA	 (Leibovitz	 et	 al.,	 1976).	 For	 this	 study	parental	(wild	type	Ras),	HRasG12V	and	KRasG12V	SW48	cell	 lines	(#HD	103-034	 and	 HD	 103-007)	 were	 purchased	 from	 Horizon	 Discovery	 (7100	
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Cambridge	 Research	 Park,	 Waterbeach,	 Cambridge,	 CB25	 9TL,	 UK),	 whereas	NRasG12V	 SW48	 cell	 line	 was	made	 in	 house	 by	 Dr	 Simon	 Oliver	 using	 AAV	technology	(Vasileva	and	Jessberger,	2005),	at	 the	University	of	Liverpool,	UK.	In	all	Ras	isoform	isogenic	cell	lines,	only	one	allele	was	targeted.	
	
2.2.2	 	 	 STO	mouse	fibroblasts			The	 STO	 cell	 line	 was	 originally	 derived	 from	 a	 continuous	 cell	 line	 of	 SIM	(Sandos	 Inbred	Mice)	mouse	embryonic	 fibroblasts	by	A.	Bernstein	at	Ontario	Cancer	Institute,	Toronto,	Canada	(Martin	and	Evans,	1975).	For	this	study	the	cell	line	was	kindly	provided	by	Dr	Patricia	Murray,	University	of	Liverpool,	UK.	
	
	
2.2.3		 	 	 R1	mouse	Embryonic	Stem	Cells	(mESCs)		The	R1	cell	 line	was	originally	derived	 from	 inner	cell	mass	of	a	3.5	day	male	blastocyst	by	crossing	two	mouse	129	substrains	(129S1/SvlmJ	and	129X1/SvJ)	in	1991	by	Andras	Nagy	in	Toronto,	Canada	(Nagy	et	al.,	1993).	For	this	study	the	cell	line	was	kindly	provided	by	Dr	Patricia	Murray,	University	of	Liverpool,	UK.	
 	
2.3		 	 Routine	cell	culture		As	a	part	of	routine	cell	culture,	all	cell	lines	were	verified	by	STR	(short	tandem	repeat)	DNA	profiling	and	were	regularly	 tested	 for	mycoplasma.	All	 cell	 lines	were	cultured	at	37˚C	in	a	humidified	5%	(v/v)	CO2	atmosphere.		
	
	
2.3.1	 	 Routine	SW48	Ras	isogenic	cell	lines	culture		SW48	 cell	 lines	 were	 routinely	 cultured	 in	 McCoy’s	 medium	 (#S6600-021,	Gibco)	 containing	10%	(v/v)	Foetal	Bovine	Serum	(FBS)	 (#10270-106,	Gibco)	and	 1%	 (v/v)	 Penicillin/Streptomycin	 (stock	 10,000	 U/ml	 Pen,	 10,000	 µg/ml	
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Strep,	29.2	mg/ml	L-Glutamine,	#10378-016,	Gibco)	on	10	cm	dishes	and	were	passaged	 after	 achieving	 80%	 confluence.	 First,	 cells	 were	washed	 once	with	0.01M	(1	x)	Phosphate	Buffered	Saline	(PBS)	(#P5493)	and	then	incubated	in	1	ml	of	0.05%	(1	x)	trypsin-EDTA	(#15400-054,	Gibco)	at	37˚C	for	5-10	mins.	The	trypsin	reaction	was	stopped	by	adding	4	ml	of	10%	FBS	McCoy’s	medium	and	cells	were	 typically	 split	 1	 in	3	 to	1	 in	5	 (Table	2.1)	 into	 another	10	 cm	dish.	Typical	seeding	densities,	depending	on	the	plate	used,	are	summarised	in	Table	2.2			
Table	2.1	A	list	of	cell	lines	used	in	this	study	and	splitting	densities.			
Cell	line	 Splitting	ratio	SW48	parental	 1	in	5	SW48	HRasG12V	 1	in	4	SW48	KRasG12V	 1	in	4	SW48	NRasG12V	 1	in	3	STO	mouse	fibroblasts	 1	in	3	R1	mouse	embryonic	stem	cells	 1	in	3			
Table	2.2	Standard	seeding	densities	for	SW48	Ras	isogenic	cell	lines.		
SW48	cell	line	 10	cm	dish	 6-well	plate	 24-well	plate	
Parental	 2.3	x	106	cells	 4.0	x	105	cells/well	 3.5	x	105	cells/well	
HRasG12V	 2.3	x	106	cells	 4.0	x	105	cells/well	 3.5	x	105	cells/well	
KRasG12V	 3.0	x	106	cells	 5.3	x	105	cells/well	 4.64	x	105	cells/well	
NRasG12V	 3.0	x	106	cells	 5.3	x	105	cells/well	 4.64	x	105	cells/well	




2.3.2.1	 	 Plate	coating	protocols		To	allow	cell	attachment	of	STOs	and	ESCs,	cell	culture	dishes	were	first	coated	with	sterile	0.1%	(w/v)	gelatin	by	incubation	at	room	temperature	for	10	mins.	7	 ml	 or	 2	 ml	 of	 gelatin	 solution	 was	 added	 to	 10	 cm	 or	 3.5	 cm	 dishes,	respectively.	 Gelatin	 solution	 was	 then	 aspirated	 and	 dishes	 were	 washed	 3	times	for	5	mins	with	warm	1	x	PBS.			For	 the	 suspension	 differentiation	 protocol,	 3.5	 cm	 non-adherent	 petri	 dishes	(Sarsted)	 were	 treated	 with	 2	 ml	 of	 0.01%	 (w/v)	 Pluronic	 F-127	 (#P6867,	Invitrogen)	 in	1	x	PBS	 for	at	 least	15	mins	and	 then	washed	3	 times	with	1	x	PBS.	
 
2.3.2.2	 	 STO	culture	as	a	feeder	layer		STOs	 were	 routinely	 cultured	 in	 Dulbecco’s	 Modified	 Eagle	 medium	 (DMEM)	high	 glucose	 (2500	 mg/L,	 #D6546)	 containing	 10%	 FBS,	 1%	 L-Glutamine	(#25030-081,	Gibco),	0.1	mM	Non	Essential	Amino	Acids	(NEAA)	(#11140-050,	Gibco),	 1%	 Penicillin/	 Streptomycin	 and	 0.01%	 (5	 µM)	 β-mercaptoethanol	(stock	50	mM,	#31350-010	Gibco),	hereafter	referred	to	as	STO	medium	(Table	2.3),	on	gelatin-coated	10	cm	dishes.	When	cells	were	about	90%	confluent,	50	µl	 of	 2	 mg/ml	 mitomycin	 C	 (20	 µg/ml,	 #M4287)	 was	 added	 to	 5	 ml	 of	 STO	medium	 to	 stop	 cell	 proliferation.	 Cells	 were	 washed	 twice	 in	 1	 x	 PBS	 and	incubated	in	5	ml	of	1	x	trypsin	for	5	mins	at	37˚C.	7	ml	of	10%	FBS	DMEM	(stop	medium)	was	added	to	the	cells	to	stop	trypsinisation.	Cells	were	centrifuged	at	200	x	g	 for	3	mins,	 the	medium	was	aspirated	and	12	ml	of	STO	medium	was	added	and	mixed	with	the	cells.	1	ml	of	cells	was	added	to	each	of	the	twelve	3.5	cm	dishes	already	containing	1	ml	of	STO	medium.	STO	cells	were	then	ready	to	be	used	as	a	feeder	layer	for	mESC	culture.				
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2.3.2.3	 	 Routine	ESCs	culture		R1	embryonic	stem	cells	were	cultured	on	a	feeder	layer	of	STOs	(2.3.2.2)	on	3.5	cm	 cell	 culture	 dishes	 using	 the	 following	 protocol	 (Fig.	 2.1	 A,	 derived	 from	(Xiong	et	al.,	1998)).	Cells	were	grown	in	filtered	R1	ESC	medium	(DMEM	high	glucose	 (#D6546)	 containing	 15%	 FBS,	 1%	 L-glutamine,	 0.1	 mM	 NEAA,	 1%	Penicillin/Streptomycin,	 0.01%	 (5	 µM)	 β-mercaptoethanol	 and	 260	 U/ml	leukemia	 inhibitory	 factor	 (LIF)	 (107	 U/ml	 #ESG1107,	 lot	 #JBC1872217,	Chemicon,	 Millipore))	 (Table	 2.3)	 and	 split	 when	 they	 were	 around	 90%	confluent.	 Cells	 were	 trypsinised	 and	 after	 centrifugation	 the	 medium	 was	aspirated	and	 the	cells	were	re-suspended	 in	3	ml	of	R1	ESC	medium.	1	ml	of	cells	was	transferred	to	each	of	the	3	gelatinised	3.5	cm	dishes	with	STO	feeder	layer,	which	already	contained	1	ml	of	R1	ESC	medium.			


























Fig.	 2.1	 Schematic	 illustrations	 of	 cell	 culture	 conditions	 for	
undifferentiated	and	differentiating	R1	mouse	embryonic	stem	cells	ESCs.	





















Medium	 (#12648-010,	 Gibco)	 and	 1	 ml	 transferred	 into	 individual	 cryovials	(#BR114840).	
	Cryovials	 for	 all	 cell	 lines	 were	 placed	 into	 a	 freezing	 chamber	 containing	isopropanol	and	left	in	-80˚C	freezer	overnight	to	allow	slow	freezing	by	1˚C	per	hour.	The	next	day,	cells	were	transferred	into	a	 liquid	nitrogen	tank	for	 long-term	storage.		
2.3.4	 	 Cell	thawing	protocols			All	cell	 lines	were	first	thawed	in	a	water	bath	at	37˚C.	SW48	Ras	isogenic	cell	lines	 were	 gently	 mixed	 by	 pipetting	 and	 then	 transferred	 to	 25	 cm2	 flasks	containing	9	ml	of	10%	FBS	McCoy	medium.	Once	thawed,	1	ml	of	stop	medium	was	 added.	 Cells	 were	 gently	 mixed,	 transferred	 to	 15	 ml	 Falcon	 tubes	containing	 3	ml	 stop	medium	 and	 centrifuged	 at	 200	 x	 g	 for	 3	mins	 and	 the	medium	 was	 aspirated.	 For	 STO	 cells,	 10	 ml	 of	 STO	 medium	 was	 added	 for	subsequent	routine	cell	culture	on	10	cm	gelatinised	tissue	culture	dishes.	For	R1	mESCs,	2	ml	of	R1	ESC	medium	was	added,	mixed	and	pipetted	gently	onto	3.5	cm	tissue	culture	dish	with	STO	feeder	layer,	from	which	STO	medium	was	aspirated.	
	
	
2.3.5	 	 Cell	counting			Cells	 were	 trypsinised	 and	 transferred	 to	 15	 ml	 Falcon	 tubes.	 10	 µl	 of	 cell	suspension	 was	 pipetted	 onto	 a	 Hausser	 Scientific	 haemocytometer	 and	 cells	were	 observed	 under	 the	 microscope	 (Leica	 DM	 IL	 Microsystems	 Type	 090-135.001)	using	10	x	objective	lens.	Viable	cells	that	appeared	round	and	healthy	were	counted	in	four	squares	and	the	average	number	of	cells	was	multiplied	by	a	chamber	factor	of	104,	which	gave	the	cell	number	per	1	ml	of	cell	suspension.	The	required	number	of	cells	was	then	calculated	and	diluted	in	the	appropriate	amount	of	medium	for	seeding.		
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2.3.6	 	 Separation	of	R1	ESCs	from	STO	feeder	layer		To	extract	RNA	and	protein	from	undifferentiated	R1	ESCs,	these	cells	had	to	be	first	 separated	 from	 the	 STO	 feeder	 layer.	 In	 order	 to	 do	 this,	 cells	were	 first	trypsinised	as	described	before	 (section	2.3.2.3).	After	 the	centrifugation	step,	the	medium	was	 aspirated	 and	 the	 cells	were	 re-suspended	 in	5ml	 of	R1	ESC	medium,	and	then	transferred	onto	gelatinised	10	cm	dishes	containing	5	ml	of	R1	ESC	medium.	The	dish	was	left	at	37˚C	for	at	least	20	mins	to	allow	STOs	to	attach	to	the	plate.	As	the	rate	of	attachment	to	the	gelatinised	plate	is	faster	for	STOs	than	R1	ESCs,	separation	of	the	two	cell	lines	was	possible.	The	cells	were	observed	under	the	microscope	to	see	whether	STO	attachment	to	the	plate	was	complete.	10	ml	of	the	R1	ESCs	suspension	in	the	medium	was	then	transferred	to	a	Falcon	 tube	and	centrifuged	at	200	x	g	 for	3	mins.	Cells	were	 then	either	counted	 using	 a	 haemocytometer	 (section	 2.3.5)	 and	 split	 onto	 a	 gelatinised	dish	 for	 imaging,	 or	 re-suspended	 in	 RNA	 lysis	 buffer	 for	 RNA	 and	 protein	extraction	(section	2.7.8	and	2.8.2).		 	 	 	 	 	 	
	
2.4	 	 Suspension	differentiation	protocols		R1	mESCs	were	grown	in	suspension	to	form	embryoid	bodies	(EB)	as	a	model	to	 study	 cell	 differentiation,	 according	 to	 an	 established	 protocol	 (Fig.	 2.1	 B,	derived	from	(Murray	and	Edgar,	2000,	Rak-Raszewska	et	al.,	2012)).	First,	cells	were	cultured	on	an	STO	 feeder	 layer	on	3.5	cm	dishes	 in	R1	ESC	medium,	as	described	in	section	2.3.2.3,	and	then	passaged	several	times	onto	gelatinised	6	cm	dishes	without	the	feeder	 layer	 in	5	ml	of	R1	ESC	medium	to	deplete	STOs	from	 the	 culture.	When	 cells	were	90%	confluent,	 they	were	 split	 1	 in	6	onto	gelatinised	6	cm	dishes	(Thermo	Scientific,	NuncTM)	in	5	ml	of	R1	ESC	medium	for	endoderm	differentiation	or	in	5	ml	of	MESO	ESC/EB	medium	(10%	FBS,	1%	L-glutamine,	 1%	 Penicillin/Streptomycin,	 0.15%	 monothioglycerol	 (MTG,	100mM	stock,	#M6145),	 1,000	U/ml	 LIF	 in	 IMDM	 (#13390,	 Iscove’s	modified	Dulbecco’s	 medium))	 for	 mesoderm	 differentiation	 (ESC/EB	 medium,	 Table	2.3).	 When	 the	 cells	 achieved	 90%	 confluence,	 they	 were	 trypsinised	 and	counted	for	seeding	on	Pluronic	F-127-coated	dishes	(section	2.3.2.1).		
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For	endoderm	differentiation,	50,000	cell/ml	were	seeded	onto	the	Pluronic	F-127-treated	dishes	 in	2	ml	of	ENDO	EB	medium	(R1	ESC	medium	without	LIF,	Table	2.3).	For	mesoderm	differentiation,	30,000	cells/ml	were	seeded	onto	the	dishes	in	2	ml	of	MESO	EB	medium	(15%	FBS,	1%	L-glutamine,	0.45%	MTG,	1%	ITS	 (insulin	 transferrin	 selenium,	 #25-800-CI,	 Mediatech),	 1%	 Penicillin/	Streptomycin,	 0.1%	 ascorbic	 acid	 (500mM	 stock)	 in	 IMDM,	 Table	 2.3).	 The	embryoid	bodies	that	started	to	form	were	cultured	for	a	maximum	of	20	days	and	the	EB	media	were	changed	every	2	days.				
2.5		 								Phenotypic	assays		
2.5.1	 	 Microscopy		To	take	bright-field	images,	SW48	cells	were	placed	in	a	chamber	at	37	˚C	and	viewed	 under	 Nikon	 Ti-E	 microscope	 using	 a	 20	 x	 objective	 lens.	 STOs,	undifferentiated	 R1	 ESCs	 and	 embryoid	 bodies	 were	 viewed	 under	 a	 Leica	DFC420C	microscope	using	10	x	 and	20	x	objective	 lenses	 to	 take	bright-field	images.	
	
	
2.5.2		 	 	 Cell	viability	assay		CellTiter-Glo®	Luminescent	 Cell	 Viability	Assay	 (#G7571,	 Promega)	was	used	according	to	manufacturer’s	instructions	to	measure	cell	viability	by	quantifying	the	 amount	of	ATP	produced	by	metabolically	 active	 cells.	 SW48	Ras	 isogenic	cell	lines	were	seeded	in	5	technical	replicates	at	specified	densities	(250-5000	cells/well)	onto	96-well	plates	and	cultured	in	10%	FBS	McCoy’s	medium	for	1-5	 days.	 As	 a	 control	 for	 background	 luminescence,	 5	wells	 contained	medium	only.	Before	the	assay,	cells	were	taken	out	of	the	incubator	and	equilibrated	at	room	 temperature	 for	 30	 mins.	 100	 µl	 of	 CellTiter-Glo®	 Reagent	 (CellTiter-Glo®	Buffer	mixed	with	CellTiter-Glo®	Substrate)	was	then	added	per	well	and	the	 plate	 was	 shaken	 at	 250	 rpm	 on	 an	 orbital	 plate	 shaker	 (Rotamax	 120,	Heidolph)	 for	 2	 mins	 to	 induce	 cell	 lysis	 and	 left	 at	 room	 temperature	 for	 a	
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Inhibitor	 Target	 IC50	 Reference	AZD6244	 MEK1	ERK1/2	 14	nM	10	nM	 (Garon	et	al.,	2010,	Huynh	et	al.,	2007)	
Sorafenib	 c-Raf-1	BRAF	(wt)	BRAFV600E	
6	nM	22	nM	38	nM	 (Wilhelm	et	al.,	2004)	LY294002	 PI(3)K	Pim-1	kinase	 1.4	uM	4.0	uM	 (Mena	et	al.,	2014,	Wu	et	al.,	2014)	Rapamycin	 mTOR	 ~0.1	nM	 (Edwards	and	Wandless,	2007)	
	
	
2.6		 			 	 Preparation	of	murine	tissues		
2.6.1	 		 	 Organ	dissection	and	tissue	harvesting	Adult	CD1	mice	(Charles	River)	were	sacrificed	by	increasing	CO2	concentration	in	CO2	chamber	and	by	cervical	dislocation	as	stated	in	Schedule	1	procedure	of	Home	Office	Regulations.	Mouse	embryos	were	dissected	from	time-mated	mice	at	 embryonic	 days	 (E)	 11.5,	 13.5	 and	 16.5.	 First,	 the	 uterine	 horns	 were	removed	from	mothers	at	room	temperature	and	then	placed	in	ice	cold	1x	PBS	(Invitrogen).	 Next,	 embryos	 were	 removed	 from	 extraembryonic	 membranes	and	decapitated	according	to	Schedule	1	procedure	of	Home	Office	Regulations.	Organs	 were	 dissected	 using	 a	 stereoscopic	 microscope	 (Leica	 MZ6)	 starting	from	the	 limbs/skeletal	muscle,	 the	heart	and	 the	 lungs,	 followed	by	 the	 liver,	stomach,	intestine,	kidney	rudiments/kidney	and	finally	the	brain.	Neonates	at	postnatal	 days	 (P)	 0,	 5,	 10,	 15,	 20,	 25	 and	 30,	 as	 well	 as	 adult	 mice,	 were	sacrificed	and	dissected	accordingly.	Dissected	organs	and	tissues	were	placed	in	1.5	ml	microcentrifuge	tubes	(#3621,	CostarTM),	 immediately	snap-frozen	in	liquid	nitrogen	and	stored	at	-80	˚C	before	tissue	homogenisation.	
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2.6.2		 	 	 Tissue	homogenisation	Frozen	mouse	 tissues	were	placed	 in	1.5	ml	microcentrifuge	 tubes	on	dry	 ice.	Small	pieces	of	 tissue	were	cut	with	a	curved	surgical	blade	(Sterile	Blade	No.	12,	 Swann-Morton),	 transferred	 to	 pre-weighed	 2	 ml	 tubes	 (#UC-13119-500,	Cambio)	 containing	 6	 x	 2.8	 mm	 ceramic	 beads	 (#13114-325,	 Cambio)	 and	weighed	 on	milligram	 digital	 balance	 (AVI14C	 Adventurer®	 Pro,	 OHAUS).	 For	RNA	 extraction,	 300	 µl	 of	 RNA	 Lysis	 Buffer	 (#17215,	 Lot	 #582484,	 Norgen	Biotek	 Corp;	 XI-0718	 Geneflow)	 containing	 1%	 (v/v)	 β-mercaptoethanol	 was	added	 per	 10	 mg	 of	 tissue	 and	 the	 tissues	 were	 homogenised	 using	 a	PowerLyzer®	24	 (#13155,	MO	BIO	Laboratories)	 using	 the	 following	protocol	(based	on	manufacturer’s	recommended	settings	for	RNA	isolation	from	animal	tissues):	 3,500	 rpm	 (~5.7	m/sec),	 2	 x	 45	 sec.,	 30	 sec.	 dwell	 time.	 For	 protein	extraction,	 100	 µl	 of	 RIPA	 buffer	 (10	mM	 TrisHCl	 pH	 7.5,	 150	mM	 NaCl,	 1%	(w/v)	 Triton-X,	 0.1%	 (w/v)	 SDS,	 1%	 (w/v)	 sodium	 deoxycalate)	 containing	mammalian	 Protease	 Inhibitor	 Cocktail	 (#P8340)	 was	 used	 per	 10	 mg	 of	tissues.	 The	 lysates	 were	 transferred	 to	 RNase-free	 microcentrifuge	 tubes	(#3621,	Costar)	 and	 centrifuged	 for	2	minutes	at	18,000	x	g	 to	pellet	 any	 cell	debris.	 600	 µl	 of	 the	 supernatant	 was	 transferred	 to	 fresh	 microcentrifuge	tubes,	snap	frozen	in	liquid	nitrogen	and	stored	at	-80˚C	before	RNA	and	protein	extraction	(section	2.7.8	and	2.8.2).	
	
2.7		 	 	 Molecular	Biology	
2.7.1		 Agarose	gel	electrophoresis	Agarose	 gel	 electrophoresis	 was	 run	 to	 check	 the	 size	 of	 DNA	 products	amplified	 in	 PCR	 reactions	 (section	 2.7.11)	 and	 restriction	 digests	 (section	2.7.7),	and	to	check	the	quality	of	RNA	samples	(section	2.7.8).	1.2	–	2%	agarose	gels	 were	 made	 by	 boiling	 agarose	 powder	 (#161-3101EDU,	 Bio-Rad)	 in	 1	 x	TBE	 (Tris/Borate/EDTA)	 buffer	 (89	 mM	 Tris-borate,	 2	 mM	 EDTA,	 pH	 8.3,	#T3913)	 and	 adding	 ethidium	 bromide	 to	 a	 final	 concentration	 of	 0.5	 µg/ml.	Gels	were	set	in	gel	tanks	(Bio-Rad)	and	1	x	TBE	running	buffer	was	added.	The	DNA	or	RNA	samples	were	prepared	 in	1	x	sample	buffer	 (0.5%	w/v	glycerol,	
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0.01	mM	EDTA,	0.004%	bromophenol	blue)	 and	electrophoresed	at	120	V	 for	1.5	–	2	hours,	along	with	HyperLadder	IV	(#BIO-33029,	Bioline),	HyperLadder	VI	(#BIO-33033,	Bioline)	or	MassRuler	(#SM0403,	Life	Technologies)	molecular	weight	markers.	DNA	and	RNA	bands	were	visualised	by	ultraviolet	light	using	GeneFlash	 gel	 documentation	 system	 (Syngene).	 For	 RNA	 samples,	 all	 buffers	and	 solutions	 were	 made	 in	 nuclease-free	 water	 treated	 with	 diethyl	pyrocarbonate	(DEPC)	and	all	equipment	was	treated	with	RNaseZAP	(#R2020)	before	use.		
	
2.7.2	 Gel	extraction	of	DNA	fragments	Following	agarose	gel	electrophoresis,	appropriate	DNA	fragments	were	excised	and	weighed	on	a	milligram	digital	balance	(AVI14C	AdventureTM	Pro,	OHAUS).	DNA	was	extracted	using	QIAquick	gel	extraction	kit	 (#28704,	QIAGEN)	and	a	microcentrifuge,	 according	 to	manufacturer’s	 instructions.	Briefly,	 one	volume	of	 agarose	 gel	 was	 dissolved	 in	 3	 volumes	 of	 Buffer	 QG	 at	 50°C,	 and	 one	 gel	volume	of	isopropanol	was	added	and	mixed.	The	sample	was	then	added	onto	the	QIAquick	column	and	centrifuged	for	1	min	at	10,000	x	g	to	bind	DNA.	The	column	was	washed	with	0.75	ml	Buffer	PE	and	the	extracted	DNA	was	eluted	in	a	 final	 volume	 of	 30	 µl	 of	 Elution	 Buffer	 (10	 mM	 Tris-Cl,	 pH	 8.5).	 DNA	concentrations	 were	 determined	 using	 a	 NanoDrop	 Spectrophotometer	 ND-1000	(Thermo	Scientific)	based	on	absorbance	at	a	wavelength	of	260	nm.	The	eluted	DNA	fragments	were	subsequently	used	for	subcloning	(section	2.7.3)	or	were	 sent	 for	 sequencing	 to	 DNA	 Sequencing	 &	 Services	 (MRC	PPU	MSI/WTB/JBC	 Complex,	 College	 of	 Life	 Sciences,	 University	 of	 Dundee,	Dundee,	Scotland,	DD1	5EH,	UK).	
	
2.7.3		 TOPO	cloning	Gel-purified	 DNA	 fragments	 were	 subcloned	 into	 pCR4®Blunt-TOPO	 vector	using	TOPO	technology	(Invitrogen).	A	typical	TOPO	ligation	mixture	is	detailed	in	Table	2.5.	The	reaction	was	 left	at	 room	temperature	 (RT)	 for	15	mins	and	then	put	on	ice	just	before	bacterial	transformation	(secton	2.7.4).	
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Table	2.5	TOPO-cloning	reaction	mixture.		
Reagent	 Volume	pCR4®Blunt-TOPO	vector	(10	ng/µl)	 1	µl	Salt	solution	(200	mM	NaCl,	10	mM	MgCl2)	 1	µl	Extracted	PCR	product	(~10	ng)	 4	µl	Total	 6	µl	
		
2.7.4	 	 	 Bacterial	transformation	50	 µl	 of	 TOP10	 chemically	 competent	E.	 coli	 cells	 (#C4040,	 Invitrogen)	 were	thawed	on	 ice	 and	briefly	 spun	down	 to	 collect	 the	 cells	 at	 the	 bottom	of	 the	tube.	6	µl	of	TOPO	ligation	reaction	(section	2.7.3)	was	added	to	the	cells,	which	were	then	left	on	ice	for	20	mins.	To	transform	the	cells,	the	bacteria	were	heat-shocked	at	42˚C	 for	60	sec	and	 then	 left	on	 ice	 for	about	2	minutes.	200	µl	of	Lysogeny	 broth	 (LB)	 (1%	 (w/v)	 tryptone,	 0.5%	 (w/v)	 yeast	 extract,	 170	mM	NaCl)	was	added	to	the	cells,	which	were	then	incubated	at	37˚C	for	50-60	mins	in	a	thermoshaker	at	180	rpm.	After	incubation,	the	cell	suspension	was	spread	onto	 LB/agar	 plates	 with	 appropriate	 antibiotic	 (100	 µg/ml	 Ampicillin	 or	 50	µg/ml	Kanamycin),	which	were	left	to	dry	for	about	10	mins	and	then	inverted	and	incubated	at	37˚C	overnight.	





2.7.5	 	 	 Glycerol	stock	To	make	glycerol	stocks,	800	µl	of	overnight	bacterial	culture,	which	was	grown	from	a	single	bacterial	colony,	was	gently	mixed	with	200	µl	of	sterile	glycerol	and	left	on	ice	for	30mins.	Glycerol	stocks	were	then	stored	at	-80˚C.	
	
2.7.6	 	 	 Plasmid	preparation	(miniprep)	5	ml	 of	 overnight	 LB	 culture	 from	 a	 single	 bacterial	 colony	was	 pelleted	 and	used	 for	 plasmid	 preparation	 using	 QIAprep	 Spin	 Miniprep	 Kit	 (#27104,	QIAGEN)	 and	 a	 microcentrifuge	 according	 to	 manufacturer’s	 instructions.	Briefly,	the	bacterial	pellet	was	resuspended	in	250	µl	Buffer	P1	and	mixed	first	with	250	µl	Buffer	P2	and	then	with	350	µl	Buffer	N3	in	a	microcentrifuge	tube.	The	sample	was	centrifuged	for	10	min	at	17,900	x	g	and	the	supernatant	was	transferred	onto	QIAprep	spin	column	and	centrifuged	for	1	min	to	bind	DNA.	The	column	was	washed	with	0.75	ml	Buffer	PE	and	the	purified	plasmid	DNA	was	eluted	in	a	final	volume	of	40	µl	of	Elution	Buffer	(10	mM	Tris-Cl,	pH	8.5).	DNA	 concentration	 was	 checked	 using	 a	 NanoDrop,	 as	 described	 in	 section	2.7.2.	
	














2.7.8		 	 	 RNA	extraction	and	purification	Total	 RNA	 was	 extracted	 from	 tissues	 or	 cell	 lysates	 using	 an	 RNA/Protein	Purification	Kit	in	a	96-well	format	(#37900,	Norgen;	Geneflow	code:	P4-0085,	cat	 #582782)	 or	 columns	 (#23000,	 Norgen;	 Geneflow	 lot	 no	 #581790),	 by	 a	centrifugation	procedure	according	to	the	manufacturer’s	instructions.	In	short,	the	protocol	was	as	 follows:	600	µl	of	 tissue	 lysate	(section	2.6.2)	or	350	µl	of	cultured	cell	lysate	was	combined	with	an	equal	volume	of	70%	ethanol	or	with	150	µl	of	isopropanol	(#I9516),	respectively,	and	vortexed	for	10	seconds.	Next,	this	mix	was	applied	onto	 the	 column,	600	µl	 at	 a	 time,	 and	 centrifuged	 for	1	min	at	14,000	x	g.	The	flow-through	was	retained	for	protein	extraction.	400	µl	of	 Nucleic	 Acid	Wash	 Solution	was	 applied	 per	 column	 and	 centrifuged	 for	 1	
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min.	 To	 eliminate	 genomic	 DNA	 contamination,	 100	 µl	 of	 Enzyme	 Incubation	Buffer	(40	mM	Tris-HCl,	pH	8.0,	10	mM	MgSO4,	1	mM	CaCl2)	mix	containing	25	U	of	 DNase	 I	 (RQ1	 RNase-Free	 DNase	 #M6101,	 Promega)	 was	 added	 to	 the	column	and	centrifuged	for	1	min.	To	ensure	maximum	DNA	removal	and	RNA	yield,	the	flow	through	was	re-applied	to	the	column	and	incubated	at	RT	for	15	mins	before	washing	the	column	with	400	µl	of	Nucleic	Acid	Wash	Solution	and	drying	 for	 2	mins	 at	 14,000	 x	 g.	 	 The	 column	was	 placed	 into	 a	 fresh	 1.7	ml	elution	 tube	 and	 RNA	 was	 eluted	 by	 adding	 50	 µl	 of	 Nucleic	 Acid	 Elution	Solution	and	centrifuging	for	2	mins	at	200	x	g,	followed	by	1	min	at	14,000	x	g.	The	columns	were	retained	for	the	protein	purification	step	(section	2.8.2)	and	eluted	RNA	was	stored	at	-80˚C.		
For	the	96-well	format,	300	µl	of	tissue	lysate	(section	2.6.2)	was	combined	with	120	 µl	 of	 isopropanol,	 mixed	 and	 applied	 onto	 the	 well.	 The	 plate	 was	centrifuged	 for	 2	 mins	 at	 3,000	 x	 g	 and	 the	 flow	 through	 was	 retained	 for	protein	 purification	 (section	 2.8.2).	 400	 µl	 of	Nucleic	Acid	Wash	 Solution	was	applied	per	well	and	centrifuged	for	2	mins.	75	µl	of	RQ1	DNase	Reaction	Buffer	mix	containing	18.75	U	of	DNase	 I	was	added	per	well,	centrifuged	 for	30	sec,	pipetted	back	onto	the	wells	and	incubated	for	15	mins.	The	wells	were	washed	twice	with	400	µl	of	Nucleic	Acid	Wash	Solution	and	dried	for	5	mins	at	3,000	x	g.	 	The	96-well	filter	plate	was	placed	on	top	of	the	Elution	Plate	and	RNA	was	eluted	by	adding	75	µl	 of	Nucleic	Acid	Elution	Solution	and	 centrifuging	 for	2	mins.	at	3,000	x	g.	The	96-well	filter	plate	was	retained	for	protein	purification	and	RNA	was	stored	at	-80˚C.	
RNA	 integrity	 was	 assessed	 by	 running	 agarose	 gel	 electrophoresis	 (section	2.7.1).	 The	presence	of	 two	distinct	 bands	of	 28S	 and	18S	 rRNA	 subunits	 and	lack	 of	 smears	 indicated	 intact	 RNA.	 RNA	 concentration	 was	 determined	 by	measuring	 absorbance	 at	 260nm	 using	 a	 NonaDrop,	 as	 described	 for	 DNA	 in	section	2.7.2.	In	addition,	RNA	quality	was	determined	from	the	260nm/280nm	and	and	260nm/280nm	ratios,	which	respectively	indicate	protein	or	chemical	contamination.	
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2.7.9	 	 	 Reverse	transcription	(RT)	Extracted	mRNA	was	reverse	transcribed.	Either	0.5	µg	or	1	µg	of	RNA	was	used	as	 a	 template	 for	 cDNA	 synthesis	 and	 in	 a	 parallel	 “-RT”	 control	 reaction,	 to	which	 no	 reverse	 transcriptase	 enzyme	 was	 added.	 The	 volume	 of	 RNA	 was	adjusted	 to	 10	 µl	with	 nuclease-free	water	 (#W4502)	 and	 1	 µl	 of	 Oligo(dT)15	Primer	 (500	 µg/ml,	 #C1101,	 Promega)	 was	 added,	 which	 hybridises	 to	 the	poly(A)	tail	of	mRNA.	The	reaction	mixture	was	incubated	at	70˚C	for	5	minutes,	then	snap-cooled	on	ice	and	8	µl	of	the	RT	buffer	mixture	(Table	2.8)	was	added.	The	 reactions	were	 incubated	 at	 37˚C	whilst	 adding	 1	 µl	 of	M-MuLV	 Reverse	Transcriptase	 (200U,	 #EPO451,	 Thermo	 Fisher	 Scientific).	 No	 reverse	transcriptase	 was	 added	 to	 the	 negative	 “-RT”	 tubes.	 All	 reactions	 were	incubated	at	42˚C	for	1	hour	and	then	at	70˚C	for	10	mins	to	heat	inactivate	the	reverse	 transcriptase.	 cDNA	and	 “-RT”	 samples	were	 snap-cooled	 on	 ice	 for	 5	mins,	diluted	5	x	with	80	µl	of	nuclease-free	water	to	the	final	volume	of	100	µl	and	stored	at	-20˚C.	
	
Table	2.8	Reverse	transcription	buffer	mixture.	
	 5	x	Reverse	Transcription	Buffer	(MBI-Fermentas)		 4	µl	PCR	Nucleotide	Mix,	10mM	(#C1145,	Promega)	 2	µl	RNasin(R)	Plus	RNase	Inhibitor	(#N2615,	Promega)	 0.5	µl	Nuclease-free	deionised	water	 1.5	µl	Total	volume	 8	µl					
















































Reaction	(qRT-PCR)	Real	 time	 qRT-PCR	 (Higuchi	 et	 al.,	 1992)	 was	 used	 to	 measure	 the	 absolute	levels	of	Ras	isoform	transcripts	in	RNA	extracted	from	mouse	embryonic	stem	cells	and	mouse	tissues.	First,	cDNA	(section	2.7.1)	was	diluted	1:4	in	nuclease-free	 water,	 from	 which	 4	 µl	 was	 used	 in	 10	 µl	 reaction	 in	 96-well	 plates	(#HSS9601,	 Bio-Rad).	 The	 protocol	 was	 based	 on	 the	 manufacturer’s	instructions	 for	 the	 SYBR®	Green	qPCR	kit	 (Bio-Rad),	 and	 is	 detailed	 in	Table	2.15.	The	PCR	primers	were	designed	in-house	(as	described	in	Chapter	3),	and	are	listed	in	Table	2.8.		
	
Table	2.15	qRT-PCR	reaction	mixture.	













Initial	denaturation	 1	 95˚C	 3	mins	Denaturation	 40	 94˚C	 30	sec.	Annealing	 62˚C	 30	sec.	Extension	 72˚C	 30	sec.	Melting	curve	 41	 55˚C	to	95˚C	 30	sec.	for	every	0.5	˚C		
	
Fluorescence	 was	 measured	 in	 real	 time	 after	 each	 extension	 step	 of	 the	 40	cycles.	To	be	able	to	compare	between	different	qPCR	plates,	cDNA	synthesised	from	 RNA	 of	 undifferentiated	 R1	 mESCs	 was	 used	 as	 an	 on-plate	 internal	control.	 Standard	 curves	 based	 on	 a	 5-fold	 dilution	 series	 of	 linearised	 Ras	isoform-specific	 plasmids	 (section	 2.7.7)	 were	 used	 to	 calculate	 the	 absolute	transcript	copy	numbers	 in	 the	mRNA	of	 interest.	An	example	of	 the	standard	curve	concentrations	and	corresponding	copy	numbers	for	the	KRasB	plasmid	is	shown	in	Table	2.17.	Each	sample	was	analysed	in	duplicate	or	triplicate	(as	on-plate	technical	repeats).	To	calculate	statistical	significance,	at	least	3	biological	replicates	experiments	were	analysed.		
As	a	standard	quality	control	measure,	melt	curves	(run	after	qRT-PCR	protocol	in	0.5˚C	 increments)	were	assessed	for	evidence	of	primer-dimer	formation	or	non-specific	 amplicons.	 Furthermore,	 to	 control	 for	 non-specific	 PCR	 product	formation	(e.g.	from	genomic	DNA),	negative	“-RT”	controls	(section	2.7.9)	and	water	blanks	were	run	alongside	qPCR	reactions	with	cDNA.	
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2.8.1	 	 Cell	lysis	and	harvesting	After	drug	treatment	and/or	stimulation	SW48	cells	were	placed	on	a	metal	tray	on	ice	and	washed	3	times	with	ice-cold	1	x	PBS.	Depending	on	the	dish	size,	an	appropriate	 amount	 of	 RIPA	 buffer	 containing	mammalian	 Protease	 Inhibitor	Cocktail	and	1	PhosStop	Phosphatase	Inhibitor	Cocktail	tablet	(#04906837001,	Roche)	was	added	on	 the	cells	 (for	amount	of	 lysis	buffer	used	per	dish	–	 see	Table	2.2).	Cells	were	lysed	for	30	mins	on	ice	with	gentle	shaking.	Cell	lysis	was	assessed	under	a	microscope	(Invertoscope	ID	03,	Zeiss)	with	phase–contrast	to	determine	 the	 extent	 of	 cell	 membrane	 disruption	 and	 cellular	 debris.	 The	lysates	 were	 then	 transferred	 to	 Eppendorf	 microcentrifuge	 tubes	 and	centrifuged	at	18,000	x	g	for	15	mins	at	4˚C.	The	supernatants	were	transferred	to	fresh	eppendorf	tubes	and	vortexed	before	measuring	protein	concentration	using	the	BCA	assay	(section	2.8.3)	and	storage	at	-20	˚C.	
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2.8.2		 	 	 Protein	purification		To	 extract	protein	 from	mouse	 tissues	or	 cell	 lines,	 the	 flow-through	 retained	from	the	Norgen	RNA	extraction	step	(section	2.7.8)	was	processed	according	to	the	manufacturer’s	 instructions	 for	 RNA/Protein	 Purification	 Kit	 in	 a	 96-well	plate	format	(#37900,	Norgen;	Geneflow	code:	P4-0085,	cat	#582782)	or	using	spin	 columns	 (#23000,	 Norgen;	 Geneflow	 lot	 no	 #581790).	 When	 using	columns,	 up	 to	100	µl	 of	 flow-through	was	 adjusted	 to	575	µl	with	Molecular	Biology	Grade	Water	(#W4502)	and	24	µl	of	pH	Binding	Buffer	was	added	and	mixed.		600	µl	of	the	pH-adjusted	protein	sample	was	applied	at	a	time	onto	the	column	and	centrifuged	for	2	mins	at	5,200	x	g.	The	column	was	washed	with	500	µl	of	Protein	Wash	Buffer	by	centrifuging	for	2	mins	at	5,200	x	g.	Then	9.3	µl	of	Neutralizer	(containing	45	mM	citric	acid	and	45	mM	phosphoric	acid)	was	added	to	a	fresh	1.7	ml	elution	tube	and	protein	was	eluted	in	100	µl	of	Protein	Elution	Buffer	(10	mM	sodium	phosphate,	pH	12.5)	by	centrifuging	for	2	mins	at	5,200	x	g.	Purified	protein	samples	were	stored	at	-80˚C.	
For	 the	 96-well	 format,	 100	 µl	 of	 flow	 through	 was	 adjusted	 to	 400	 µl	 with	Molecular	Biology	Grade	Water	and	16	µl	of	pH	Binding	Buffer	was	added	and	mixed.	The	pH-adjusted	protein	samples	were	applied	into	the	wells	of	the	96-Well	Filter	Plate	and	centrifuged	for	2	mins	at	3,000	x	g.	The	plate	was	washed	with	400	µl	of	Protein	Wash	Buffer	by	centrifuging	for	2	mins	at	3,000	x	g.	Then	9.3	µl	of	Neutralizer	was	added	per	well	 into	a	new	96-Well	Elution	Plate	and	protein	was	eluted	in	100	µl	of	Protein	Elution	Buffer	by	centrifuging	for	2	mins	at	3,000	x	g.			
	








Table	 2.18	Recipes	 for	 10%	 resolving	 and	 4%	 stacking	 gel	 solutions	 for	




Stacking	gel	ProtoGel	 3.35	ml	 0.65	ml	Resolving/Stacking	buffer	 2.6	ml	 1.25	ml	Deionised	water	 3.95	ml	 3.05	ml	10%	APS	 75	µl	 25	µl	TEMED	 7.5	µl	 5	µl	Total	 10	ml	 5	ml			
	
2.8.5	 	 Western	Blotting			Following	 SDS-PAGE,	 the	 gel	 was	 removed	 from	 plates,	 trimmed	 and	 briefly	rinsed	 in	 transfer	buffer	 (25	mM	Tris,	 192	mM	glycine,	20%	(v/v)	methanol).	Next,	the	gel	was	transferred	into	a	Genie	blotter	tank,	which	was	assembled	in	the	 following	 order:	 2	 grids	 ridged	 side	 up,	 cathode	 plate,	 1	 grid	 ridged	 side	down,	 pad,	 Whatman	 paper,	 gel,	 nitrocellulose	 membrane	 (#10600001,	 GE	Healthcare	 Life	 Sciences,	 Amersham	 Protran,	 0.2	 µm	 pore	 size),	 Whatman	paper,	pads	up	to	top	(3-4),	grid	ridged	side	up,	anode	plate,	plastic	cover.	The	pads,	 paper	 and	membrane	were	 previously	 immersed	 in	 transfer	 buffer	 and	care	was	 taken	 to	 remove	 all	 bubbles	 as	 transfer	 buffer	was	 poured	 into	 the	assembly.	 The	 container	 was	 then	 put	 into	 Genie	 blotter	 tank	 and	 the	 whole	assembly	 was	 run	 for	 1	 hour	 at	 constant	 current	 of	 0.5	 A	 (around	 30	 V)	(Burnette,	1981).			
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Manufacturer	(code)	 Dilution	Donkey	anti-mouse	IRDye	800CW	 LICOR	Biosciences	(926-32212)	 1/15000	Donkey	anti-mouse	IRDye	680CW	 LICOR	Biosciences	(926-32222)	 1/15000	Donkey	anti-rabbit	IRDye	800CW	 LICOR	Biosciences	(926-32213)	 1/15000	Donkey	anti-goat	IRDye	800CW	 LICOR	Biosciences	(926-32214)	 1/15000				
2.9	 	 Proteomics		
2.9.1	 	 Ras	standards		The	 Ras	 standards	 were	 kindly	 provided	 by	 Dr	 Craig	 Mageean	 (Prior	Laboratory,	 University	 of	 Liverpool,	 UK)	 (Mageean	 et	 al.,	 2015).	 In	 brief,	 the	standards	were	27kDa,	his-tagged,	full-length	Ras	proteins,	labelled	with	Arg10	and	Lys8	and	grown	in	auxotrophic	AT713	E.	coli	bacteria	that	do	not	generate	their	own	arginine	or	lysine	(obtained	from	The	Coli	Genetic	Stock	Center,	Yale).	The	 standards	were	 purified	 through	 his-tag	 pull	 down	 using	 a	metal-affinity	column	 and	 then	 gel	 filtration	 through	 Superdex	 200(GE	 Healthcare).	 The	standards	were	over	98%	 labelled	with	heavy	 isotopes	of	 arginine	and	 lysine.	To	measure	the	concentration	of	the	standards,	a	known	quantity	of	light	KRasB	reference	protein	was	used	in	a	mix	with	heavy	labelled	Ras	proteins.	The	light	KRasB	protein	was	accurately	quantified	using	BCA	assay,	as	well	as	Nanodrop	1000,	using	an	absorbance	at	280	nm	(Mageean	et	al.,	2015).	For	quality	control,	standards	were	run	on	a	12-4%	Bis-Tris	NuPAGE	gel	and	stained	using	Colloidal	Blue	 Staining	 Kit	 (#LC6025,	 Invitrogen)	 according	 to	 manufacturer’s	instructions,	which	showed	minimal	contamination	with	non-specific	proteins.	
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	The	 standards	were	 stored	 in	 standard	 buffer	 (20mM	Tris	 (pH	 7.4),	 150	mM	NaCl,	2mM	DTT,	5mM	MgCl2)	 in	1.5	ml	Protein	LoBind	tubes	(#0030	108.116,	Eppendorf)	that	were	pre-treated	with	2%	BSA	for	2	hours	at	RT,	before	all	the	BSA	was	removed	and	any	remaining	liquid	was	allowed	to	evaporate	in	a	tissue	culture	hood	for	over	3	hours.	All	dilutions	of	the	standards	were	performed	in	standard	buffer	plus	0.1%	BSA.	Stock	 solutions	were	 stored	at	 -80˚C	and	 final	standard	 concentrations	 were	 freshly	 prepared	 for	 use	 in	 quantitative	proteomics	experiments.	The	standards	were	always	thawed	on	ice	and	flicked	gently	to	mix.	They	were	stored	at	-80˚C	and	flash-frozen	in	liquid	nitrogen	after	use	 (up	 to	 3	 times).	 10	 ng	 of	 KRas-4B	 and	 5	 ng	 of	 each	 H-Ras	 and	 N-Ras	standards	were	used	per	50	µg	of	protein	lysate.		
	
	
2.9.2	 	 In-gel	digest	protocol		The	 Ras-specific	 in-gel	 digest	 protocol	 was	 optimised	 by	 Dr	 Craig	 Mageean	(Prior	 Laboratory,	 University	 of	 Liverpool,	 UK).	 In	 brief,	 45-50	 µg	 of	 protein	lysates	 in	 Laemmli	 sample	 buffer	 (section	 2.8.4)	 were	 spiked	 with	 Ras	standards	and	run	on	10-well,	1.5mm,	12-4%	Bis-Tris	NuPAGE	gel	 in	1	x	MES	buffer	 at	 50V	 for	 10	 mins	 and	 then	 at	 150V	 until	 the	 samples	 had	 migrated	halfway	down	the	gel.	The	gel	was	 fixed	 in	10%	acetic	acid,	40%	HPLC	water,	50%	HPLC	methanol	 for	15	mins	using	gentle	shaking	and	 then	washed	 twice	with	HPLC	grade	water	(#	97063-722,	VWR	Chemicals).			The	 gel	 was	 transferred	 to	 a	 laminar	 flow	 cabinet	 and	 placed	 in	 non-tissue	culture	 treated	15	 cm	polystyrene	Petri	 dish	 (#P5981-100EA).	 The	 gel	 pieces	were	excised	between	the	31	kDa	and	17	kDa	markers.	The	gel	pieces	were	then	diced	 into	 cubes	 1	 mm	 in	 diameter,	 carefully	 transferred	 to	 1.5	 ml	 LoBind	Eppendorf	tubes	in	their	entirety	and	then	briefly	centrifuged	for	15	sec.		150	µl	of	50	mM	ammonium	bicarbonate/	50%	(w/w)	acetonitrile	was	added	to	the	gel	pieces	and	incubated	at	37°C	for	15	mins	in	a	thermoshaker	at	900	rpm.	
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2.9.3	 	 Mass	spectrometry		The	 protein	 pellets	 were	 re-suspended	 with	 25	 µl	 0.1%	 trifluoroacetic	 acid	(TFA),	vortexed	thoroughly	and	centrifuged	at	18,000	x	g	for	15	mins	at	4	˚C	in	a	bench-top	centrifuge.	25	µl	was	transferred	into	a	glass	vial	and	5	µl	was	loaded	onto	 the	 5500	 QTRAP	 (AB	 SCIEX)	 to	 measure	 diagnostic	 peptides	 and	transitions	 (Mageean,	 2014)	 in	 Pharmacology	 Mass	 Spectrometry	 Facility,	University	of	Liverpool	(measured	by	Dr	Rosalind	Jenkins).	
	
	







3.1	 	 	 Introduction	This	chapter	describes	the	design,	optimisation	and	performance	of	quantitative	reverse	 transcription-polymerase	 chain	 reaction	 (qRT-PCR)	 assays	 used	 to	investigate	the	abundance	of	Ras	isoforms	at	transcripts	by	SYBR®	Green	assays	in	mouse	embryonic	stem	cell	line	and	in	mouse	tissues.	As	described	in	detail	below,	 many	 variables	 must	 be	 taken	 into	 account	 to	 design	 specific	 and	sensitive	assays.	
PCR	primers	were	individually	designed	that	were	specific	for	each	Ras	isoform	using	 the	 BLAST	 online	 tool	 (Altschul	 et	 al.,	 1990,	 Ye	 et	 al.,	 2012)	 and	 Net	primer	software	(PREMIER	Biosoft	International).	As	different	assays	would	be	run	on	the	same	plates,	a	common	optimal	annealing	temperature	was	chosen.	The	 primers	were	 then	 tested	 for	 specificity	 between	 Ras	 isoforms	 and	 their	efficiency	in	product	amplification.	The	Ras	primers	described	in	this	thesis	met	all	 the	 criteria	 for	 primer	 design	 and	 RT-PCR	 reaction	 optimisation	 (Bio-Rad	Laboratories,	2006,	Degen	et	al.,	2006).		
Different	 quantification	 methods	 were	 also	 evaluated.	 Plasmids	 encoding	 the	Ras	 isoforms	 were	 subcloned	 and	 linearised	 to	 generate	 standard	 curves	 for	absolute	quantification	of	Ras	transcripts	in	qRT-PCR	reactions.	In	addition,	the	use	of	a	reference	transcript	that	might	be	applicable	across	tissues	and	through	development	was	considered	for	relative	quantification.	
	
3.1.1	 qRT-PCR	 as	 a	 method	 for	 accurate	 quantification	 of	
transcript	abundance	In	 qRT-PCR	 the	 amount	 of	 amplified	 product	 is	measured	 in	 real	 time	 as	 the	reaction	 proceeds	 (Higuchi	 et	 al.,	 1992,	 VanGuilder	 et	 al.,	 2008).	 qRT-PCR	requires	 a	 set	 of	 target-specific	 primers,	 a	 template	 DNA,	 a	 heat-stable	 Taq	
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polymerase	(Chien	et	al.,	1976,	Saiki	et	al.,	1988,	Eckert	and	Kunkel,	1990)	and	a	fluorescent	dye	to	monitor	the	product	accumulation	(Kubista	et	al.,	2006).	qRT-PCR	 has	 many	 advantages	 over	 other	 nucleic	 acid	 quantitative	 techniques,	including	 wide	 dynamic	 range,	 high	 accuracy	 and	 cost	 effectiveness	 of	 the	detection	 of	 defined	 sets	 of	 transcripts	 (Schmittgen	 et	 al.,	 2000,	 Heid	 et	 al.,	1996).	A	variety	of	qRT-PCR	strategies	are	available,	including	the	use	of	FRET	probes	 such	as	Taqman,	or	 sequence-independent	 intercalators,	 such	as	 SYBR	green	(Kubista	et	al.,	2006,	McPherson	and	Møller,	2006).	
A	 common	 feature	 of	 qRT-PCR	 assay	 is	 that	 accumulation	 of	 the	PCR	product	with	 each	 PCR	 cycle	 is	 directly	 proportional	 to	 detection	 of	 a	 fluorescent	 dye	(Nolan	 et	 al.,	 2006,	 VanGuilder	 et	 al.,	 2008).	 These	 raw	 data	 are	 used	 to	determine	the	cycle	threshold	(CT)	value	for	each	reaction,	that	is	the	number	of	cycles	required	to	achieve	a	defined	fluorescence	signal	above	noise.	Thresholds	are	 set	 in	 the	 exponential	 phase	 of	 the	 PCR	 reaction,	 where	 product	 doubles	with	 each	 cycle,	 so	 there	 is	 linear	 relationship	 between	 the	 CT	 value	 and	 the	logarithm	(base	2)	of	the	initial	amount	of	template	(Higuchi	et	al.,	1993).		
In	 this	 study,	 qRT-PCR	was	 based	 on	 SYBR®	 Green	 I	 (Ponchel	 et	 al.,	 2003),	 a	fluorescent	dye	that	binds	to	the	double-stranded	DNA	(dsDNA)	(Vitzthum	et	al.,	1999,	Morrison	et	al.,	1998,	Bengtsson	et	al.,	2003).	Interaction	of	SYBR	Green	I	with	single-stranded	DNA	(ssDNA)	is	about	11-fold	weaker	than	intercalation	to	dsDNA	(Zipper	et	al.,	2004),	which	enhances	its	fluorescence	more	than	1,000-fold	 (Dragan	 et	 al.,	 2012).	 This	 fluorescence	 is	 recorded	 by	 qRT-PCR	thermocyclers	 after	 each	 cycle	 as	 the	 when	 double-stranded	 amplicons	 are	generated.	Overall,	SYBR	Green	I	is	a	very	good	DNA	intercalating	dye,	which	is	routinely	used	in	RT-PCR	experiments,	due	to	its	thermal	stability	and	ability	to	detect	any	dsDNA	sequence.	Because	of	this,	however,	 there	are	some	caveats.	SYBR	 Green	 I	 binds	 to	 non-specific	 amplification	 products	 and	 to	 primer-dimers,	 which	 can	 lead	 to	 false	 positive	 signals	 in	 non-optimal	 qRT-PCR	reactions	(McPherson	and	Møller,	2006).		For	 this	 reason,	 qPCR	 instruments	 can	 characterise	 the	 final	 PCR	 reaction	components	 by	melt	 curve	 analysis	 (Ririe	 et	 al.,	 1997,	Wilhelm	 and	 Pingoud,	
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2003).	The	DNA	is	slowly	denatured,	by	incremental	temperature	increases	and	the	loss	of	fluorescence	signal	is	monitored.	When	the	temperature	reaches	the	melting	 temperature	(Tm)	of	an	amplicon,	 the	 fluorescence	decreases	abruptly	as	 the	 dsDNA	 melts	 (Nygren	 et	 al.,	 1998,	 Kubista	 et	 al.,	 2006).	 This	 shift	 in	fluorescence	can	be	plotted	as	a	peak	on	a	negative	derivative	melt	curve	graph.	As	 specific	 and	 non-specific	 amplicons	 such	 as	 primer-dimers	 have		distinct	 Tm	 they	 are	 easily	 distinguished	 as	 separate	 peaks	 on	 melt	 curves.		
	
3.1.2	 Considerations	 for	 the	 design	 and	 optimisation		
of	qRT-PCR		The	design	of	Ras	isoform-specific	primers	and	optimisation	of	qRT-PCR	assays	were	 based	 on	 generally	 accepted	 guidelines	 described	 in	 the	 Bio-Rad	 Real-Time	 PCR	 Applications	 Guide	 (Bio-Rad	 Laboratories,	 2006),	 Roche	 PCR	Applications	 Manual	 (Degen	 et	 al.,	 2006),	 PREMIER	 Biosoft	(http://www.premierbiosoft.com)	and	key	reviews	(Kubista	et	al.,	2006,	Bustin,	2000,	Lutfalla	and	Uze,	2006,	McPherson	and	Møller,	2006,	Kramer	and	Coen,	2006).		
3.1.2.1	 	 						Primer	design	The	efficiency	of	the	amplification	reaction	depends	on	the	amplicon	size,	which	should	 be	 between	 75	 to	 200	 base	 pairs	 (bp).	 Longer	 amplicons	 lead	 to	 less	efficient	reactions	and	potentially	saturating	fluorescence	signal.	However,	very	short	 amplicons	 may	 not	 be	 distinguishable	 from	 primer-dimers.	 It	 is	 also	important	to	consider	the	properties	of	primer	pairs	(Williams,	1989,	Wu	et	al.,	1991).	The	length	of	primer	pairs	should	be	similar	and	within	the	range	of	18-30	bases,	which	 is	sufficient	 for	 target	specificity,	even	within	complex	human	genomic	 DNA.	 Primers	 that	 are	 too	 short	 may	 bind	 non-specifically,	 whereas	longer	primers	can	reduce	PCR	efficiency	 through	slow	hybridisation	rate	and	hence	decrease	the	yield.		The	balance	of	nucleotides	within	a	primer	is	also	important.	For	a	given	primer	pair,	the	Tm	should	be	similar	and	allow	annealing	to	the	template	at	55	to	65˚C.	The	 Tm	 is	 defined	 as	 the	 temperature	 at	 which	 50%	 of	 the	 primer-template	duplexes	melts	and	becomes	single-stranded.	The	Tm	reflects	the	stability	of	the	
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primer-template	 complex	 and	 is	 dependent	 on	 the	 percentage	 of	 G	 and	 C	nucleotides	(GC%).	As	G-C	hydrogen	bonding	provides	higher	stability	than	A-T	bonding,	it	contributes	to	a	higher	Tm	(Wu	et	al.,	1991).	Ideally,	the	overall	%GC	for	each	primer	should	be	40-60%.	Primer	should	also	be	designed	with	a	G	or	C	at	the	3’	end,	referred	to	as	a	GC	clamp,	to	aid	in	the	correct	priming	from	the	template.	However,	GC	runs	exceeding	three	bases	should	be	avoided	at	the	3’	end,	 as	 this	 can	 lead	 to	 mispriming	 of	 GC-rich	 regions	 and	 can	 contribute	 to	primer-dimer	formation.	Long	GC	runs	can	also	lead	to	non-Watson-Crick	base	pairing	within	a	primer,	which	can	impede	primer-template	binding	or	result	in	mispriming.	 Di-nucleotide	 repeats	 should	 also	 be	 avoided,	 as	 repeats	 of	more	than	four	(e.g.	TATATATA),	can	also	cause	mispriming.		Primer	 design	 should	 avoid	 sequences	 that	 may	 form	 stable	 secondary	structures,	 as	 these	 hinder	 primer	 annealing	 to	 the	 template	 and	 lead	 to	 low	product	 yield	 (Wang	 and	 Seed,	 2003,	 Hoebeeck	 et	 al.,	 2005).	 Intramolecular	hybridisation	occurs	due	to	 internal	complementarity	within	a	primer	and	can	lead	to	stable	formation	of	a	hairpin.	Predicted	3’	end	hairpins	with	Gibbs	free	energy	G	(ΔG)	of	 -2	kcal/mol	and	 internal	hairpins	with	ΔG	of	 -3	kcal/mol	are	generally	acceptable.		Secondary	structure	can	also	arise	from	intermolecular	interactions	that	lead	to	the	 formation	 of	 primer-dimers:	 either	 homo-dimers	 due	 to	 self-complementarity,	or	hetero-	dimers	that	can	form	by	complementarity	between	forward	and	reverse	primers.	3’	end	primer-dimers	with	ΔG	=	-5	kcal/mol	and	internal	primer-dimers	with	ΔG	=	 -6	kcal/mol	are	generally	accepted.	Primer-dimer	 formation	often	 leads	 to	misquantification	 in	qRT-PCR	experiments	and	therefore	any	base-pairing	at	the	3’	ends	of	primer	sequences	should	be	avoided	(Wang	 and	 Seed,	 2003).	 Primer-dimer	 formation	 can	 be	 monitored	 by	 melt	curve	analysis	as	described	in	section	3.1.1.		
3.1.2.2	 	 						Annealing	temperature	
	The	annealing	temperature	(Ta)	used	during	the	PCR	reaction	is	critical	for	the	specificity	 and	 efficiency,	 as	 primer-template	 hybridisation	 is	 temperature-
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dependent	(Williams,	1989,	Rychlik	et	al.,	1990).	If	the	Ta	is	too	high,	this	causes	dissociation	 of	 the	 template	 and	 the	 primers,	 leading	 to	 reduced	 yield	 of	 PCR	product	 (Don	et	 al.,	 1991).	On	 the	other	hand,	 if	 the	Ta	 is	 too	 low,	 this	 allows	partial	hybridisation	decreasing	the	specificity	of	priming.	Therefore,	an	optimal	Ta	should	yield	minimal	amount	of	non-specific	PCR	products	and	maximise	the	correct	amplicon.			For	 optimal	 stringency,	 the	 Ta	 should	 be	 within	 5°C	 of	 the	 Tm	 of	 primers	(Rychlik	et	al.,	1990).	Sufficient	annealing	of	the	primers	to	the	template	already	occurs	at	the	primer	Tm	(von	Ahsen	et	al.,	2001),	but	the	maximum	specificity	of	the	 PCR	 assay	 is	 achieved	 using	 the	 highest	 Ta,	 at	 which	 amplification	 of	 the	correct	 PCR	 product	 still	 occurs	 (Wu	 et	 al.,	 1991).	 Although	 theoretical	calculation	 of	 optimal	 Ta	 is	 possible	 (Rychlik	 et	 al.,	 1990),	 each	 primer	 pair	should	be	tested	empirically	using	a	range	of	Ta	to	optimise	product	specificity	and	reaction	efficiency	.			
3.1.2.3		 	 Primer	efficiency	
	The	final	aspect	to	consider	in	PCR	optimisation	is	the	reaction	efficiency	for	a	given	primer	set.	During	the	exponential	phase	of	amplification,	the	reaction	is	100%	efficient	if	the	amount	of	the	amplicon	doubles	every	cycle	(Higuchi	et	al.,	1993).	 However,	 reaction	 efficiency	 is	 often	 limited	 by	 a	 number	 of	 factors,	including	 primer	 secondary	 structures,	 self-complementarity	 of	 the	 DNA	template	sequences	(Wang	and	Seed,	2003)	and	non-optimal	Ta	(Rychlik	et	al.,	1990,	Chou	et	al.,	1992).	Therefore,	it	is	important	to	empirically	determine	the	reaction	efficiency	for	each	primer	pair.	The	equation	Q	=	q02n	denotes	how	the	amount	of	PCR	product	Q	 correlates	 to	 the	number	of	 cycles	n	with	a	 starting	amount	of	DNA	template	q0	if	the	reaction	is	100%	efficient.	
		Typically	 serial	 dilution	 of	 a	 DNA	 template	 is	 used	 to	 determine	 reaction	efficiency.	Recorded	CT	values	are	plotted	against	 the	 logarithm	(base	dilution	factor)	 of	 starting	 quantity	 of	 the	 template	 for	 regression	 analysis.	 Accurate	calculation	of	reaction	efficiency	depends	on	the	number	of	dilution	points	and	the	 dilution	 factor	 used	 (Hellemans	 et	 al.,	 2007).	 Based	 on	 the	 previous	
	 69	
equation,	calculation	of	efficiency	of	the	reaction	E	uses	the	formula	E	=	2(m1/m2),	where	m1	denotes	the	perfect	gradient	and	m2	–	the	gradient	of	the	regression	line.	In	case	of	a	2-fold	dilution	series,	the	perfect	gradient	m1	would	be	-1	and	the	reaction	efficiency	would	be	2.	To	calculate	the	percentage	efficiency	of	the	reaction	%E,	 the	 equation	%E	 =	 (E-1)	 ·	 100%	 is	 used.	 Ideally,	%E	 should	 be	between	 90-105%,	 as	 low	 values	 indicate	 poor	 optimisation	 of	 the	 reaction	conditions	 or	 primer	 design.	 Values	 that	 are	 too	 high	 usually	 imply	 pipetting	errors	or	amplification	of	primer-dimers.			
3.1.2.4		 	 Quantification	of	qRT-PCR	In	 general,	 there	 are	 two	methods	 that	 can	be	 employed	 to	quantify	 the	qRT-PCR	 results:	 the	 absolute	 quantification	 method	 using	 a	 template	 standard	curve	and	the	relative	quantitation	using	a	reference	gene.			For	 absolute	 quantitation,	 CT	 values	 obtained	 from	 the	 qRT-PCR	 data	 are	converted	to	copy	number	using	standard	curves	generated	by	a	serial	dilution	of	the	template,	for	example	cloned	into	a	plasmid.	However,	the	CT	values	of	the	chosen	 dilutions	 must	 reflect	 the	 range	 of	 CT	 values	 obtained	 from	 the	 test	samples,	 so	 that	 any	 calculated	 data	 could	 be	 interpolated,	 not	 extrapolated,	from	the	standard	curve.	The	calculated	data	can	be	normalised	to	unit	mass,	for	example	data	may	be	expressed	as	copy	number	per	pg	of	RNA.		The	alternative	method	of	quantifying	transcripts	by	qRT-PCR	relies	on	relative	quantification.	In	essence,	this	is	a	method	of	normalising	the	expression	level	of	a	 target	gene	 to	 those	of	a	 reference	gene	 (Karge	et	al.,	1998).	 In	brief,	 the	CT	values	of	a	target	gene	are	subtracted	from	the	CT	values	of	a	reference	gene	in	each	 test	 sample,	 using	 the	 equation	 ∆CT	 (relative	 expression)	 =	 2CT(reference)	 -	CT(target)	 to	determine	the	target/reference	gene	expression	ratio.	Thus,	relative	expression	of	the	target	gene	can	be	compared	to	across	samples.	The	data	may	be	 further	 normalised	 to	 a	 calibrator,	 e.g.	 a	 control	 sample	 within	 the	experiment.			One	benefit	of	such	∆CT	method	that	normalised	expression	of	a	target	gene	to	a	reference	 gene	 is	 reduction	 of	 experimental	 noise	 arising	 from	 technical	
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variations	 between	 test	 samples,	 such	 as	 differences	 in	 input	 RNA	 amount	 or	reverse	 transcription	 efficiency	 (Karge	 et	 al.,	 1998,	 Derveaux	 et	 al.,	 2010).	However,	 choosing	 a	 reliable	 reference	 gene	 is	 crucial.	 	 First,	 the	 efficiency	of	amplification	for	the	reference	gene	and	target	gene	should	be	similar	to	ensure	that	the	∆CT	equation	is	valid	(Kozera	and	Rapacz,	2013).	Secondly,	a	reference	gene	must	be	ubiquitously	and	stably	expressed	across	all	test	samples.		
3.1.2.5		 	 Selection	 of	 reference	 genes	 for	 relative	 quantitation	 in	
qRT-PCR	
To	enable	relative	quantitation,	the	expression	levels	of	a	reference	gene	must	be	 constant	 across	 all	 test	 samples,	 regardless	 of	 developmental	 stage,	 tissue	type	 or	 treatment	 method.	 In	 some	 cases	 it	 is	 not	 possible	 to	 find	 a	 single	candidate	 gene	 that	 would	 fulfil	 these	 criteria	 (Carnahan	 et	 al.,	 2013),	 as	expression	 levels	 of	 all	 genes	 are	 tightly	 regulated	 and	 depend	 on	 different	physiological	 states	 (Kraemer	 et	 al.,	 2012).	 Hence,	 several	 reference	 genes	should	be	independently	assessed	for	any	given	experimental	context.	Although	it	is	recommend	to	normalise	qRT-PCR	data	to	more	than	one	reference	gene	to	achieve	better	accuracy	(Kozera	and	Rapacz,	2013,	Nicot	et	al.,	2005),	the	use	of	a	 single	 optimised	 reference	 gene	 might	 be	 sufficient	 (Willems	 et	 al.,	 2006,	Thellin	et	al.,	1999).		
Among	 the	 most	 commonly	 used	 reference	 genes	 in	 qRT-PCR	 are	 so-called	housekeeping	 genes.	 These	 are	 essential	 metabolic	 or	 structural	 genes,	 and	were	the	first	to	be	considered	as	reference	genes	(Thellin	et	al.,	1999,	Kozera	and	Rapacz,	 2013).	One	 example	 is	 cytoskeletal	 β–actin,	 for	which	 expression	levels	 have	 been	 shown	 to	 be	 stable	 in	 various	 samples	 under	 different	treatments	(Giulietti	et	al.,	2001).	However,	certain	conditions	can	affect	β–actin	mRNA	 levels,	 e.g.	 hypoxia	 (Suzuki	 et	 al.,	 2000).	 Another	 housekeeping	 gene,	glyceraldehyde-3-phosphate	 dehydrogenase	 (GAPDH),	 is	 also	 widely	 used	 for	normalisation	of	qRT-PCR	data	(McPherson	and	Møller,	2006).	It	 is	an	enzyme	primarily	 involved	 in	 glycolysis,	 but	 also	 in	 a	 number	 of	 non-metabolic	processes.	Although	its	expression	is	ubiquitous	and	generally	stable	across	cell	
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types,	 levels	 can	 be	 affected	 by	 certain	 treatments,	 such	 as	 programmed	neuronal	cell	death	(Suzuki	et	al.,	2000,	Ke	et	al.,	2000).		An	alternative	reference	gene	commonly	used	in	qRT-PCR	is	the	ribosomal	RNA	(rRNA)	 subunit	 18S	 (Kozera	 and	 Rapacz,	 2013).	 There	 are,	 however,	 several	pitfalls	associated	with	its	use	for	normalisation.	First,	this	iRNA	is	synthesised	by	RNA	polymerase	I,	independently	to	mRNA	synthesis	by	RNA	polymerase	II	(Radonic	et	al.,	2004).	The	18S	expression	level	is	also	much	higher	than	that	of	many	 mRNAs	 (Paolacci	 et	 al.,	 2009),	 and	 the	 rRNA:mRNA	 ratios	 can	 also	significantly	 differ	 between	 test	 samples	 (Vandesompele	 et	 al.,	 2002),	making	18S	rRNA	unsuitable	for	normalisation	of	lower	abundance	transcripts.	What	is	more,	 rRNA	 is	 more	 stable	 than	 mRNA	 (Paolacci	 et	 al.,	 2009),	 meaning	 that	normalisation	to	18S	would	not	account	for	differences	in	mRNA	degradation	in	the	 test	 samples.	 18S	 rRNA	 expression	 can	 also	 be	 affected	 by	 certain	treatments	(Nicot	et	al.,	2005).	Overall,	18S	it	is	not	a	good	representation	of	the	mRNA	population	within	a	cell	(Suzuki	et	al.,	2000).	









3.2	 	 	 Results	
3.2.1	 	 						Primer	design	
 Based	on	the	general	recommendations	for	primer	design	(section	3.1.2.1),	Ras	primers	were	designed	to	generate	amplicons	of	approximately	200	bp	that	met	the	GC	content	criteria.	The	Ras	isoform	primers,	together	with	their	properties,	are	 listed	 in	 Table	 3.1.	 Primer	 sequence	 positions	 within	 the	 Ras	 isoform	transcripts	 are	 illustrated	 in	 Fig.	 3.1	 –	 3.4,	 based	 on	 AceView	 sequence	representation	 (http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/)	(Thierry-Mieg	 and	 Thierry-Mieg,	 2006,	 Durbin	 and	 Thierry-Mieg,	 1994)	 and	BLAST	(Altschul	et	al.,	1990).		To	 avoid	 the	 detection	 and	 amplification	 of	 any	 contaminating	 genomic	 DNA,	primers	 that	 span	 exon-exon	 boundaries	 or	 flank	 introns	 were	 designed	(McPherson	and	Møller,	2006,	Degen	et	al.,	2006,	Huang	et	al.,	1996,	Wang	and	Seed,	2003).	For	the	former,	at	least	one	primer	within	each	pair	was	designed	to	 span	 an	 intron,	 so	 that	 it	 would	 partially	 hybridise	 to	 the	 first	 exon	 and	partially	 to	 the	 following	 exon.	 Hence,	 such	 primers	 would	 not	 amplify	 any	contaminating	genomic	DNA,	which	contains	the	intron.	This	method	of	primer	design	was	used	for	primer	pairs	that	specifically	amplify	KRas-4B	(Fig.	3.3)	and	NRas	 (Fig.	 3.4)	 transcripts.	 	 The	 design	 of	 primers	 on	 exon-exon	 boundaries	aided	 in	 the	 specific	 amplification	 of	 alternatively	 spliced	 KRas	 isoforms	 (Fig.	3.3).		The	other	option	was	to	design	primers	that	flank	introns,	so	that	the	forward	and	reverse	primer	anneal	entirely	to	different	exons	separated	by	at	least	one	intron.	 Thus,	 genomic	 DNA	 templates	would	 be	 longer	 than	 intron-less	 cDNA	templates	 and	 unlikely	 to	 be	 amplified	 during	 the	 qRT-PCR	 reaction	 cycles.	 If	genomic	amplicons	were	produced,	these	could	be	distinguished	by	melt	curve	analysis	(section	3.2.2)	or	by	performing	an	end-point	PCR	reaction	and	running	the	 PCR	 products	 on	 an	 agarose	 gel.	 Primer	 pairs	 flanking	 an	 intron	 were	designed	for	specific	amplification	of	ERas	(Fig.	3.1),	HRas	(Fig.	3.2)	and	KRas-
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Fig.	 3.2	 HRas	 sequence	 and	 position	 of	 qRT-PCR	 primers.	A	 A	 schematic	gene	 overview	with	 exons	 (boxes)	 and	 introns	 (lines)	 and	 the	 corresponding	lengths	 in	 base	 pairs	 (bp).	B.	 Transcript	 variants	 showing	 coding	 (alternating	blue	and	green;	alternative	exon	in	orange)	and	non-coding	sequences	(black)	in	exons	with	aligned	qRT-PCR	primers	(arrows).	C.	mRNA	sequence	with	primer	positions	 (red	 arrows	 and	 underlined	 sequences).	 Non-coding	 sequence	 is	depicted	in	lower	case,	coding	exons	in	alternating	blue	and	green.		












































Fig.	 3.3	 KRas	 sequence	 and	 position	 of	 qRT-PCR	 primers.	A	 A	 schematic	gene	 overview	with	 exons	 (boxes)	 and	 introns	 (lines)	 and	 the	 corresponding	lengths	 in	 base	 pairs	 (bp).	B.	 Transcript	 variants	 showing	 coding	 (alternating	blue	and	green;	alternative	exon	in	orange)	and	non-coding	sequences	(black)	in	exons	with	aligned	qRT-PCR	primers	(arrows).	C.	and	D.	mRNA	sequence	with	primer	positions	(red	arrows	and	underlined	sequences).	Non-coding	sequence	is	 depicted	 in	 lower	 case,	 coding	 exons	 in	 alternating	 blue	 and	 green	 and	alternative	exon	in	orange.	

























































	Each	 step	 of	 the	 RT-PCR	 reaction	 (extension,	 denaturation	 and	 annealing)	utilising	 SYBR	 Green	 I,	 as	 well	 as	 primers	 used	 in	 the	 assay,	 require	 further	optimisation	 (McPherson	 and	Møller,	 2006,	 Bio-Rad	 Laboratories,	 2006).	 The	qRT-PCR	reaction	cycles	were	based	on	previous	assays	established	 in	 the	 lab	and	 are	 described	 in	 Chapter	 2.	 The	 primers	 selected	 in	 section	 3.2.1	 were	tested	 empirically.	 Subsequent	 sections	 will	 describe	 annealing	 temperature	optimisation	(section	3.2.2.2),	testing	of	primer	specificity	(section	3.2.2.3)	and	efficiency	 (section	 3.2.2.4),	 as	well	 as	 generation	 of	 standard	 curves	 to	 assess	RT-PCR	 reaction	 performance	 (section	 3.2.2.5).	 Section	 3.2.2.1	 describes	 the	generation	of	Ras	isoform-specific	plasmids	for	use	as	control	templates	and	the	final	 section	 3.2.2.6	 addresses	 selection	 of	 a	 reference	 gene	 for	 qRT-PCR	data	normalisation.	
 	
3.2.2.1	 	 	 Generation	of	plasmids		Plasmids	 encoding	 murine	 Ras	 isoforms	 were	 used	 to	 test	 the	 Ras	 primer	specificity	 (section	 3.2.2.3)	 and	 to	 generate	 standard	 curves	 for	 absolute	quantification	 of	 Ras	 isoforms	 in	 qRT-PCR	 reactions	 (section	 3.2.2.5).	 Mouse	ERas,	 KRasA	 and	 KRasB	 plasmids	 were	 purchased	 from	 Source	 Bioscience.	Mouse	HRas	and	NRas	fragments	were	cloned	from	undifferentiated	R1	mouse	ESCs	 cDNA	 for	 TOPO	 cloning	 (vector	maps	 are	 shown	 in	 Appendix	 Fig.	 A3.1-A3.2).		For	HRas,	the	whole	coding	DNA	sequence	(CDS),	as	well	as	a	small	non-coding	DNA	 fragment	 from	 exon	 1	 (Fig.	 3.2),	 were	 amplified	 from	 the	 cDNA	 using	previously	 designed	 HRas	 forward	 primer	 (Table	 3.1,		F:	 5’	 GCTGTAGAAGCTATGACAGAATAC	 3’)	 and	 a	 cloning	 reverse	 primer		(R:	 5’	 ACCTCGAGATCAGGACAGCAC	 3’)	 that	 recognised	 the	 3’	 end	 of	 the	 CDS	(exon	4B	of	all	transcript	variants,	Fig.	3.2).	The	properties	of	the	forward	and	reverse	primers	are	summarised	in	Table	3.2.	Although	NetPrimer	predicted	the	formation	 of	 a	 cross-dimer	 and	 a	 self-dimer	 for	 the	 reverse	 primer	 (∆G	 was	lower	than	6	kcal/mol),	any	non-specific	products	would	be	unlikely	to	prevent	
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amplification	of	the	required	product.	Primer-BLAST	confirmed	that	the	specific	amplicon	 would	 be	 582	 bp	 long,	 whereas	 any	 amplification	 of	 genomic	 DNA	would	 yield	 an	 amplicon	 longer	 than	 3,000	 bp,	 which	 would	 be	 easily	distinguished	on	an	agarose	gel.	Primer-BLAST	also	predicted	amplification	of	additional	sequences,	which	included	a	664	bp	product	from	HRas	transcript	1	variant	X4	(XM_006536160.1).			
	
Table	 3.2	 Properties	 of	 HRas	 cloning	 primers.	 Primers	 were	 used	 for	amplifying	 mouse	 HRas	 transcript	 1	 coding	 DNA	 sequence	 and	 a	 short	 non-coding	 fragment	 for	 subsequent	TOPO	 cloning.	Nt	 –	 nucleotides,	 Tm	 –	melting	temperature,	GC%	-	percentage	of	G	and	C	bases,	∆G	–	Gibbs	free	energy.	
	 Primer	 Length	(nt)	 Tm	(˚C)	 GC%	 ∆G	(kcal/mol)	Hairpin	 Self-dimer	 Cross-dimer	Forward	 24	 53.23	 41.67	 -0.59	 -4.89	 -9.03	Reverse	 21	 58.84	 57.14	 -0.57	 -9.96			The	PCR	reactions	were	performed	using	annealing	 temperature	gradient	and	PfuUltra	Hotstart	 polymerase	 that	 has	 a	 proofreading	 ability	 (Lundberg	 et	 al.,	1991)	 (section	 2.7.12).	 PCR	 products	 were	 run	 on	 a	 2%	 agarose	 gel	 and	visualised	by	UV	transilluminator	(Fig.	3.5).	The	reaction	revealed	an	additional	band	at	 a	molecular	weight	 (MW)	above	600	bp	 (Fig	3.5,	 red	asterisk),	which	might	have	been	the	predicted	HRas	transcript	1	amplicon.		For	NRas	cloning,	the	PCR	primers	designed	for	RT-PCR	(Table	3.1)	were	used	to	amplify	a	213	bp	 fragment	 from	 the	CDS	and	3’UTR	of	NRas	 (Fig.	3.4).	The	PCR	products	were	run	on	a	2%	agarose	gel	(Fig.	3.5).	The	Ras	sequences	were	gel-purified	and	subcloned	into	pCR4-TOPO	and	transformed	into	competent	E.	





Fig.	 3.5	 Generation	 of	 mouse	 isoform-specific	 Ras	 fragments	 for	









	First,	 all	 Ras-isoform	 primer	 pairs	 were	 amplified	 at	 Ta	 =	 60˚C	 for	 40	 cycles	using	cDNA	from	undifferentiated	R1	ESCs	as	a	 template	(Fig.	3.6	A).	Negative	controls	with	“-RT”	and	with	nuclease-free	water	were	included	in	each	primer	set.	 The	PCR	products	 of	 all	 reactions	were	 run	 on	2%	agarose	 gels	 to	 reveal	correct	amplification	products	for	each	Ras	isoform-specific	primers.	However,	primer-dimer	product	 formation	was	present	 in	 all	 negative	 control	 reactions	for	 all	 primer	 pairs	 and	 in	 reactions	 with	 cDNA	 for	 ERAS,	 HRAS	 and	 KRASA	primers.	 Although	 no	 other	 unspecific	 amplicons	 were	 present,	 formation	 of	primer-dimer	 products	 alone	 meant	 that	 the	 PCR	 conditions	 were	 not	 fully	optimised.		Next,	an	annealing	temperature	gradient	was	used	in	end-point	PCR	for	a	series	of	 PCR	 assays	 with	 Ta	 below	 and	 above	 the	 Tm	 of	 each	 Ras	 isoform-specific	primer	 pair.	 A	 negative	 control	 (blank)	 with	 nuclease-free	 water	 instead	 of	cDNA	was	included	for	each	primer	set	and	the	PCR	products	were	run	on	2%	agarose	 gels	 (Fig.	 3.6B).	 For	 HRas,	 two	 different	 primer	 pairs	 were	 tested	initially	–	HRAS1,	specific	only	for	HRAS	transcript	1,	and	HRAS,	specific	for	all	HRAS	transcripts.	Both	primer	pairs	amplified	the	desired	PCR	products	of	171	bp	 and	188	bp	 for	 the	HRAS1	 and	HRAS	primer	 pairs,	 respectively.	However,	PCR	 reactions	 with	 the	 HRAS1	 primer	 pair	 led	 to	 primer-dimer	 products	 at	lower	 annealing	 temperatures	 (55.1-57.8˚C)	 and	 in	 the	 reaction	 with	 no	template	 cDNA	 (blank).	 Thus,	 this	 primer	 set	 was	 not	 ideal	 for	 qRT-PCR	 as	primer-dimer	 formation	 depletes	 primers	 from	 binding	 to	 the	 DNA	 template	and	 reduces	 reaction	 efficiency	 (Chou	 et	 al.,	 1992).	 No	 non-specific	 product	formation	was	seen	for	HRAS	primer	pair,	hence,	these	were	chosen	for	further	optimisation.	








Fig.	 3.6	Optimising	 annealing	 temperature	 (Ta)	 for	 Ras	 isoform	primers.	Ras	 isoform-specific	 primers	 were	 used	 to	 amplify	 20	 ng	 of	 cDNA	 from	undifferentiated	R1	ESCs.	“-RT”	and	nuclease-free	water	were	used	in	reactions	as	 negative	 controls.	 Reaction	 products	were	 run	 on	 2%	 agarose	 gels.	A	 PCR	conditions:	95˚C	for	5	mins,	94˚C	for	30sec,	60˚C	for	30	sec,	72˚C	for	30	sec,	40	cycles;	blank	–	no	reaction.	B	PCR	conditions:	95˚C	for	5	min,	94˚C	for	30	sec,	Ta	(gradient	55-65˚C)	for	30	sec,	72˚C	for	20	sec;	35	cycles.	Blanks	represent	PCR	with	no	 cDNA	 (Ta	=	60.9˚C	 for	KRASB,	Ta	=	59.0˚C	 for	other	primers).	 Specific	amplicons	 for	Ras	 isoforms:	ERAS	–	230bp,	HRAS	transcript	1	–	171	bp,	HRAS	(all	transcripts)	–	188	bp,	KRASA	–	184	bp,	KRASB	–	142	bp,	NRAS	–	213	bp.	Red	asterisks	indicate	primer-dimer.		
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was	 no	 PCR	 product,	 possibly	 because	 of	 mispipetting	 of	 one	 of	 the	 PCR	constituents.	 Negative	 controls	 (blanks)	 did	 not	 show	 formation	 of	 primer-dimer	 products.	 Representative	 bands	 from	 each	 primer	 pair	 reaction	 were	excised,	 purified	 and	 sequence-verified	 (Dundee	 Sequencing	 Services).	 As	higher	 Ta	 contributes	 to	 better	 primer-template	 specificity,	 a	 Ta	 of	 62˚C	 was	chosen	for	the	subsequent	PCR	reactions	for	all	primer	pairs.			
3.2.2.3		 	 Primer	specificity	




Fig.	 3.7	 Ras	 isoform	 primer	 specificity.	 Ras	 isoform-specific	 primers	 were	used	in	end-point	PCR	reactions	with	10	pg	of	each	Ras	isoform	plasmid	as	DNA	template.	Nuclease-free	water	 instead	of	 cDNA	was	used	as	a	negative	control	for	 each	 primer	 set.	 The	 PCR	 products	 were	 run	 on	 2%	 agarose	 gels;	 PCR	conditions:	95˚C	for	5	mins,	94˚C	for	30	sec,	62˚C	for	30	sec,	72˚C	for	30	sec,	40	cycles.	PCR	specific	products	had	the	following	lengths:	ERAS	–	230bp,	HRAS	–	188,	KRASA	–	184bp,	KRASB	–	142bp,	NRAS	–	213bp.		
	
	
3.2.2.4			 	 Primer	efficiency	Relative	quantification	in	qRT-PCR	relies	on	the	assumption	that	the	amount	of	DNA	 product	 doubles	 during	 each	 PCR	 cycle,	 which	 means	 the	 reactions	 are	100%	efficient.	To	test	this	assumption,	cDNA	from	undifferentiated	mouse	R1	ESCs	was	used	to	generate	a	2-fold	dilution	series	(Fig.	3.8)	to	measure	reaction	efficiency,	as	described	 in	section	3.1.2.3.	Fig.	3.8	summarises	the	 linear	graph	equations,	as	well	as	the	calculated	percent	efficiency	of	qRT-PCR	reactions	for	each	 Ras	 isoform	 primer	 set.	 Overall,	 Ras	 isoform-specific	 primers	demonstrated	good	reaction	efficiency.	Only	the	HRAS	primer	pair	had	>105%	efficiency,	 although	 no	 non-specific	 amplification	 products	 were	 detected	 by	melt	curve	analysis	that	might	account	for	this	over	amplification.	Moreover,	all	experimental	data	fit	well	with	the	regression	line,	which	was	represented	by	a	
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high	 coefficient	 of	 determination	R2	(above	 0.980,	 Fig.	 3.8).	 In	 summary,	 qRT-PCR	 optimisation	 for	 each	 Ras	 isoform	 primer	 pair	 gave	 good	 results	 both	 in	






Primers	 Ct	value	range	 Equation	 !!	 %E	ERas	 24-30	 y	=	-1.0047x	+	38.586	 0.99946	 99	HRas	 28-34	 y	=	-0.8907x	+	40.798	 0.99659	 118	KRasA	 28-34	 y	=	-0.9934x	+	41.582	 0.98435	 101	KRasB	 24-30	 y	=	-1.0389x	+	37.734	 0.99494	 95	NRas	 24-30	 y	=	-1.0236x	+	38.134	 0.99921	 97	
	







































Primers	 Ct	value	range	 Equation	 !!	 %E	POL2RE	 22-28	 y	=	-0.9524x	+	35.24	 0.99202	 107	
	


























Fig.	 3.11	 Generation	 of	 mouse	 POL2RE	 reference	 gene	 fragment	 for	
subsequent	 subcloning	 into	 pCR4-TOPO	 plasmid.	 40	 ng	 of	 cDNA	 from	undifferentiated	R1	ESCs	was	used	in	end-point	PCR	with	POL2RE	primers	and	proofreading	Pfu	polymerase.	Annealing	 temperature	gradient	of	55-65˚C	was	used.	 PCR	 products	 were	 run	 on	 2%	 agarose	 gel	 and	 excised,	 purified	 and	subcloned	 into	 pCR4-TOPO.	 PCR	 conditions:	 95˚C	 for	 5	 mins,	 94˚C	 for	 30sec,	54.3˚C	for	30	sec,	72˚C	for	30	sec,	40	cycles.	POL2RE	–	RNA	polymerase	II,	MW	–	molecular	weight	marker,	bp	–	base	pair.			
Table	3.4	5-fold	dilution	 series	of	mouse	POL2RE	plasmid	 standards.	0.2	ng/µl	 of	 pCR4-TOPO-POL2RE	 plasmid	 was	 used	 in	 5-fold	 dilution	 series	containing	12	dilution	points	 (standard	number).	The	 standards	were	used	 in	qRT-PCR	 assays	 to	 generate	 RNA	 polymerase	 II	 (POL2RE)	 standard	 curve,	which	 was	 used	 to	 absolutely	 quantify	 POL2RE	 expression	 in	 test	 samples.	Plasmid	copy	numbers	were	calculated	based	on	plasmid	size	in	daltons	(Da).		
	 Standard	number	 Plasmid	concentration	(fg/µl)	 Plasmid	amount	per	assay/4	µl	(fg)	 Plasmid	copy	number	1	 200000	 800000	 1.69	·	108	2	 40000	 160000	 3.37	·	107	3	 8000	 32000	 6.74	·	106	4	 1600	 6400	 1.35	·	106	5	 320	 1280	 2.70	·	105	6	 64	 256	 5.39	·	104	7	 12.8	 51.2	 1.08	·	104	8	 2.56	 10.24	 2.16	·	103	9	 0.512	 2.048	 4.32	·	102	10	 0.1024	 0.4096	 86.3	11	 0.02048	 0.08192	 17.3	12	 0.004096	 0.016384	 3.45		
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3.3	 	 Summary	and	conclusions	









	Embryonic	 stem	 cells	 (ESCs)	 are	 pluripotent	 stem	 cells	 derived	 from	 the	undifferentiated	 inner	 cell	mass	 (ICM)	 of	 a	 blastocyst,	 at	 day	 4	 to	 5	 of	 a	 pre-implantation	 embryo.	 ESCs	 that	 could	 be	 cultured	 in	 vitro	 were	 first	 isolated	from	 the	mouse	 embryo	 (mESC)	 in	 1981	 (Evans	 and	 Kaufman,	 1981,	Martin,	1981).	The	isolation	of	human	ESCs	(hESC)	followed	almost	two	decades	later	in	1998	(Thomson	et	al.,	1998).	Both	mouse	and	human	ESC	are	able	to	self-renew	and	 show	 no	 signs	 of	 senescence	 after	 long-term	 culture;	 hence,	 ESCs	 are	considered	 to	 be	 “immortal”	 (Evans	 and	 Kaufman,	 1981,	 Suda	 et	 al.,	 1987,	Brimble	et	al.,	2004,	Zalzman	et	al.,	2010).		There	 is	 evidence	 that	 hESC	 might	 be	 at	 a	 higher	 developmental	 stage	 than	mESC,	as	their	expression	profile	more	closely	resembles	mouse	epiblast	stem	cells	(mEpiSC),	which	are	derived	from	the	post-implantation	embryo	(Nichols	et	al.,	2009,	Tesar	et	al.,	2007).	Developmental	stage	differences	are	reinforced	by	distinct	culturing	conditions	for	mESC	and	hESC.	The	former	are	maintained	in	the	undifferentiated	state	by	co-culture	on	a	feeder	layer	of	mouse	embryonic	fibroblasts	(mEFs)	and/or	by	using	mouse	cytokine	leukaemia	inhibitory	factor	(LIF)	 in	 the	medium	(Koestenbauer	et	 al.,	 2006,	Williams	et	 al.,	 1988).	On	 the	other	hand,	hESC	require	basic	fibroblast	growth	factor	(bFGF)	(Xu	et	al.,	2005)	and	maintenance	on	mEFs	(Humphrey	et	al.,	2004)	or	on	either	human-serum	matrix	or	Matrigel	with	or	without	a	conditioned	medium	(Koestenbauer	et	al.,	2006,	 Schatten	 et	 al.,	 2005,	 Stojkovic	 et	 al.,	 2005).	 By	 contrast,	 bFGF	 causes	differentiation	of	mESC	(Stavridis	and	Smith,	2003).			
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Both	mESC	and	hESC	are	pluripotent	cells	that	are	able	to	differentiate	into	any	cell	type	of	the	three	germ	layers:	ectoderm,	endoderm	and	mesoderm.	In	vivo,	following	 transplantation	 into	 blastocysts,	 mESC	 can	 support	 foetal	development	and	produce	viable,	completely	cell	culture-derived	mice	(Nagy	et	al.,	1990,	Nagy	et	al.,	1993).	In	vitro,	mESC	and	hESC	differentiate	into	embryoid	bodies	 (EBs),	 which	 are	 cell	 aggregates	 that	 resemble	 the	 developing	 early	embryo	(Arnold	and	Robertson,	2009,	Doetschman	et	al.,	1985,	Itskovitz-Eldor	et	 al.,	 2000).	 EBs	 have	 been	 extensively	 used	 as	 a	 model	 to	 study	 normal	embryonic	development	and	early	stages	of	cell	 lineage	specifications	(O'Shea,	2004,	Robertson,	1987).		To	induce	spontaneous	EB	formation,	mESC	are	cultured	in	suspension	in	non-adherent	 dishes	 in	 the	 absence	 of	 LIF	 (Doetschman	 et	 al.,	 1985,	 Leahy	 et	 al.,	1999,	 Murray	 and	 Edgar,	 2004).	 Following	 cell	 aggregation	 after	 2	 days	 of	culture	 (Murray	 and	Edgar,	 2001),	 the	 peripheral	 cells	 of	 the	 EB	 differentiate	into	 extraembryonic	 primitive	 endoderm	 cells,	 which	 recapitulate	 primitive	endoderm	(hypoblast)	formation	in	vivo	from	the	ICM	of	a	blastocyst	(Nadijcka	and	 Hillman,	 1974).	 Fig.	 4.1	 illustrates	 the	 morphology	 of	 the	 EB	 during	 the	initial	 steps	 of	 spontaneous	 differentiation	 (endoderm	protocol),	 employed	 in	this	study.	Around	day	4	of	suspension	culture,	the	primitive	endoderm	cells	of	the	 EB	 start	 to	 deposit	 extracellular	matrix	 (ECM)	 in	 the	 form	 of	 a	 basement	membrane	(BM)	that	separates	them	from	the	underlying	undifferentiated	cells	(Leahy	 et	 al.,	 1999).	 This	 parallels	 the	 Reichert’s	 membrane,	 a	 thick	 BM	 that	develops	 in	 vivo	 in	 the	 peri-implantation	 embryo	 from	 the	 trophoblast	 cells	(that	 give	 rise	 to	 the	 placenta)	 and	 primitive	 endoderm	 cells	 (Salamat	 et	 al.,	1995).		In	 the	EB,	 the	cells	underlying	the	BM	become	polarised	and	differentiate	 into	primitive	 ectoderm	 epithelium	 (Li	 et	 al.,	 2001,	Murray	 and	Edgar,	 2000).	 The	unpolarised	cells	 that	do	not	make	contact	with	 the	BM	undergo	programmed	cell	 death,	 which	 is	 coordinated	 by	 the	 BM	 itself.	 This	 process	 leads	 to	 the	formation	of	central	cavity,	which	resembles	the	proamniotic	cavity	as	seen	 in	the	 developing	 embryo	 (Coucouvanis	 and	Martin,	 1995).	 By	 day	 8	 of	 in	 vitro	culture	 the	 EBs	 enlarge	 and	 the	 majority	 of	 them	 transition	 to	 cystic	 EBs	
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Fig.	 4.1	 Morphological	 changes	 of	 embryoid	 bodies	 (EBs)	 during	












4.1.2			 Functions	of	Ras	isoforms	in	ESCs		Based	on	a	limited	number	of	studies,	distinct	Ras	isoforms	play	different	roles	during	 cellular	differentiation.	Dominant	negative	HRas	mutant	was	 shown	 to	inhibit	 nerve-growth	 factor	 (NGF)-induced	 neuronal	 differentiation	 of	 PC12	cells	 (Szeberenyi	 et	 al.,	 1990).	 Subsequently,	 active	 HRas	 was	 shown	 to	 be	crucial	 for	 induction	 of	 extraembryonic	 endoderm	 differentiation	 in	 mouse	ESCs,	 through	 signalling	 via	 the	 Raf-MEK-ERK	 pathway	 (Yoshida-Koide	 et	 al.,	2004),	whereas	constitutively	active	K-Ras	was	 found	 to	enhance	self-renewal	and	proliferation	of	mouse	ESCs	in	an	undifferentiated	state	(Luo	et	al.,	2007).	Also,	 signalling	 of	 activated	 KRas	was	 shown	 to	 be	 associated	with	 cancer	 in	endodermal	 stem	 cells,	 whereas	 activated	 HRas	 was	 shown	 to	 contribute	 to	endoderm	differentiation	and	growth	arrest	(Quinlan	et	al.,	2008,	Quinlan	and	Settleman,	2008).	However,	these	studies	generally	involved	overexpression	of	Ras	isoforms	rather	than	studying	endogenous	protein	function.	Besides,	little	is	known	 about	 isoform-specific	Ras	 effector	 pathways	 involved	 in	 regulation	 of	stemness/differentiation.		
	It	has	been	recently	discovered	that	a	new	Ras	isoform,	ERas,	is	solely	expressed	in	mESCs	and	is	responsible	for	their	transforming	potential	(Takahashi	et	al.,	2003).	ERas	 is	 constitutively	 active	 without	 mutation	 and	 it	 binds	 preferentially	 to	downstream	 PI3K,	 but	 not	 to	 Raf.	 ERas-null	 mESCs	 maintain	 pluripotency,	 but	display	reduced	tumourigenicity	and	growth.	These	findings	may	substantiate	the	importance	of	Ras	isoform-specific	signalling,	especially	in	early	development.	The	human	ERAS	 homologue,	 however,	 contains	 a	premature	polyadenylation	 signal	and	is	not	expressed	at	protein	level	in	hESCs	(Kameda	and	Thomson,	2005).	The	Ras	isoform-specific	differences	in	affecting	self-renewal	and	differentiation	of	SCs	might	be	attributed	to	either	distinct	functions	of	individual	isoforms	or	to	 disparity	 of	 timing	 and/or	 level	 of	 their	 gene	 expression	 in	 particular	 cell	types	(Castellano	and	Santos,	2011).	To	investigate	the	possibility	of	the	latter,	this	study	aimed	to	determine	endogenous	expression	levels	of	Ras	isoforms	in	undifferentiated	 and	 differentiating	 R1	 mESCs	 using	 qRT-PCR	 to	 calculate	mRNA	copy	number	per	cell.		
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4.2		 	 	 Results	
4.2.1	 	 	 Establishing	ESC	culture	protocols	
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Fig.	 4.2	 Separation	 of	 undifferentiated	 R1	 embryonic	 stem	 cells	 (ESCs)	




































shape,	as	mesodermal	cells	started	to	differentiate	and	migrate	outside	the	EB		(Fig.	 4.3,	 day	 6,	 MESO).	 EBs	 became	 also	 more	 complex,	 as	 during	 this	 time	primitive	 endoderm	 and	 the	 central	 cavity	 start	 to	 form,	 leading	 to	differentiation	of	all	three	germ	layers	(Rak-Raszewska	et	al.,	2012).		Overall,	 the	 micrographs	 of	 differentiating	 EBs	 depicted	 the	 formation	 of	distinct	morphological	features	specific	for	each	differentiation	protocol.	These	methods	were	used	for	studying	early	endoderm	and	mesoderm	differentiation	to	measure	Ras	isoform	transcript	levels.									
















Fig.	 4.4	 Assessment	 of	 RNA	 quality	 by	 agarose	 gel	 electrophoresis	 of	
mouse	 R1	 ESCs	 samples.	 RNA	 was	 extracted	 using	 Norgen	 RNA/protein	extraction	 kit	 and	 1µg	 of	 RNA	 was	 run	 per	 lane	 on	 1.2%	 agarose	 gel.	 Two	distinct	 28S	 and	 18S	 rRNA	 bands	 were	 visible	 in	 each	 sample,	 indicated	 by	arrows.	A	 RNA	 from	undifferentiated	 ESCs.	 #1-3	 indicate	 biological	 replicates	(see	 text).	 B	 RNA	 from	 ESCs	 undergoing	 endoderm	 and	 mesoderm	differentiation,	 as	 well	 as	 from	 mouse	 liver	 (E11.5).	 C	 RNA	 from	undifferentiated	 and	 mesoderm	 differentiating	 ESCs.	 bp	 –	 base	 pairs	 of	 DNA	ladder,	undiff.	–	undifferentiated	sample	R1	#4	(see	text),	diff.	–	differentiation,	d	–	day	of	differentiation,	(m)	–	pre-differentiation	medium,	28S	and	18S	–	rRNA	subunits.	
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4.2.3	 	 	 Ras	 isoform	 transcript	 expression	 in	 undifferentiated		
R1	mESC		RNA	 extracted	 from	 4	 biological	 replicates	 (#1-4)	 of	 undifferentiated	 ESCs	(Section	 4.2.2)	was	 analysed	 by	 qRT-PCR	 to	 quantify	 Ras	 isoform	 transcripts.	The	 expression	 levels	 of	 POL2RE	 reference	 transcript,	 determined	 from	 the	plasmid	standard	curve,	averaged	around	6	copies	per	pg	of	RNA.	However,	 in	one	of	the	biological	replicates	(#4,	used	along	with	differentiation	experiment	in	Fig.	4.7)	less	than	1	copy	per	pg	of	RNA	was	detected,	which	was	significantly	lower	than	in	the	remaining	samples	(7-8	copies/pg)	(Table	4.1,	Fig.	4.5	B).	As	the	quality	of	RNA	was	good	in	all	samples	(Fig.	4.4	A	and	C)	and	the	expression	levels	 and	 percentage	 contribution	 of	 Ras	 isoforms	 across	 the	 four	 biological	replicates	did	not	vary	significantly	(Fig.	4.5	A),	the	downregulation	of	POL2RE	expression	in	only	one	sample	was	unexpected	and	may	be	due	to	either	sample	handling	 error	 or	 to	 fluctuating	 expression	 of	 POL2RE	 in	 ESCs	 colonies.	Moreover,	 percentage	 amplification	 efficiency	 as	 determined	 by	 POL2RE	standard	curves	remained	consistent	 for	all	 replicates	at	around	77-78%	with	
R2	values	>0.99	(Appendix,	Fig.	A4.1	and	A4.2).	Due	to	this	uncertainty,	the	Ras	isoform	transcript	levels	were	not	normalised	to	POL2RE	reference	gene	using	the	∆CT	method,	as	this	could	introduce	a	bias	into	the	final	results.			Instead,	 the	 abundance	 of	 Ras	 isoform	 transcripts	 was	 calculated	 using	 Ras	isoform-specific	plasmid	standard	curves.	Table	4.1	and	Fig.	4.5	summarise	the	expression	levels	of	the	tested	genes	in	4	biological	replicates	of	R1	ESCs	(#1-4).	Transcripts	 for	 all	 Ras	 isoforms	were	 expressed	 and	 are	 represented	 as	 copy	number	 per	 pg	 of	 RNA	 and	 copy	 number	 per	 cell.	 To	 estimate	 Ras	 transcript	abundance	per	undifferentiated	ESC,	the	average	total	RNA	content	per	cell	was	calculated	based	on	 the	number	of	 cells	used	 for	RNA	extraction	and	 the	RNA	yields,	 and	 was	 approximately	 20	 pg.	 This	 value	 corresponds	 to	 previous	findings	in	mouse	ESCs	(Calabrese	et	al.,	2007).			The	most	abundant	Ras	 isoform	was	KRasB	with	about	3	transcripts	per	pg	of	RNA	(57	copies	per	cell),	followed	by	NRas	with	almost	1.5	copies/pg	(29	copies	
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per	cell)	and	ERas	with	about	1	copy/pg	(20	copies	per	cell).	The	least	abundant	Ras	 isoforms	were	HRas	 and	KRasA,	with	 0.1	 and	 0.04	 copies	 per	 pg	 of	 RNA,	respectively,	equivalent	to	just	over	2	copies	per	cell	and	less	than	1	copy/cell.	Total	Ras	transcripts	(pan	Ras)	levels	added	up	to	around	5.5	transcript	copies	per	pg	of	RNA,	which	was	equal	to	109	copies	per	cell.			
	
Table	 4.1	 Ras	 isoform	 and	 reference	 gene	 RNA	 polymerase	 II	 (POL2RE)	







ERas	 HRas	 KRasA	 KRasB	 NRas	 Pan	Ras	 POL2RE	
R1	#1	 1.152	(23.0)	 0.091	(1.8)	 0.024	(0.5)	 2.284	(45.7)	 1.496	(29.9)	 5.047	(100.9)	 7.880	(157.6)	
R1	#2	 1.249	(25.0)	 0.111	(2.2)	 0.026	(0.5)	 3.900	(78.0)	 1.579	(31.6)	 6.865	(137.3)	 8.168	(163.4)	R1	#3	 0.975	(19.5)	 0.089	(1.8)	 0.019	(0.4)	 2.863	(57.3)	 1.763	(35.3)	 5.709	(114.2)	 7.821	(156.4)	R1	#4	 0.604	(12.1)	 0.185	(3.7)	 0.073	(1.5)	 2.436	(48.7)	 0.956	(19.1)	 4.254	(85.1)	 0.712	(14.2)	












E	 –	ERas,	H	 –	HRas,	KA	 –	KRasA,		
KB	 –	 KRasB,	N	 –	 NRas,	 NS	 –	 not	significant,	*	p	≤	0.05,	**	p	≤	0.01,		***	p	≤	0.001,	****	p	≤	0.0001				










































































































4.2.4	 	 Ras	 isoform	 transcript	 expression	 in	 differentiating		
R1	mESCs	








Fig.	 4.6	 Ras	 isoform	 transcript	 expression	 during	 endoderm	 and	





































































































































































































mesoderm" endoderm" undiﬀ ren<at d"
	 109	














































































































































































During	 mesoderm	 differentiation,	 the	 percentage	 contribution	 of	 ERas	 was	steadily	 decreasing	 over	 time	until	 day	10	 (Fig.	 4.8).	 This	 again	 confirms	 that	ERas	is	expressed	exclusively	in	undifferentiated	mESC	(Takahashi	et	al.,	2003),	which	diminish	 in	number	as	 the	EB	matures.	 Interestingly,	during	mesoderm	differentiation	there	was	a	peak	in	contribution	of	KRasA	abundance	at	days	2	and	4	in	both	experiments.		To	sum	up,	the	expression	pattern	of	Ras	isoform	transcripts	during	endoderm	differentiation	was	different	 than	that	during	mesoderm	differentiation	and	 in	undifferentiated	R1	mESCs.	During	endoderm	differentiation,	KRasB,	NRas	and	ERas	 contribution	 to	 total	 Ras	 was	 similar	 at	 around	 30%	 of	 total	 Ras	expression.	 In	 contrast,	 during	 mesoderm	 differentiation	 and	 in	undifferentiated	mESC,	the	most	abundant	isoform	was	KRasB,	with	over	50%	contribution	to	total	Ras	expression	levels,	 followed	by	NRas	(about	30%)	and	ERas	 (up	 to	18%).	KRasA	and	HRas	were	 the	 least	abundant	 isoforms	 in	both	protocols,	comprising	only	up	to	4%	of	all	Ras	isoform	levels.		
 	
4.3		 	 	 Discussion	In	this	chapter	the	ESC	and	EB	mouse	models	of	self-renewal	and	differentiation	(Evans	and	Kaufman,	1981,	Leahy	et	al.,	1999,	Martin,	1981,	Rak-Raszewska	et	al.,	2012)	were	used	to	study	abundance	of	Ras	isoforms	during	early	stages	of	mouse	 development.	 Methods	 for	 extracting	 RNA	 from	 undifferentiated	 and	differentiating	R1	ESCs	and	performing	qRT-PCR	were	 successfully	 optimised.	Four	biological	 replicates	were	analysed	 from	undifferentiated	ESCs,	however,	due	 to	 time	 constraints,	 only	 one	 or	 two	biological	 replicates	 of	 endoderm	or	mesoderm	differentiation	 protocols	were	 examined.	 Bearing	 this	 in	mind,	 the	results	 of	 these	 experiments	 remain	 inconclusive,	 and	 require	 further	 repeats	and	validation.	




comprises	cells	of	all	three	germ	layers	(Leahy	et	al.,	1999).	Thus,	the	extracted	RNA	from	the	differentiating	EBs	is	not	specific	for	a	given	germ	layer,	but	it	is	only	enriched	in	one	of	them	and	is	generally	heterogeneous.	Therefore,	future	work	 on	 this	model	 should	 include	 separation	 of	 germ	 layers	 before	 the	RNA	extraction	 step.	 One	 of	 the	 techniques	 to	 employ	 would	 be	 fluorescence	activated	cell	sorting	(FACS)	that	would	enable	separation	of	cells	expressing	a	certain	 lineage	 marker,	 as	 previously	 done	 for	 mesodermal,	 Brachyury-expressing	 cells	 (Fehling	 et	 al.,	 2003,	 Rak-Raszewska	 et	 al.,	 2012).	 For	 this	purpose,	however,	a	specifically	labelled	cell	line	should	be	used,	e.g.	Bra-GFP,	in	which	 the	Brachyury	 locus	also	expresses	 the	green	 fluorescent	protein	(GFP).	Similarly,	to	select	neural	cells	and	primitive	neurons	that	derive	from	ectoderm	germ	layer,	GFP	may	be	expressed	from	the	Tau	and	nestin	enhancer	loci	(Lenka	et	al.,	2002,	Tucker	et	al.,	2001).	Definite	endoderm	(DE)	cells,	however,	can	be	separated	from	differentiating	mESC	using	DE-specific	surface	marker	Cxcr4	by	FACS	(Li	et	al.,	2011,	Mfopou	et	al.,	2014).		
Another	aspect	of	EB	heterogeneity	is	that	a	population	of	undifferentiated	cells	is	usually	present,	possibly	because	differentiated	cells	produce	LIF	(Rathjen	et	al.,	 1990),	 which	 supports	 self-renewal	 of	 ESC	 (Koestenbauer	 et	 al.,	 2006,	Williams	 et	 al.,	 1988).	 On	 the	 other	 hand,	 ESC	maintained	 in	 undifferentiated	state	may	spontaneously	differentiate	in	culture	(Smith,	2001),	again	leading	to	heterogeneous	 cell	 populations.	 Such	 effect	 could	 be	 controlled	 by	 separating	undifferentiated	 cells	 using	 FACS	 sorting	 based	 on	 GFP	 expressed	 from	 Oct4	locus,	 a	 transcription	 factor	 that	 controls	 self-renewal	 (Ensenat-Waser	 et	 al.,	2006).	Moreover,	the	STO	feeder	layer	that	maintains	self-renewing	ESCs,	could	be	 efficiently	 removed	 by	 magnetic	 separation	 using	 MACS	 technology	 and	 a	fibroblast-specific	 marker	 mEF-SK4,	 leaving	 behind	 less	 than	 0.15%	 of	contaminating	 mEFs	 (Knoebel	 et	 al.,	 2010).	 These	 methods	 could	 also	 be	employed	in	obtaining	pure	cell	populations	in	future	studies	on	Ras	abundance	in	ESC.	
Despite	 these	 limitations,	 some	 preliminary	 conclusions	 may	 be	 drawn	 from	this	study.	Undifferentiated	mESC	express	all	Ras	isoforms,	where	KRasB	is	the	most	abundant	 transcript,	with	over	50%	contribution	 to	 total	Ras	expression	
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levels,	 followed	 by	 NRas	 (about	 30%)	 and	 ERas	 (up	 to	 18%)	 (Fig.	 4.5	 C).	 A	similar	 trend	 is	 also	 reflected	 throughout	 mesoderm	 differentiation.	Interestingly,	 ERas	 expression	 decreases	 over	 time	 in	 differentiating	 EBs,	suggesting	a	gradual	 loss	of	self-renewal	and	stemness	potential	(Takahashi	et	al.,	2003).	During	endoderm	differentiation,	the	distribution	of	KRasB,	NRas	and	ERas	 is	 approximately	 equal	 and	 comprises	 around	 30%	 of	 total	 Ras	 isoform	transcripts.	 KRasA	 and	HRas	 are	 the	 least	 abundant	 isoforms	 in	 all	 protocols,	comprising	only	up	to	4%	of	all	Ras	isoform	levels.		
The	 total	Ras	 isoform	 transcript	 levels	 sum	up	 to	 around	109	 copies	per	ESC,	which	places	Ras	isoforms	among	~6%	of	the	most	abundant	transcripts,	based	on	 expression	 data	 from	 NIH3T3	 mouse	 fibroblasts	 (Schwanhausser	 et	 al.,	2011).		According	to	the	same	study,	which	used	metabolic	pulse	labelling,	NRas	transcripts	comprise	around	23	copies	per	cell,	 close	 to	 the	median	 transcript	level	 of	 17	 copies	 per	 cell.	 In	 the	 current	 study,	 NRas	 abundance	 in	undifferentiated	ESC	was	similar	and	around	29	copies	per	cell,	which	supports	previous	 findings.	 However,	 the	 abundance	 of	 other	 Ras	 isoforms	 was	 not	quantified	in	the	afore-mentioned	study	and	the	data	was	only	available	for	fully	differentiated	fibroblasts,	which	may	not	be	directly	comparable	to	pluripotent	and	differentiating	ESC	used	in	the	current	study.	
More	relevant	data	may	arise	from	the	analysis	of	the	transcriptional	profile	in	single	mouse	blastomeres	derived	from	2-	and	4-cell	stage	embryos	(Tang	et	al.,	2011).	 In	 that	 study,	 TaqMan	 RT-PCR	 detected	 all	 Ras	 isoforms	 at	 both	developmental	stages,	apart	from	ERas,	which	was	only	detected	in	2-cell	stage	embryo.	 That	 data,	 however,	 does	 not	 provide	 any	 quantitative	 information	about	relative	transcript	abundance,	as	it	was	not	normalised	and	presented	as	CT	values	only.		
Unfortunately,	 no	 previous	 findings	 present	 Ras	 isoform	 abundance	 in	 ESC	 in	absolute	transcript	copy	numbers.	Therefore,	to	validate	the	data	in	this	study,	more	biological	 replicates	of	undifferentiated	and	differentiating	mESC	should	be	analysed.	As	a	further	confirmation	of	the	results,	a	panRas	primer	pair	could	be	 designed	 for	 qRT-PCR.	However,	 one	 crucial	 finding	 of	 this	work	was	 that	
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KRasB	was	 the	most	 abundant	 isoform	 in	 almost	 all	 analysed	mESC	 samples,	apart	 from	 endoderm	 differentiating	 EBs,	 in	 which	 it	 was	 equally	 expressed	with	NRas	 and	ERas.	This	 is	 particularly	 interesting,	 as	KRasB	 is	 the	only	Ras	isoform	essential	 for	mouse	development	 (Koera	et	al.,	1997,	Nakamura	et	al.,	2008,	 Plowman	 et	 al.,	 2003).	 This	 could	 indicate	 that	 functional	 differences	between	 Ras	 isoforms	 arise	 from	 differences	 in	 their	 expression	 levels	 and	possibly	different	sites	of	expression.	A	previous	study	demonstrated	that	HRas	can	 substitute	 essential	 functions	 of	 KRas,	when	 expressed	 from	 its	 locus,	 i.e.	HRas	knock	in	(KI)	mice	are	viable,	but	develop	cardiovascular	problems	later	in	adulthood	(Potenza	et	al.,	2005).	This	gives	further	evidence	that	Ras	isoform	functional	 difference	 could	 be	 due	 to	 differences	 in	 the	 control	 of	 gene	expression	and,	hence,	also	different	transcript	abundance.		







5.1	 	 	 Introduction	
5.1.1	 Ras	 isoform-specific	 mutation	 frequency	 and	 role	 in	
development	
HRAS,	KRAS	 and	NRAS,	 the	 genes	 of	 the	Ras	 subfamily,	 represent	 some	of	 the	most	frequently	mutated	proto-oncogenes.	The	incidence	of	Ras	mutations	in	all	human	 cancers	 ranges	 between	 9	 to	 30%,	 depending	 on	 the	 database	 used:	COSMIC (v72)	 (Forbes	et	 al.,	 2015),	 cBioPortal	 (Cerami	et	 al.,	 2012,	Gao	et	 al.,	2013),	TumorPortal	(Lawrence	et	al.,	2014),	ICGCDataPortal	(v3.8.2.1	-	API	v1	-	d21bce2)	(International	Cancer	Genome	et	al.,	2010),	which	were	sumarised	in	two	 recent	 reviews	 (Prior	 et	 al.,	 2012,	 Cox	 et	 al.,	 2014).	Although	KRas	 is	 the	most	commonly	mutated	Ras	isoform	across	all	tested	human	tumour	samples	(86%),	 the	 mutation	 frequency	 of	 each	 Ras	 isoform	 is	 not	 uniform	 across	different	 cancer	 types.	 KRas	mutations	 constitute	 almost	 all	 Ras	mutations	 in	pancreatic	and	lung	cancers	and	are	predominant	in	multiple	myeloma	as	well	as	in	endometrial,	stomach	and	colorectal	cancers	(Cox	et	al.,	2014,	Forbes	et	al.,	2015).	 NRas	 mutations	 are	 prevalent	 in	 cutaneous	 melanoma,	 acute	myelogenous	 leukaemia	 (AML)	 and	 thyroid	 cancer.	 HRas	 mutations	 are	infrequent	overall	(3%),	but	they	are	the	most	common	Ras	mutations	in	head	and	neck	squamous	cell	carcinoma	(HNSCC)	as	well	as	in	bladder	cancer.			The	reason	why	KRas	mutations	are	prevalent	 in	tissues	of	endodermal	origin	(pancreas,	colon	and	lung)	might	be	due	to	the	fact	that	mutated	KRas	promotes	proliferation	 and	 maintenance	 of	 stem-like	 properties	 of	 endodermal	progenitors,	 therefore	 leading	 to	 expansion	 of	 cell	 populations	 that	 carry	 the	mutation	 (Quinlan	 et	 al.,	 2008,	 Quinlan	 and	 Settleman,	 2008).	 On	 the	 other	hand,	 mutated	 HRas	 or	 NRas	 causes	 either	 differentiation	 of	 or	 no	 effect	 on	endodermal	 progenitor	 cells,	 respectively.	 An	 alternative	 explanation	 for	 the	
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abundance	 of	 KRas	 mutations	 was	 suggested	 recently	 based	 on	 the	 high	frequency	of	rare	codons	in	KRas	(Lampson	et	al.,	2013).	This	was	suggested	to	result	 in	 impaired	 expression	 of	 KRas.	 Since	 high	 expression	 of	 Ras	 protein	leads	 to	 senescence	 rather	 than	 proliferation,	 the	 authors	 suggested	 that	 the	lower	expression	of	KRas	versus	 the	other	 isoforms	might	be	advantageous	 in	avoiding	 this	 non-productive	 phenotype	when	KRas	 is	 oncogenically	mutated.		Hence,	more	work	 is	 necessary	 to	 better	 understand	 Ras	 isoform	 coupling	 to	different	human	cancers.	
	The	 importance	 of	 KRas	 is	 also	 highlighted	 during	 development,	 as	 its	 KRasB	splice	variant	 is	 the	only	Ras	 isoform	essential	 for	normal	development	 in	 the	mouse	 (Koera	 et	 al.,	 1997,	 Johnson	 et	 al.,	 1997,	 Plowman	 et	 al.,	 2003).	 KRas	knock	 out	 (KO)	 mice	 die	 prenatally	 between	 E12.5	 and	 birth	 due	 to	 thin	ventricular	walls	of	the	heart,	motoneuron	death	in	the	medulla	and	the	spinal	cord	 and	 liver	 defects.	 However,	 KO	 of	 KRasA-specific	 exon	 in	 inbred	 and	crossbred	mice	has	no	effect	on	growth	and	development.	 Interestingly,	HRas-	or	NRas-deficient	mice	separately	exhibit	a	normal	phenotype	(Ise	et	al.,	2000,	Umanoff	et	al.,	1995).	A	double	knockout	of	both	HRas	and	NRas	loci	also	yields	normal	 viable	 mice,	 further	 suggesting	 that	 both	 of	 these	 Ras	 isoforms	 are	dispensable	for	normal	mouse	growth,	development	and	fertility	(Esteban	et	al.,	2001,	Nakamura	et	al.,	2008).	However,	double	knockout	mice	are	born	at	lower	than	 expected	 Mendelian	 frequency.	 This	 finding	 may	 suggest	 a	 partial	functional	 overlap	 of	 Ras	 isoforms.	 Furthermore,	 although	 KRas+/-	 mice	(heterozygous	 for	 KRas	 deletion)	 are	 viable,	 KRas+/-;	 NRas-/-	 mice	 die	 during	embryonic	 development	 or	 perinatally	 due	 to	 severe	 anaemia	 (Johnson	 et	 al.,	1997).	Also,	double	homozygous	mutant	KRas-/-;	NRas-/-	or	KRas-/-;	HRas-/-	mice	die	before	E9.5	or	between	E9.5	and	E11.5,	respectively,	suggesting	that	 these	phenotypes	 are	 more	 severe	 than	 single	 KRas	 deletion	 (Johnson	 et	 al.,	 1997,	Nakamura	 et	 al.,	 2008).	 Altogether,	 current	 studies	 imply	 that	 KRas	 alone	 is	both	 crucial	 and	 sufficient	 for	 normal	 growth	 and	 development	 in	 mice,	 but	partial	functional	overlap	of	other	Ras	isoforms	also	exists.	HRas	knock	in	(KI)	mice,	which	 express	HRas	 from	KRas	 locus	 and	 have	 no	 detectable	 KRas,	 are	viable	 and	 born	 at	 predicted	Mendelian	 ratios,	 hence	 showing	 that	 HRas	 can	functionally	 replace	 KRas	 during	 mouse	 development	 (Potenza	 et	 al.,	 2005).	
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However,	 KRas-/-	 phenotype	 is	 only	 rescued	 until	 adulthood,	 as	 HRasKI	 mice	develop	 later	 cardiovascular	 problems,	 suggesting	 a	 KRas-specific	 role	 in	cardiovascular	 homeostasis.	 Similarly,	 KRas-/-	 phenotype	 can	 be	 rescued	 by	 a	HRas	human	transgene,	which	encodes	human	HRas	protein	identical	to	that	of		mouse	 protein	 (Nakamura	 et	 al.,	 2008).	 The	 transgene	 is	 also	 able	 to	functionally	 substitute	 all	 three	Ras	 genes	 in	Ras	 triple	mutant	mice	 (KRas-/-;	NRas-/-;	HRas-/-).	
	
5.1.2	 Ras	isoform-specific	abundance	in	normal	tissues	Whether	Ras	isoform	functional	redundancy	seen	in	the	above-described	mouse	models	 is	 due	 to	 the	 pattern	 and	 timing	 of	 Ras	 isoform	 expression,	 could	 be	better	understood	by	measuring	Ras	transcript	and	protein	levels	in	a	range	of	normal	mouse	 tissues	and	at	different	developmental	 stages.	Such	work	could	also	 aid	 in	 delineating	 why	 KRasB	 is	 the	 key	 Ras	 isoform	 for	 mouse	development	 (Koera	 et	 al.,	 1997,	 Plowman	 et	 al.,	 2003)	 and	may	 explain	why	certain	 Ras	 isoforms	 couple	 to	 specific	 cancer	 types	 (Castellano	 and	 Santos,	2011).		
	Current	 data	 from	 a	 limited	 number	 of	 studies	 from	 both	 human	 and	mouse	suggests	 that	 distinct	 Ras	 isoforms	 are	 not	 equally	 abundant	 across	 different	tissues	 and	 cell	 lines	 (Fig.	 5.13).	 To	 compare	 Ras	 isoform	 expression	 at	transcript	 level,	 a	 range	 of	 semi-quantitative	 techniques	 has	 been	 used	 in	previous	studies.	For	example,	Northern	blotting	of	mouse	mRNA	(Leon	et	al.,	1987)	allowed	for	relative	comparison	of	 isoform	expression	across	a	panel	of	tissues,	derived	from	both	adult	and	postnatal	animals.	However,	comparison	of	mRNA	levels	between	the	different	Ras	isoforms	was	not	possible	and	the	study	did	not	account	for	the	two	KRas	splice	variants.	On	the	other	hand,	studies	that	aimed	 at	 comparing	 transcript	 expression	 levels	 of	 KRas	 splicing	 isoforms	(using	 Northern	 blotting	 and	 semi-quantitative	 RT-PCR),	 did	 not	 include	 the	remaining	Ras	 isoforms	 in	their	work	(Pells	et	al.,	1997,	Plowman	et	al.,	2006,	Plowman	et	al.,	2003,	Wang	et	al.,	2001).		
	Current	data	on	Ras	isoform	abundance	at	protein	level	in	different	tissue/cell	types	 is	also	derived	mainly	 from	semi-quantitative	methods,	such	as	Western	
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blotting.	 Most	 studies	 are	 not	 comprehensive	 and	 only	 focus	 on	 some	 Ras	isoforms	or	only	certain	tissues	(Nunez	Rodriguez	et	al.,	2006,	Sithanandam	et	al.,	1998).	Our	laboratory	previously	found	that	Ras	isoform-specific	antibodies	are	 not	 very	 accurate	 and	 difficult	 to	 work	 with,	 and	 instead,	 used	 a	 panRas	antibody	 and	 siRNA	 approach	 to	 estimate	 Ras	 isoform	 abundance	 in	 Ras	isoform	knock	 down	 (KD)	 human	 cancer	 cell	 lines	 (Omerovic	 et	 al.,	 2008).	 In	that	study,	KRas	was	observed	to	be	the	most	abundant	isoform	across	a	panel	of	cancer	cell	lines.		A	more	quantitative	method	to	measure	Ras	protein	levels	is	quantitative	mass	spectrometry,	which	was	used	 in	previous	 studies	utilising	peptide	 standards.	Up-to-date	results	mostly	show	conflicting	data,	 in	which	 total	Ras	abundance	ranges	over	5	orders	of	magnitude	(<100	to	>5,000,000	copies/cell)	(Halvey	et	al.,	2012,	Nagaraj	et	al.,	2011,	Ruppen-Canas	et	al.,	2012,	Schwanhausser	et	al.,	2011,	 Wang	 et	 al.,	 2011).	 However,	 these	 methods	 did	 not	 account	 for	 the	inefficiencies	 linked	 to	 antibody-based	 enrichment,	 sample	 handling	 or	proteolysis.	 Together,	 these	 studies	 do	 not	 give	 a	 fully	 comprehensive	comparison	of	all	Ras	isoforms	and	use	mainly	semi-quantitative	methods,	often	leading	 to	 contradicting	 results	 (Fig.	 5.13).	Moreover,	most	 of	 the	 data	 comes	from	 adult	 tissues	 or	 cell	 lines,	 missing	 the	 developmental	 outlook	 on	 Ras	isoform	 expression	 during	 embryogenesis	 and	 postnatal	 development.	Therefore,	 the	 aim	of	 the	 current	 study	 is	 to	 provide	 a	 complete	 comparative	map	 of	 all	 four	 major	 Ras	 isoform	 expression	 profiles	 across	 different	 tissue	types	 as	 well	 as	 between	 the	 isoforms.	 The	 expression	 profiles	 are	 to	 be	measured	at	different	developmental	time	points	using	a	mouse	model.	Also,	as	transcript	 expression	 levels	 do	 not	 necessarily	 reflect	 protein	 abundance	(Schwanhausser	 et	 al.,	 2011),	 it	 is	 important	 to	 measure	 both	 mRNA	 and	peptide	levels.	The	quantitative	methods	used	in	this	study	comprise	qRT-PCR	(Chapter	3	describes	method	development),	 for	measuring	absolute	 transcript	copy	 number,	 and	 mass	 spectrometry	 (MS)	 with	 protein	 standard	 absolute	quantification	(Mageean	et	al.,	2015)	to	estimate	protein	copy	number	in	SW48	colorectal	cancer	cell	lines	isogenic	for	Ras.	In	combination,	they	will	allow	the	
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first	 comparative	 analysis	 of	 absolute	 transcript	 and	 protein	 abundance	between	Ras	isoforms.	
	
5.2		 	 	 Results		
5.2.1	 Expression	studies	using	a	mouse	model	
A	 model	 of	 normal	 mouse	 development	 (Fig.	 5.1)	 was	 used	 to	 obtain	 three	biological	 replicates	 of	 a	 range	 of	 tissues:	 brain,	 liver,	 lungs,	 heart,	 stomach,	intestine,	kidneys,	skin	and	skeletal	muscle.	A	widely	used	outbred	strain	of	CD1	mice	 was	 chosen	 due	 to	 a	 good	 breeding	 performance	 and	 to	 reflect	 the	heterogeneity	 found	 in	 the	wild	mice	 (Aldinger	 et	 al.,	 2009,	Chia	 et	 al.,	 2005).	Hence,	CD1	strain	was	likely	to	reflect	a	generic	mouse	Ras	expression	profile.			During	 mouse	 embryonic	 development	 and	 at	 birth,	 tissues	 were	 harvested	from	separate	litters	at	embryonic	days	(E)	11.5,	13.5,	16.5	and	at	postnatal	day	(P)	 0	 (birth).	 During	 postnatal	 development,	 pups	 were	 sacrificed	 from	 the	same	 litters	at	P5,	P10,	P15,	P20,	P25	and	P30,	as	well	as	 their	corresponding	mothers.	 Therefore,	 biological	 replicates	 for	 the	 embryonic	 tissues	 represent	pools	of	individuals	from	a	single	litter.	Whereas	the	biological	replicates	for	the	postnatal	 samples	 represent	 separate	 litters	where	 littermates	 represent	 each	time-point.	 The	 adult	 sample	 is	 the	mother	 from	 the	 cognate	post-natal	 litter.	Three	biological	replicates	representing	litters	and	mothers	for	each	tissue	type	were	 analysed	 in	 this	 study	 to	measure	 Ras	 isoform	 transcript	 abundance.	 In	total,	 there	were	27	 individual	mouse	adult	 tissue	samples	and	240	pooled	or	individual	 tissue	 samples	 collected	 throughout	 mouse	 development.	 Pooled	samples	 always	 represented	 distinct	 litters	 and	 were	 only	 collected	 when	individual	tissue	samples	were	lighter	than	10	mg	(section	2.6).	Mouse	protein	samples	 were	 first	 collected	 alongside	 RNA	 using	 the	 Norgen	 kit	 for	simultaneous	extraction	of	RNA	and	protein	(section	2.7.8	and	2.8.2).			The	 rationale	 behind	 choosing	 11	 developmental	 stages	 in	 the	mouse	 in	 this	study,	 was	 to	 represent	 the	 best	 possible	 range	 of	 developmental	 changes,	starting	from	the	earliest	time	point,	from	which	accurate	manual	collection	of	
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distinct	 tissues/organs	 was	 possible.	 The	 first	 developmental	 stage	 of	 mouse	development	chosen	for	this	study	was	E11.5,	at	which	the	mouse	embryo	has	43-48	 pairs	 of	 somites	 and	 the	 buds	 of	 most	 major	 organs	 have	 already	developed	 (brain,	 heart,	 liver,	 lungs,	 stomach)	 and	 are	 distinguishable	(Kaufman,	1992).	The	developmental	changes	during	mouse	embryogenesis	and	postnatal	period	are	described	in	detail	in	the	introduction	(section	1.1.4.2.1). 	Most	 importantly,	 it	 has	 been	 known	 that	 KRas-deficient	 mice	 die	 prenatally	between	E12.5	and	birth	(Koera	et	al.,	1997).	Hence,	in	this	study,	tissues	were	collected	 from	 developmental	 time	 points	 before,	 during	 and	 after	 this	 lethal	stage	 (time	 points:	 E11.5,	 E13.5,	 E16.5,	 P0	 and	 P5,	 Fig.	 5.1).	 Also,	 abnormally	thin	ventricular	walls	of	the	heart	were	observed	in	KRas-/-	mouse	embryos	at	E15.5,	 but	 not	 at	 E13.5	 (Koera	 et	 al.,	 1997).	 Therefore,	 it	 was	 of	 interest	 to	measure	Ras	isoform	expression	in	the	embryonic	heart.	Skeletal	muscle	tissue	was	 used	 to	 compare	 Ras	 levels	 to	 those	 in	 cardiac	 muscle.	 The	 remaining	tissues	 were	 chosen	 in	 order	 of	 Ras	 isoform	 mutation	 frequency:	 lungs,	stomach,	 intestine	 and	 kidneys	 are	 the	 sites	 of	 cancers	 with	 frequent	 KRas	mutations,	 while	 brain	 and	 skin	 are	 the	 equivalent	 sites	 for	 NRas	 and	NRas/HRas	mutations,	respectively.	
		
5.2.2	 Extraction	 and	 quality	 control	 of	 RNA	 from	 mouse	





























































































































































































































































































































Fig.	 5.2	 Assessment	 of	 RNA	 quality	 by	 agarose	 gel	 electrophoresis	 of	
mouse	 tissues:	 intestine,	 stomach,	 liver	 and	 kidneys,	 throughout	





Fig.	 5.3	 Assessment	 of	 RNA	 quality	 by	 agarose	 gel	 electrophoresis	 of	
mouse	 tissues:	 heart,	 limb/muscle,	 brain	 and	 lungs,	 throughout	
development.	RNA	was	extracted	using	Norgen	RNA/protein	extraction	kit	and	1µg	 of	 RNA	was	 run	 per	 lane	 on	 1.2%	agarose	 gel.	 Two	distinct	 28S	 and	 18S	rRNA	bands	are	indicated	by	arrows.	The	figure	is	a	representative	example	of	three	 biological	 replicates	 of	 tissues	 harvested	 from	 the	 same	 litter	 and	 the	corresponding	 adult	mothers.	 Limb/muscle	 denotes	 either	 limb	 harvested	 on	E11.3	and	E13.5	or	skeletal	muscle	harvested	on	the	remaining	developmental	time	points.	E	–	embryonic	day,	P	–	postnatal	day,	bp	–	base	pairs,	28S	and	18S	–	rRNA	subunits.	
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5.2.3	 Absolute	 transcript	 copy	 number	 of	 Ras	 isoforms	 in	
mouse	adult	tissues	and	during	development	















































































































































































































































































































To	 measure	 Ras	 isoform	 abundance	 during	 mouse	 development,	 a	 restricted	panel	 of	 tissues	 used	 for	 the	 adult	 investigation	 was	 chosen.	 The	 analysis	consisted	 of	 10	 developmental	 time	 points	 using	 three	 biological	 replicates	representing	 distinct	 litters.	 Data	was	 collated	with	 that	 for	 adult	 tissue	 from	the	corresponding	mothers	 (Fig.	5.5	and	Fig.	5.6).	Overall,	 as	observed	 for	 the	adult	 tissues,	 KRasB	 was	 the	 most	 abundant	 transcript	 in	 all	 tested	 tissues.	Generally,	expression	levels	of	each	Ras	isoform	remained	constant	throughout	mouse	development;	the	two	notable	exceptions	were	for	NRas	and	KRasA,	for	which	statistical	analysis	was	performed	and	summarised	in	Fig.	5.7.			NRas	 transcript	 levels	 showed	 a	 progressive	 decrease	 during	 embryonic	development	across	many	tissues.	This	can	be	most	clearly	seen	in	the	brain	and	liver,	where	NRas	exhibits	a	10-fold	decrease	between	day	E11.5	and	post-natal	day	30	(Fig.	5.5	and	Fig.	5.6).	Intriguingly,	the	slope	of	these	decreases	differs;	in	liver	the	reduction	in	NRas	transcript	abundance	ceases	by	post-natal	day	5.	In	contrast,	 the	 brain	 exhibits	 a	 constant	 decrease	 over	 the	 entire	 time	 course;	although	 the	 values	 for	 post-natal	 day	 30	 are	 equivalent	 to	 the	 adult	 brain	levels,	suggesting	that	further	decreases	are	unlikely.		On	 the	 other	 hand,	 KRasA	 was	 the	 most	 dynamically	 regulated	 isoform.	 It	showed	a	marked	≥10-fold	increase	in	transcript	levels	in	the	intestine,	stomach	and	kidney	(Fig.	5.5)	during	embryonic	development,	which	stabilised	at	adult	levels	 just	 after	 birth	 (P0).	 Also,	 to	 a	 lesser	 extent,	 KRasA	 expression	 was	increasing	until	around	P25	in	the	liver	(Fig.	5.5).	Remarkably,	given	that	KRasA	has	not	previously	been	detected	in	the	heart	(Plowman	et	al.,	2003),	a	transient	peak	reaching	10-fold	baseline	levels	was	observed	just	before	and	at	birth	(Fig.	5.6,	E16.5	and	P0).	In	contrast,	KRasA	transcript	expression	was	continually	low	during	development	in	skeletal	muscle,	lung	and	brain	(Fig.	5.6).						
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Fig.	 5.7	 Statistical	 significance	 of	 Ras	 isoform	 transcript	 expression	 data	






























































































































































































































































To	 better	 illustrate	 a	 full	 mouse	 developmental	 profile	 for	 each	 Ras	 isoform	across	all	tested	tissues,	hierarchical	clustering	was	performed	on	the	qRT-PCR	data	from	this	study	(Fig.	5.8,	Fig.	5.9).	This	representation	of	the	data	revealed	that	 panRas	 expression	 levels	 decrease	 during	 development	 in	 all	 tissues	examined	(Fig.	5.8).	The	same	trend	was	also	seen	in	the	majority	of	tissues	for	most	Ras	 isoforms,	except	 for	KRasA	(Fig.	5.9).	The	 tissues	co-clustered	based	on	trends	in	transcript	levels,	highlighting	similar	upregulation	of	KRasA	in	the	kidney,	 stomach,	 intestine	 and	 liver.	 Strikingly,	 intestine,	 kidney	 and	 stomach	cluster	was	also	evident	in	the	KRasB	and	NRas	expression	profiles.	In	contrast	to	 KRasA,	 however,	 KRasB	 and	 NRas	 transcript	 levels	 decreased	 during	postnatal	 development	 in	 these	 tissues.	 HRas,	 on	 the	 other	 hand,	 showed	 a	distinct	expression	pattern	 from	other	 isoforms,	with	a	 less	clear	clustering	of	the	kidney,	stomach	and	intestine.																		
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Fig.	 5.8	 Heat	 map	 representing	 relative	 total	 Ras	 (panRas)	 transcript	

































































































































































To	investigate	whether	the	Ras	transcript	expression	profiles	were	indicative	of	expression	 at	 the	 protein	 level,	 absolute	 quantification	 of	 Ras	 isoforms	 using	mass	 spectrometry	 was	 employed.	 First,	 isotopically	 labelled	 Ras	 protein	standards	 were	 quality	 checked	 by	 gel	 electrophoresis	 and	 Colloidal	 Blue	staining	(Fig.	5.10).	The	gel	revealed	distinct	~30	kDa	bands	of	equal	densities	representing	 purified	 Ras	 standards	 of	 equal	 abundance.	 The	 NRas	 standard	showed	a	high-density	bovine	serum	albumin	(BSA)	band,	which	was	used	as	a	quenching	solution	to	stop	protein	standards	from	attaching	to	the	surface	of	a	tube.	 The	 standards,	 apart	 from	 KRasA,	 were	 subsequently	 spiked	 at	 known	concentrations	 into	 protein	 samples	 extracted	 from	 mouse	 tissues	 for	 Ras	isoform	quantification.	
	
	
Fig.	 5.10	 Assessment	 of	 protein	 quality	 of	 Ras	 standards	 labelled	 with	
heavy	 arginine	 (Arg10)	 and	 lysine	 (Lys8)	 for	 proteomics	 by	 gel	
electrophoresis.	50	ng	of	each	His-tagged	Ras	standard	(supplied	by	Dr	Craig	Mageean,	 University	 of	 Liverpool,	 UK)	 and	 a	 BSA	 control	were	 run	 on	 4-12%	Bis-Tris	 NuPAGE	 gel	 and	 stained	with	 the	 Colloidal	 Blue	 Staining	 Kit.	 All	 Ras	standards	showed	a	distinct	band	of	around	30	kDa	(denoted	by	arrow	“Ras”)	of	similar	abundance.	50	ng	of	bovine	serum	albumin	(BSA)	was	run	alongside	as	a	quantity	 control	 (denoted	 by	 arrow	 “BSA”).	 The	 BSA	 in	 the	 NRas	 standard	 is	from	the	BSA-coated	tube	that	was	used	to	reduce	adsorption	of	the	standard.	
	 135	














Fig.	 5.11	 Ras	 isoform	 protein	 levels	 in	 adult	 mouse	 tissues.	 A	 Total	 Ras	(panRas)	 as	well	 as	 individual	Ras	 isoform	protein	 levels	 per	 50µg	 of	 protein	based	 on	 absolute	 quantification	 by	 mass	 spectrometry	 (MS)	 of	 adult	 mouse	tissues	are	represented	as	means	±	SD	(n	=	3	technical	replicates)	on	a	log	scale.		
































































































In	 summary,	 proteomics	 data	 from	 this	 study	 shows	 a	 similar	 order	 of	decreasing	 expression	 level	 of	 total	 Ras	 as	 compared	 to	 mRNA	 levels	 in	 the	following	 tissues:	 brain,	 lung,	 intestine	 and	 liver	 (Fig.	 5.4	 A	 and	 Fig.	 5.11	 A).	However,	 the	 relative	 isoform	 contributions	 to	 total	 Ras	 abundance	 are	 not	equivalent	at	the	transcript	versus	protein	level.	For	example,	HRas	represented	only	2.4%	of	total	Ras	transcripts	in	the	brain	versus	the	KRasB	contribution	of	~90%,	yet	>50%	of	total	Ras	protein	abundance	measured	by	quantitative	mass	spectrometry	was	HRas.	Fig.	5.12	summarises	the	correlation	between	panRas	abundance	at	 transcript	 and	protein	 level	 in	 the	 four	mouse	organs	 for	which	both	transcript	and	protein	data	was	obtained.	Yet,	it	is	important	to	emphasise	that	this	proteomics	study	should	be	interpreted	with	some	caution	as	it	is	only	preliminary	and	represents	technical,	not	biological	repeats.						
5.3	 Discussion	











Fig.	 5.12	 Protein	 and	 transcript	 levels	 of	 Ras	 isoforms	 in	 normal	 adult	






















































































































































































































































5.3.1		 	 	 Comparison	with	previous	studies	
In	 general,	 transcript	 abundance	 results	 of	 the	 current	 study	 on	 adult	mouse	tissues	 showed	 little	 similarity	 with	 previous	 Northern	 blotting	 data,	 when	compared	 across	 tissues	 per	Ras	 isoform	 (Fig.	 5.13)	 (Leon	 et	 al.,	 1987).	HRas	transcript	abundance	was	 found	to	be	high	 in	 the	adult	mouse	skin,	brain	and	skeletal	 muscle	 and	 lowly	 abundant	 in	 the	 spleen.	 However,	 the	 earlier	 data	identified	the	liver	and	ovary	as	sites	with	the	least	HRas	expression,	whereas	in	this	 chapter	 they	were	 close	 to	median	values	 for	HRas	expression	across	 the	tissue	studied.	In	the	current	study,	NRas	transcripts	were	most	abundant	in	the	thymus,	ovary	and	uterus.	The	thymus	was	also	identified	as	a	site	of	high	NRas	expression	 in	 the	 Leon	 study	 and	 similarly	 to	 this	 earlier	 work,	 this	 study	showed	 that	 NRas	 abundance	 is	 lowest	 in	 the	 liver.	 Finally,	 there	 is	 some	similarity	with	previous	data	that	found	high	expression	of	KRas	in	the	thymus	and	low	in	the	skeletal	muscle	and	liver.	




Transcript	 expression	 of	 KRasA	 and	 KRasB	 splice	 isoforms	 in	 adult	 mouse	tissues	 in	the	current	study	(Fig.	5.4)	 is	similar	to	the	results	of	a	more	recent	work	 that	 investigated	 transcript	 levels	 of	 both	 these	 splice	 variants	by	 semi-quantitative	RT-PCR	in	adult	mice	(Plowman	et	al.,	2003).	It	showed	that	KRasA	was	highly	abundant	in	the	intestine,	kidneys	and	liver	and	was	also	expressed	in	the	stomach	and	lungs,	but	not	present	in	the	adult	heart	and	brain	and	that	KRasB	was	the	dominant	splice	variant	expressed	at	high	levels	in	all	tissues.	A	similar	 transcript	 expression	 pattern	 of	 KRasA	 and	 KRasB	 isoforms	 was	 also	previously	 shown	 in	 normal	 adult	 human	 tissues	 (Plowman	 et	 al.,	 2006,	Plowman	et	al.,	2003).		
According	to	the	current	work,	 transcript	expression	 levels	of	all	Ras	 isoforms	(panRas)	averaged	around	26	copies	per	pg	RNA	across	all	 the	normal	 tissues	examined	in	adult	mice.	Based	on	the	estimated	RNA	amount	per	cell	(Alberts	et	al.,	1994,	Copois	et	al.,	2003,	Ramskold	et	al.,	2012),	this	value	is	equivalent	to	around	520	Ras	transcripts	per	cell.	
After	 internal	 normalisation	 to	 total	 Ras	 transcript	 levels,	 both	 KRas	 splice	variants	 constituted	 the	most	 abundant	 Ras	 isoforms	 across	 all	 tested	mouse	adult	 tissues.	 One	 way	 to	 compare	 the	 tissues	 is	 to	 divide	 them	 into	 groups	based	 on	 their	 germ	 layer	 origin.	 The	 liver,	 lungs	 and	 the	 epithelium	 of	 the	gastrointestinal	 tract	 (including	 intestine	 and	 stomach)	 are	 of	 endodermal	origin	 (Gilbert,	2010).	Whilst	 the	pattern	of	Ras	 isoform	 transcript	expression	across	all	 these	 tissues	 is	varying,	 it	 is	notable	 that	 these	are	all	of	 the	 tissues	where	 KRasA	 is	 expressed	 at	 high	 levels,	 apart	 from	 the	 lungs	 (Fig.	 5.4	 B).	Another	exception	to	this	is	the	kidney,	which	harbours	high	KRasA	levels,	but	is	of	mesodermal	origin	(Gilbert,	2010).	Other	mesoderm-derived	tissues,	cardiac	and	skeletal	muscles,	have	very	low	KRasA	levels	(Fig.	5.4	B).	Finally,	the	skin,	which	is	both	of	mesodermal	and	ectodermal	origin	(Gilbert,	2010),	shows	low	levels	of	KRasA,	whereas	the	brain,	which	is	derived	from	the	ectoderm	(Gilbert,	2010),	 is	 the	 site	where	 Ras	 expression	 almost	 exclusively	 consists	 of	 KRasB.	Therefore, whilst	 it	 is	 difficult	 to	 identify	 clear	 correlations	 between	 tissue	origin	 and	 Ras	 expression,	 the	 link	 between	 endoderm-derived	 tissues	 and	KRasA	expression	may	be	of	interest.	
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5.3.2		 	 	 Dynamic	KRasA	expression	
Very	low	KRasA	abundance	detected	by	qRT-PCR	in	mouse	adult	heart,	skeletal	muscle	and	brain,	among	the	others,	may	actually	indicate	no	KRasA	expression	(Fig.	5.4	B	and	Fig.	5.6).	The	obtained	CT	values	 for	 these	 tissues	were	around	31,	which	was	within	 the	 range	 of	 the	 CT	 values	 for	 plasmid	 standard	 curves	and,	 hence,	 KRasA	 transcript	 abundance	 was	 calculated	 by	 interpolation.	However,	 the	 analysed	 tissues	 might	 have	 had	 some	 contaminants	 of	neighbouring	 tissues,	 e.g.	 connective	 tissues	 and	 blood,	 which	 could	 contain	higher	 amounts	 of	 KRasA,	 giving	 a	 positive	 signal	 for	 the	 tested	 tissue.	 This	could	be	 further	 investigated	by	measuring	KRasA	abundance	 in	mouse	 tissue	samples	obtained	by	microdissection.	





5.3.3	 Correlation	 between	 Ras	 isoform	 expression	 and	
cancer	
Based	 on	 the	 current	 results,	 it	 was	 of	 interest	 whether	 Ras	 isoform	 tissue-specific	 expression	 pattern	 related	 to	 the	 incidence	 of	 Ras	 isoform-specific	mutations	in	tumours	derived	from	particular	tissues	type.	For	example,	 it	has	been	 previously	 shown	 that	 higher	 transcript	 levels	 of	 KRasA	 in	 mouse	 lung	tissue	 correlate	 with	 increased	 risk	 of	 developing	 lung	 tumour	 (Wang	 et	 al.,	2001).	Among	murine	tissues	examined	in	the	current	study,	stomach,	intestine,	lungs	and	kidneys	are	the	sites	of	predominantly	KRas-driven	tumours,	namely	gastric,	colorectal	and	lung	adenocarcinomas	and	renal	papillary	cell	carcinoma	(Cox	et	al.,	2014).	All	these	tissues	have	high	transcript	expression	of	KRasA	and	KRasB	isoforms,	which	contribute	to	over	68%	of	total	Ras	(Fig.	5.4	B).		More	 generally,	 it	 is	 difficult	 to	 identify	 any	 link	 between	 expression	 and	Ras	mutation	 incidence	 in	 cancer	 due	 to	 the	 high	 abundance	 of	 KRas	 transcripts	across	all	tissues	(Fig.	5.4	B	and	Fig.	5.13).	For	example,	in	the	liver,	which	is	the	origin	 of	 hepatocellular	 carcinoma,	 the	 majority	 of	 Ras	 mutations	 are	 due	 to	activation	 of	 NRas	 (60%	 of	 total	 Ras),	 followed	 by	 KRas	 (40%	 of	 total	 Ras)	(Forbes	 et	 al.,	 2015).	 In	 this	 tissue,	NRas	 transcript	 expression	 contributes	 to	12%	of	total	Ras,	whereas	both	KRas	splice	variants	constitute	83%.		Several	 studies	 suggested	 that	 there	 is	 a	 positive	 correlation	 between	 gene	expression	 level	 and	 mutation	 frequency	 (Comeron,	 2004,	 Majewski,	 2003),	especially	 for	ubiquitously	expressed	genes	 (Cui	et	al.,	2012a,	Ramskold	et	al.,	2009),	both	 in	 somatic	 cells	 (Cui	 et	 al.,	 2012a)	and	 in	 the	germline	 (Cui	 et	 al.,	2012b,	Park	et	al.,	2012).	The	underlying	reason	for	such	observation	is	thought	to	 be	 the	 imbalance	 between	 transcription-associated	 mutagenesis	 (TAM)	(Hendriks	 et	 al.,	 2010,	 Herman	 and	 Dworkin,	 1971,	 Savic	 and	 Kanazir,	 1972)	and	 transcription-coupled-repair	 (TCR)	 (Green	 et	 al.,	 2003,	 Hanawalt,	 1994,	Svejstrup,	 2002),	 resulting	 in	 the	 increased	 density	 of	 single	 nucleotide	polymorphisms	(SNP)	(Cui	et	al.,	2012a,	Cui	et	al.,	2012b,	Park	et	al.,	2012).	This	thesis	 shows,	 however,	 that	 Ras	 transcript	 expression	 pattern	 in	 different	mouse	 adult	 tissues	 does	 not	 appear	 to	 correlate	 with	 the	 incidence	 of	 Ras	
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isoform	mutations	 in	 human	 cancers.	 There	might	 be	 a	 few	 reasons	why	 this	correlation	is	not	as	expected,	based	on	the	TAM-TCR	hypothesis.	First,	the	tested	tissues	were	derived	from	mouse,	not	human	samples,	and	the	genetics	 and	 tumour	 incidence	 in	both	 species	varies	 and	may	not	be	directly	comparable	(Anisimov	et	al.,	2005).	Hence,	to	better	understand	the	association	between	 gene	 expression	 and	 mutation	 frequency,	 normal	 human	 tissues	should	 be	 studied	 instead.	 Second,	 each	 cancer	 type	 derives	 only	 from	 a	particular	 cell	 type	 or	 a	 cancer	 stem	 cell	 (Lobo	 et	 al.,	 2007)	 and	 it	 would	 be	more	appropriate	 to	examine	Ras	expression	patterns	only	 in	 these	particular	cell	 types.	The	whole	organs,	as	examined	in	this	study,	comprise	a	mixture	of	tissues,	which	may	each	have	a	distinct	Ras	isoform	expression	profile.	Finally,	the	 incidence	of	Ras	 isoform-specific	mutations	 in	different	tissues	may	rather	arise	 from	 the	 predisposition	 of	 Ras	 isoform	 loci	 to	 particular	 carcinogens,	which	 usually	 affects	 particular	 tissue	 types.	 For	 instance,	 tobacco	 smoke	carcinogens	 affect	 the	 lungs	 and	 the	 mutational	 hotspot	 caused	 by	 these	carcinogens	 is	 codon	12	of	KRas,	but	not	of	NRas	or	HRas	 (Feng	et	 al.,	 2002).	This	 preferential	mutation	 in	 one	 of	 the	 three	Ras	 loci	might	 be	 explained	 by	preferential	 DNA-carcinogen	 adduct	 formation	 and	 poor	 repair	mechanism	 at	this	 particular	 site.	 Further	 research	 suggested	 that	 such	 preferential	mechanisms	 at	 codon	 12	 of	 KRas	 might	 be	 due	 to	 an	 unknown	 epigenetic	modification	(Hu	et	al.,	2003).		Curiously,	 another	 study	 depicted	 that	 differential	 susceptibility	 for	 certain	mutations	 in	 different	 Ras	 genes	 might	 be	 due	 to	 distinct	 sequences	surrounding	 each	 Ras	 gene.	 It	 showed	 that	HrasKI	 mice,	 which	 express	 HRas	under	 the	 regulation	 of	 KRas	 promoter	 and	 completely	 lack	 KRas	 expression,	still	develop	 lung	 tumours	due	 to	mutation	 in	HrasKI	allele	when	treated	with	urethane,	which	normally	causes	only	KRas	mutations	in	wild	type	mice	(To	et	al.,	 2008).	 On	 the	 other	 hand,	 induced	 skin	 tumours	 develop	 as	 a	 result	 of	mutation	 of	 endogenous	 Hras	 allele,	 not	 the	 “knock-in”	 HrasKI.	 Hence,	 the	predisposition	of	KRas	mutations	to	induce	lung	tumour	and	HRas	mutations	to	induce	 skin	 tumour,	 may	 likely	 be	 due	 to	 both	 Ras	 genes	 having	 unique	 cis-acting	 regulatory	 elements	 (CRE).	 CREs	 are	 non-coding	 DNA	 sites	 found	 near	
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the	 gene,	 which	 are	 usually	 binding	 sites	 for	 transcription	 factors.	 Taken	together,	 the	reason	why	specific	cancers	and	mutations	couple	 to	certain	Ras	isoforms	appears	to	be	complex	and	it	is	possible	that	a	mixture	of	factors	could	affect	 it,	 including	 gene	 regulatory	 elements,	 expression	 levels	 and	 epigenetic	regulation.			
5.3.4	 Transcript	versus	protein	abundance	
To	 examine	 whether	 Ras	 isoform	 expression	 profiles	 at	 transcript	 level	 hold	true	also	at	protein	 level,	 the	 study	of	 this	 thesis	used	proteomics	analysis	on	samples	 derived	 from	 the	 same	 mouse	 tissues	 previously	 used	 for	 qRT-PCR	analysis	(section	5.2.2	and	5.2.3).	An	earlier	study	in	NIH3T3	mouse	fibroblasts	showed	 that	 41%	 genes	 correlated	 in	 relative	 abundance	 at	 the	 protein	 and	transcript	 level	 and	 that	 the	 protein	 abundance	 per	 cell	 is	 about	 900	 times	higher	than	that	of	the	corresponding	mRNA	(Schwanhausser	et	al.,	2011).	The	study	of	this	thesis	generated	preliminary	data	on	absolute	quantification	of	Ras	isoform	protein	expression	in	adult	mouse	tissues	(Fig.	5.11).		However,	the	contribution	of	individual	Ras	isoforms	to	total	Ras	abundance	at	protein	 level	did	not	parallel	 the	Ras	 transcript	profiles	 in	 this	 study	(Fig.	5.4,	Fig.	 5.12	 B).	 Specifically,	 KRas	 protein	 contributed	 far	 less	 to	 total	 Ras	abundance	 than	predicted	 from	the	 transcript	data.	The	 findings	 in	 this	 thesis	contrast	with	mass	 spectrometry	 analysis	 in	 NIH3T3	 cells	 (Schwanhausser	 et	al.,	 2011),	 which	 found	 that	 NRas	 is	 a	 dominant	 Ras	 isoform	 contributing	 to	around	85%	of	 total	Ras,	while	KRas	and	HRas	are	 lowly	abundant	with	10%	and	5%	contribution,	 respectively.	However,	 the	proteome	data	was	generally	consistent	 with	 previous	 findings	 across	 different	 human	 cancer	 cell	 lines,	 in	which	Western	 blotting	 revealed	 that	 typically	 KRas	 is	 the	 dominant	 isoform,	whereas	HRas	contributes	to	less	than	10%	of	total	Ras	(Omerovic	et	al.,	2008).		The	 method	 used	 in	 this	 thesis	 to	 quantitatively	 determine	 Ras	 protein	abundance	 at	 endogenous	 levels	 utilised	 full-length	 Ras	 standards	 that	 were	spiked	 into	 the	 lysate	 prior	 to	 any	 further	 sample	 processing,	 which	 allowed	
	 146	
avoiding	 inefficiencies	 associated	 with	 gel	 extraction	 and	 Ras	 proteolysis	(Mageean	et	al.,	2015).	This	was	in	contrast	to	previous	studies,	which	spiked	in	the	standards	just	prior	to	the	analysis	by	the	mass	spectrometer	and	resulted	in	 a	 wide	 spread	 of	 the	 data	 (Halvey	 et	 al.,	 2012,	 Ruppen-Canas	 et	 al.,	 2012,	Wang	et	al.,	2011).		The	 preliminary	 results	 presented	 in	 this	 thesis	 showed	 that	 panRas	 protein	levels	ranged	between	44-770	ng	of	panRas	per	mg	of	total	protein,	depending	on	 tissue	 type	 (Appendix	 Table	 A5.1).	 This	 value	 is	 similar	 to	 90-220	 ng	 of	endogenous	panRas	per	mg	of	total	protein	found	in	SW48	colorectal	cancer	cell	line	using	the	same	method	(Mageean	et	al.,	2015)	and	 it	 is	especially	striking	that	intestinal	tissue	examined	in	this	thesis	had	93	ng	of	panRas	per	mg	of	total	protein.	It	is	difficult	to	estimate	the	absolute	number	of	Ras	protein	molecules	per	 cell,	 as	 total	 protein	 content	 per	 cell	 is	 approximate	 and	 may	 vary	depending	on	cell	type	(Lodish	et	al.,	2000).	Unfortunately,	the	measurement	of	cell	 number	 in	 heterogeneous	 tissues	 was	 beyond	 the	 scope	 of	 this	 study.	Nevertheless,	 it	might	 be	 accurate	 to	 estimate	 the	 total	 Ras	 abundance	 in	 the	intestine	to	around	250,000	molecules	per	cell,	as	this	was	the	calculated	value	based	 on	 90	 ng	 of	 panRas	 per	 mg	 protein	 in	 SW48	 cell	 line	 (Mageean	 et	 al.,	2015).		
	The	discrepancy	between	relative	transcript	versus	protein	abundance	of	each	Ras	isoform	(Fig.	5.12	B)	might	be	explained	by	a	recent	finding,	which	showed	that	KRAS	is	poorly	translated	as	compared	to	HRAS	due	to	the	presence	of	rare	codons	 in	 the	genomic	 sequence	of	KRAS	 (Lampson	et	 al.,	 2013).	Rare	 codons	appear	infrequently	in	the	genomic	sequence	as	compared	to	other	degenerate	codons	 that	 encode	 for	 the	 same	 amino	 acid.	As	 a	 result,	 rare	 codons	 impede	translation	 and	 cause	 ribosome	 stalling,	 thus	 leading	 to	 lower	 than	 expected	protein	 levels.	 Interestingly,	 rare	 codon	 bias	 in	 the	 KRAS	 gene	 in	 conserved	across	mammalian	species	and,	hence,	is	relevant	to	the	to	mouse	KRas	protein	levels	investigated	in	this	thesis.		
	 147	





6.1	 	 Introduction	All	 cells	 express	 three	 almost	 identical	Ras	proteins	 (HRas,	KRasB	 and	NRas).		Mouse	knockout	data	demonstrates	that	KRasB	is	uniquely	required	for	normal	development,	 whereas	 HRas	 and	 NRas	 are	 dispensable,	 suggesting	 isoform-specific	 functions	of	 the	Ras	proteins	 (Koera	et	 al.,	 1997,	 Johnson	et	 al.,	 1997,	Plowman	et	al.,	2003,	Umanoff	et	al.,	1995,	Esteban	et	al.,	2001).	Similarly,	KRas	is	 far	 more	 frequently	 mutated	 in	 cancer	 implying	 a	 particular	 oncogenic	potency	that	is	not	yet	fully	understood	(Cox	et	al.,	2014,	Quinlan	and	Settleman,	2008).	
Current	 research	 suggests	 that	 stimulation	 of	 downstream	 signalling	 is	 Ras	isoform-specific,	 due	 to	 differential	 coupling	 of	 isoforms	 to	 effector	 proteins	(Voice	et	al.,	1999,	Yan	et	al.,	1998)	and	feedback	loops	(Eser	et	al.,	2014,	Fivaz	et	 al.,	 2008,	 Thevathasan	 et	 al.,	 2013).	 Early	 studies	 based	 on	 ectopic	overexpression	 of	 Ras	 isoforms	 revealed	 that	 HRas	 and	 NRas	 are	 better	activators	 of	 PI3K	whilst	 KRasA	 and	KRasB	were	 better	 activators	 of	 Raf	 and	Rac	 than	 the	 other	 Ras	 isoforms	 (Voice	 et	 al.,	 1999,	 Yan	 et	 al.,	 1998).	 A	 key	drawback	with	this	approach	is	that	overexpression	of	Ras	can	lead	to	signalling	perturbation	and	profound	phenotypic	outputs	such	as	senescence	that	are	not	seen	with	oncogenic	Ras	 signalling	 from	 the	endogenous	 locus	 (Serrano	et	al.,	1997,	Tuveson	et	al.,	2004).	More	recent	work	utilised	in	vivo	approaches,	such	as	 knock-in	 (KI)	mice	 (Di	Nicolantonio	 and	Bardelli,	 2013,	Haigis	 et	 al.,	 2008,	Tuveson	et	al.,	2006),	as	well	as	methods	to	examine	endogenous	Ras	signalling	in	 various	 cell	 lines,	 using	 siRNA	 (Fleming	 et	 al.,	 2005,	Omerovic	 et	 al.,	 2008)	and	gene	KI	(isogenic	cell	lines	–	(Arena	et	al.,	2007,	Vartanian	et	al.,	2013)).	
Unfortunately,	most	of	these	techniques	analysed	only	one	or	two	Ras	isoforms	in	 an	 endogenous	 context	 or	 likely	 showed	 compensation	 effects	 of	 other	isoforms,	as	in	case	of	siRNA	(Omerovic	et	al.,	2008).	Therefore,	the	aim	of	this	
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chapter	is	to	present	a	method,	in	which	the	signalling	of	all	three	Ras	isoforms	is	compared	 in	a	normal	physiological	environment.	The	use	of	mouse	models	bearing	specific	KI	of	a	mutation	for	each	Ras	isoform	would	be	costly	and	time-consuming.	 Thus,	 a	 panel	 of	 cell	 lines	 isogenic	 with	 an	 endogenous	heterozygous	 codon	 mutation	 for	 each	 Ras	 isoform	 represents	 a	 plausible	higher-throughput	 alternative	 allowing	 endogenous	 isoform-specific	 Ras	signalling	to	be	compared	against	the	same	genetic	background.	
Isogenic	cells	harbouring	oncogenic	KRas	variants	have	already	been	generated	and	extensively	characterised.	These	comprise	colorectal	HCT-116	(G13D)	and	DLD-1	(G13D)	and	HEC1A	(G12D)	endometrial	cells	where	the	indicated	mutant	KRas	allele	was	deleted	(Kim	et	al.,	2004,	Shirasawa	et	al.,	1993)	and	MCF10a	breast	 cancer	 cells	 where	 a	 G12V	mutation	 was	 introduced	 into	 a	 KRas	 wild	type	 allele	 (Konishi	 et	 al.,	 2007).	 There	 are	 two	 specific	 problems	with	 these	models.	The	 first	 is	 that	 for	HCT-116,	DLD-1	and	HEC1A	 the	parental	 cell	 line	has	 only	 one	 wild	 type	 KRas	 allele,	 potentially	 reducing	 endogenous	 KRas	protein	expression	compared	to	the	mutant	isogenic	cell	line.	The	second	is	that	for	all	of	the	isogenic	models	there	has	been	a	focus	on	KRas	effectors	and	there	are	 no	 corresponding	 mutations	 in	 the	 other	 Ras	 isoforms	 that	 have	 been	generated.	
More	 recently	 a	 panel	 of	 isogenic	 colorectal	 SW48	 cells	 harbouring	 different	KRas	point	mutations	has	been	generated	using	adeno-associated	virus	 (AAV)	gene	editing	technology	(De	Roock	et	al.,	2010).	These	have	been	supplemented	by	Horizon	Discovery,	 so	 that	 now	 there	 is	 a	 panel	 of	 14	 Ras	mutant	 variant	isogenic	SW48	cells.	These	include	cells	harbouring	G12V	mutations	in	HRas	or	KRas	that	have	now	been	complemented	by	NRas	G12V	SW48	cells	produced	by	the	Prior	laboratory.	
Colorectal	cancer	(CRC)	 is	 the	third	most	common	human	cancer	(Hamilton	et	al.,	 2010)	 and	 colorectal	 adenocarcinoma	 is	 its	most	 prevalent	 type,	 which	 is	derived	from	epithelial	cells	of	the	colorectal	mucosa	(Fleming	et	al.,	2012).	Ras	mutations	occur	in	over	50%	of	colorectal	adenocarcinoma	cases,	making	it	the	second	 cancer	 type	 with	 most	 prevalent	 Ras	 mutations	 (Forbes	 et	 al.,	 2015,	
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Prior	 et	 al.,	 2012).	 85%	 of	 these	 mutations	 are	 in	 the	 KRAS	 gene,	 with	 the	remaining	ones	occurring	in	the	NRAS	gene	and	no	mutations	in	HRAS.		
Although	 the	 most	 common	 KRas	 mutation	 in	 colorectal	 cancers	 is	 G12D	(Forbes	et	al.,	2015),	substitution	of	the	same	codon	with	valine	residue	(G12V)	leads	 to	 more	 aggressive	 cancer	 phenotypes	 and	 is	 associated	 with	 lower	survival	rates	in	patients,	compared	to	other	KRas	mutations,	as	well	as	the	wild	type	 protein	 (Winder	 et	 al.,	 2009).	 Indeed,	 G12V	mutation	 of	 Ras	 is	 generally	associated	with	greater	transforming	efficiency	than	G12D	and	other	mutations	(Fasano	et	al.,	1984,	Seeburg	et	al.,	1984).	In	a	mouse	colorectal	cancer	model,	KRasG12V	 also	 shows	 higher	 metastatic	 efficiency	 and	 lower	 apoptosis	 than	another	common	mutant	KRasG13D	(Alamo	et	al.,	2015).	Consistent	with	 this,	different	activating	oncogenic	mutations	of	KRas	exhibit	distinct	proteome	and	phosphoproteome	signatures	(Hammond	et	al.,	2015,	Miller	and	Miller,	2011).	This	 also	 has	 therapeutic	 implications	 since	 colorectal	 cancer	 tumours	 with	codon	12	mutations	 of	KRas	 are	 resistant	 to	 the	EGFR	 inhibitor	 cetuximab	 as	opposed	 to	 tumours	 with	 wild	 type	 KRas	 or	 bearing	 other	 KRas	 mutations	(Amado	et	 al.,	 2008,	Karapetis	 et	 al.,	 2008). Therefore,	when	 investigating	 the	differences	in	isoform-specific	oncogenic	Ras	signalling,	it	is	important	that	each	isoform	harbours	the	same	oncogenic	mutation.	





















6.2.1	 	 Cell	growth	kinetics	of	SW48	isogenic	cell	lines	To	 compare	 cell	 growth	 kinetics	 between	 SW48	 cell	 lines	 isogenic	 for	 Ras	isoform	mutations,	CellTiter-Glo®	Luminescent	Cell	Viability	Assay	was	used	to	measure	 the	 number	 of	 viable	 cells	 during	 cell	 culture.	 The	 assay	 measures	cellular	ATP	and	therefore	is	a	read-out	of	cellular	metabolism,	which	at	least	in	part	will	correlate	with	the	growth	kinetics	of	the	cells.		Parental	SW48	cell	line	was	empirically	observed	 to	be	 the	 fastest	growing	of	all	SW48	 isogenics	and,	hence,	was	chosen	to	optimise	 the	seeding	density	(Fig.	6.1).	The	cell	 line	was	seeded	 on	 a	 96-well	 plate	 at	 the	 following	 densities,	 each	 in	 5	 technical	replicates:	 0,	 250,	 500,	 750,	 1000,	 1250,	 1500,	 2000,	 2500,	 3000,	 4000	 and	5000	cells	per	well.	The	luminescence	was	measured	after	5	days	of	continuous	cell	 culture	 and	 background	 luminescence	 from	wells	 with	medium	 only	was	subtracted.	
Based	on	the	results	(Fig.	6.2),	SW48	parental	cell	line	showed	a	linear	growth	at	cell	densities	up	to	around	1000	cells	per	well,	from	which	the	growth	curve	started	to	plateau.	To	make	sure	that	the	cell	growth	is	within	the	linear	range	after	5	days	of	culture,	750	cells	per	well	were	chosen	as	a	starting	density	for	the	next	experiment,	in	which	the	growth	kinetics	of	all	SW48	isogenic	cell	lines	was	measured	(Fig.	6.3).	

























































mutation	seems	 to	negatively	affect	 the	growth	of	SW48	colorectal	 cancer	cell		line	when	present	in	NRas,	but	not	in	other	Ras	isoforms.	However,	such	effect	might	be	clone-specific	and,	hence	more	clones	bearing	Ras	mutations	should	be	tested.	
To	 investigate	 whether	 the	 G12V	 mutation	 affects	 Ras	 isoform	 abundance,	Western	 blotting	 was	 performed	 on	 lysates	 from	 all	 isogenic	 SW48	 cell	 lines	using	 isoform-specific	 antibodies	 (Fig.	 6.4).	 When	 compared	 to	 actin	 loading	control,	 the	 expression	 of	 Ras	 isoforms	 and	 total	 Ras	 was	 slightly	 variable	across	 the	different	 isogenic	 cell	 lines,	 both	when	cultured	 in	normal	medium	(10%	FBS)	or	starved.	This	experiment,	however,	represents	only	one	biological	repeat.	
	
6.2.2	 	Differential	activation	of	PI3K	and	MAPK	pathways		








































































































































































































Fig.	 6.6	 Activation	 of	 downstream	 MAPK	 signalling	 pathway	 in	 Ras	
isogenic	 SW48	 cell	 lines	 depending	 on	 stimulation	 with	 different	




































































Fig.	 6.7	 Activation	 of	 MAPK	 and	 PI3K	 pathways	 in	 Ras	 isoform	 SW48	
isogenic	 cell	 lines	 by	 EGF	 stimulation.	 A	 A	 representative	 blot	 (n	 =	 3	biological	replicates)	–	a	re-run	of	samples	from	EGF	gradient	in	Fig.	6.5	and	Fig.	6.6	 now	 in	 one	 blot.	 B	 Relative	 quantification	 of	 Akt-pS473	 (pAkt)	 and	MEK-	pS217/pS221	(pMEK)	from	A	normalised	to	actin	and	total	Akt	or	MEK	protein.		SW48	cell	lines:	P	–	parental,	H	–	HRasG12V,	K	–	KRasG12V,	N	–	NRasG12V.	Data	was	analysed	by	one-way	ANOVA	with	Fisher's	LSD	post-hoc	test.	*	p	≤	0.05,	**	p	≤	0.01	













































































Fig.	 6.8	 Differential	 response	 to	 EGF	 in	 Ras	 isoform	 SW48	 isogenic	 cell	































































































experiments	 and	 it	 was	 also	 present	 for	 downstream	 ERK.	 However,	 these	results	were	only	based	on	one	biological	repeat	and,	hence,	more	experiments	are	needed	to	determine	phosphorylation	status	of	ERK.	
All	 in	 all,	 Western	 blotting	 of	 Ras	 isogenic	 cell	 lines	 suggests	 that	 there	 are	different	 signalling	 strengths	 downstream	 of	 Ras	 depending	 on	 the	 isoform	mutated	 and	 they	 all	 respond	 differently	 to	 EGF	 stimulation	 in	 activating	canonical	pathways	PI3K	and	MAPK.	These	differences	may	arise	from	varying	sensitivity	 of	 Ras	 isoforms	 to	 stimulation	 and	 negative	 feedback	 loops	within	pathways,	which	will	be	further	discussed	in	the	next	sections.	
	
6.2.3	 	Isoform-specific	Ras	networks		The	following	sections	describe	outcomes	of	stimulation	and	inhibition	of	Ras-dependent	pathways.	For	each	experiment,	a	concentration	gradient	of	either	a	GF	 or	 an	 inhibitor	 was	 used	 to	 measure	 the	 differences	 in	 signalling	 and	phosphorylation	 status	 of	 proteins	 either	 upstream	 or	 downstream	 of	 Ras	 by	Western	blotting.	
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Fig.	 6.9	 Phosphorylation	 status	 of	 EGFR	 in	 SW48	 Ras	 isogenic	 cell	 lines.	Cells	 were	 starved	 and	 stimulated	 with	 different	 EGF	 concentrations.	 A	Immunoblot	 of	 EGFR,	 EGFR-pY1068	 (pEGFR)	 and	 representative	 actin.	 B	Relative	quantification	of	EGFR-pY1068	normalised	to	actin	and	C	 to	actin	and	total	EGFR	protein.	Arrow	indicates	the	size	of	the	blotted	protein.		
	(Fig.	6.9).	On	the	other	hand,	NRasG12V	trends	towards	the	lowest	activation	of	EGFR,	whilst	HRasG12V	 is	 similar	 to	 that	of	wild	 type	Ras.	There	may	also	be	subtle	differences	in	receptor	abundance	that	are	investigated	further	later	(Fig.	6.12).	













































































































B	 		 	 	 						C	
		
	






















































																																							EGFR	 	 	 	 									Met	
								 		 	 			IGFR1β								
Fig.	 6.12	 Differential	 expression	 of	 cell	 membrane	 receptors	 in	 SW48	






















































G12	 mutations	 (Hammond	 et	 al.,	 2015).	 Whilst	 IGFR1β	 levels	 are	 equivalent	across	 most	 of	 the	 cell	 lines,	 there	 is	 a	 trend	 for	 reduced	 expression	 in	 the	KRasG12V	cell	line.		
In	summary,	both	upstream	and	downstream	components	of	the	Ras	signalling	pathway	exhibit	clear	differences	in	abundance	or	phosphorylation	in	each	Ras	isoform	mutant	cell	 line.	Further	work	 is	required	to	reproduce	some	of	 these	data	and	to	determine	the	extent	to	which	these	changes	are	dependent	on	the	presence	of	the	mutant	Ras	protein.			
		
6.2.3.2	 Inhibition	of	Ras	downstream	signalling	 				Network	biology	analysis	requires	measurement	of	both	the	activation	of	nodes	within	a	network	and	the	network	responses	to	inhibition	of	nodes.	The	use	of	inhibitors	 helps	 to	 reveal	 the	 extent	 to	 which	 negative	 feedback	 loops	 are	engaged	 within	 the	 network.	 To	 optimise	 the	 conditions	 for	 future	 network	biology	analysis,	concentration	gradients	of	a	range	of	 inhibitors	were	used	to	measure	 attenuation	 of	 signalling	 downstream	 of	 the	 target.	 Inhibition	 was	performed	 for	 1	 hour,	 followed	 by	 stimulation	 for	 20	minutes	with	 20%	 FBS	containing	the	inhibitor.	LY294002	was	used	to	reversibly	inhibit	PI3K	(Mena	et	al.,	 2014,	Wu	 et	 al.,	 2014)	 and	 the	 level	 of	 inhibition	 of	 downstream	Akt	was	measured	 by	 Western	 blotting	 for	 pAkt	 (Fig.	 6.13).	 An	 almost	 complete	attenuation	 of	 phosphorylation	 of	 Akt	 was	 seen	 at	 around	 20µM	 drug	concentration	 and	 the	 IC50	 across	 all	 Ras	 isoforms	 were	 similar	 (0.01-0.02).		Total	Akt	protein	levels	were	equivalent	across	all	cell	lines.	
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Fig.	6.13	Inhibition	of	PI3K	in	SW48	Ras	 isogenic	cell	 lines	with	different	
LY294002	 concentrations.	A	 Immunoblotting	 of	 Akt,	 Akt-pS473	 (pAkt)	 and	representative	actin.	B	Relative	quantification	of	Akt-pS473	(pAkt)	to	actin	and	
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Fig.	 6.14	 Inhibition	 of	 MEK1/2	 in	 SW48	 Ras	 isogenic	 cell	 lines	 with	
different	 AZD6244	 concentrations.	 A	 Immunoblotting	 of	 ERK,	 ERK-pT202/pY204	 (pERK)	 and	 representative	 actin.	 B	 Relative	 quantification	 of	ERK-pT202/pY204	 (pERK)	 to	 actin	 and	 C	 to	 actin	 and	 total	 ERK	 protein. Isogenic	cells	were	serum	starved	for	24	hours	before	addition	of	AZD6244	for	1	 hour	 and	 then	 addition	 of	 20%	 FBS	 for	 20	minutes.	 n=1.	 P	 –	 parental,	 H	 –	HRasG12V,	N	–	NRasG12V,	K	–	KRasG12V	SW48	cell	lines.	



















































varying	 levels	 of	 inhibition	 depending	 on	 the	 Ras	 isoform	 that	 was	 mutated.	First	 of	 all,	 Parental	 and	 NRasG12V	 cells	 display	 only	 low	 pp70S6K	 levels	compared	 to	 the	 other	 Ras	mutant	 cell	 lines.	 This	means	 that	 it	 is	 difficult	 to	distinguish	responses	to	treatment	with	different	concentrations	of	Rapamycin	(Fig.	6.15B).	The	most	striking	observation	is	that	the	HRasG12V	and	KRasG12V	cell	 lines	 display	 reciprocal	 responses	 to	Rapamycin	 treatment	with	 pp70S6K	almost	completely	reduced	at	around	0.2	µM	in	HRasG12V	cells.	In	contrast,	the	KRasG12V cell	 line	 showed	 an	 initial	 reduction	 of	 pp70S6K	before	 it	went	 up	again	 and	 exceeded	 basal	 level	 straight	 at	 doses	 greater	 than	 0.2	 µM	 of	Rapamycin.	This	may	suggest	relief	of	a	negative	feedback	loop.	
The	final	inhibitor	used	was	Sorafenib,	which	inhibits	Raf	kinase	(Wilhelm	et	al.,	2004).	 However,	 it	 also	 inhibits	 tyrosine	 kinase	 receptors	 involved	 in	angiogenesis	 at	 higher	 doses.	 To	 measure	 its	 inhibition	 effectiveness	 at	inhibiting	Ras	in	Ras	isogenic	cell	lines,	phosphorylation	of	the	Raf	effector	MEK	was	measured	(Fig.	6.16).	Unfortunately,	pMEK	levels	did	not	seem	to	decrease	with	 higher	 Sorafenib	 concentrations	 in	 neither	 of	 the	 cell	 lines.	 This	observation	 could	 not	 be	 explained	 by	 the	 sensitivity	 of	 pMEK	 antibody,	 as	 it	was	 working	 in	 previous	 experiments	 (Fig.	 6.5,	 Fig.	 6.6,	 Fig.	 6.7).	 It	 seemed	plausible	at	first	to	check	Sorafenib	inhibition	potency	at	higher	concentrations	and/or	 longer	 inhibition	 times.	 Hence,	 optimisation	 of	 Raf	 inhibition	 by	Sorafenib	is	shown	in	the	next	section.	
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Fig.	6.15	Inhibition	of	mTOR	in	SW48	Ras	isogenic	cell	lines	with	different	
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Fig.	 6.16	 Inhibition	 of	 Raf	 in	 SW48	Ras	 isogenic	 cell	 lines	with	 different	
























































	To	optimise	Raf	inhibition	in	Ras	isogenic	cell	lines,	Sorafenib	concentration	was	increased	to	100	µM	and	incubation	time	to	either	2	or	16	hours.	Parental	SW48	cell	 line	 was	 treated	 as	 a	 representative.	 To	 check	 whether	 Sorafenib	 was	working	properly,	a	control	sample	treated	with	the	same	inhibitor,	but	from	a	different	 supplier	 (Santa	 Cruz),	was	 used	 alongside	 the	 old	 one	 on	 a	Western	blot	(Fig.	6.17).		Moreover,	pERK	levels	were	measured	together	with	pMEK	and	the	corresponding	non-phosphorylated	protein.		




hours.	Cells	were	grown	either	in	normal	(10%	FBS)	medium	(non-starved)	or	were	serum-starved	and	stimulated	with	20%	FBS	 for	20	min.	 	 Sorafenib	was	added	for	the	indicated	amounts	of	time	before	stimulation	and	cell	harvesting.	The	 figure	 represents	 immunoblotting	 of	 MEK,	 MEK-pS217/pS221	 (pMEK),	ERK,	 ERK-pT202/pY204	 (pERK)	 and	 representative	 actin.	 Soraf.	 inc.	 t	 [h]	 –	Sorafenib	incubation	time	in	hours.			
Complete	 response	 to	 inhibition	 by	 Sorafenib	 was	 achieved	 already	 at	 30µM	after	16	hours	of	incubation	for	the	parental	cell	line.	Hence,	this	concentration	was	used	as	a	maximum	in	the	concentration	gradient	to	measure	the	response	to	 inhibition	 in	 the	remaining	 isogenic	cell	 lines	 (Fig.	6.18).	Unfortunately,	 the	previously	observed	response	in	the	parental	cell	line	was	not	reproduced.	After	16	 hours	 of	 inhibition,	 pMEK	 levels	 seemed	 to	 increase	 with	 higher	concentrations	of	Sorafenib.	Such	increase	in	phosphorylation	was	also	seen	for	KRasG12V	 cell	 line.	 However,	 for	 NRasG12V	 and	 HRasG12V	 cell	 lines,	 the	increase	in	pMEK	levels	was	followed	by	a	rapid	decrease	in	phosphorylation	at	30µM	and	20µM	of	Sorafenib,	 respectively.	For	HRasG12V	very	 few	cells	were	recovered	 from	 the	 treatment	 with	 Sorafenib	 at	 30µM	 and	 therefore	 the	corresponding	lane	on	the	Western	blot	was	left	blank	(Fig.	6.18).	It	seemed	that	
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both	 HRasG12V	 and	 NRasG12V	 cell	 lines	 were	 more	 responsive	 to	 Sorafenib	treatment	 than	 the	 parental	 and	 KRasG12V	 cell	 lines.	 Nonetheless,	 the	inhibitory	 effect	 seemed	 also	 to	 contribute	 to	 cellular	 toxicity,	 at	 least	 in	HRasG12V	cell	line.		




Fig.	 6.18	 Inhibition	 of	 Raf	 with	 Sorafenib	 for	 16	 hours	 in	 SW48	 Ras	




Fig.	 6.19	 Micrographs	 of	 SW48	 Ras	 isogenic	 cell	 lines	 treated	 with	 Raf	
inhibitor	 Sorafenib.	 Cells	 were	 grown	 in	 full	 medium	 (10%	 FBS)	 or	 were	serum	 starved	 (0%	 FBS)	 for	 24	 hours,	 followed	 by	 incubation	 with	 30µM	Sorafenib	 for	 16	 or	 4	 hours.	 Cells	were	 then	 stimulated	with	20%	FBS	 for	 20	minutes	and	visualised	by	contrast	microscopy.	Scale	bar	=	100	μm.		
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When	grown	in	full	medium	(10%	FBS),	the	cell	size	for	SW48	HRasG12V	was	bigger	than	for	the	remaining	SW48	cell	lines	(Fig.	6.19).	The	cell	size	difference	was	even	more	striking	 for	 serum-starved	cell	 lines.	When	 treated	with	30µM	Sorafenib	 for	 16	 hours,	 in	 non-starved	 cell	 lines,	 cell	 size	 decreased	substantially	 as	 compared	 to	 non-treated	 cells,	 as	 if	 the	 cells	 were	 shrinking,	perhaps	 due	 to	 apoptosis	 or	 the	 loss	 of	 adhesion.	 Remarkably,	 cell	 density	seemed	to	be	constant,	regardless	of	Sorafenib	treatment.		
In	starved	cells	incubated	with	Sorafenib,	the	cells	also	looked	apoptotic,	but	the	density	dramatically	decreased,	especially	in	KRasG12V	cell	line,	as	compared	to	non-starved	cells.	In	SW48	HRasG12V	cell	line,	clumps	of	cells	detached	from	the	plate	 surface	 were	 floating	 in	 the	 medium,	 suggesting	 that	 the	 reduction	 in	density	may	be	due	to	dysfunctional	adhesion.	
The	shrinking/apoptotic	effect	of	Sorafenib	treatment	was	also	apparent	in	cells	which	 were	 starved	 and	 stimulated	 with	 20%	 FBS	 for	 20	 minutes.	 SW48	parental	 cell	 line	 seemed	 to	 maintain	 higher	 density	 than	 its	 Ras	 isogenic	derivative	cell	 lines.	This	might	be	due	to	a	 lower	number	of	apoptotic	cells	 in	SW48	 parental	 cell	 line	 and	 may	 indicate	 better	 resistance	 to	 Sorafenib	treatment.	For	HRasG12V	cell	line,	a	cluster	of	floating	cells	was	present	again,	which	could	explain	why	a	low	number	of	cells	were	recovered	in	the	previous	experiment	 (Fig.	 6.18).	 Finally,	when	 treated	with	 Sorafenib	 for	 only	 4	 hours,	the	 shrinking	 effect	 was	 still	 preserved	 in	 parental	 cell	 line,	 but	 not	 in	 the	remaining	 cell	 line.	 Cell	 densities	 also	 appeared	 to	 be	 higher,	 as	 compared	 to	treatment	for	16	hours.		




6.3		 	 	 Discussion	This	 chapter	 focused	 on	 endogenous	 Ras	 isoform-dependent	 signalling	 in	 a	context	 of	 a	 human	 colorectal	 cancer	 cell	 line.	 Fully	 diploid	 SW48	 cell	 lines	isogenic	 for	 a	 heterozygous	 G12V	 mutation	 in	 each	 of	 the	 three	 RAS	 genes	allowed	 to	 directly	 compare	 Ras	 isoform	 signalling	 outcomes	 by	 providing	identical	genetic	background	for	each	cell	line	and	endogenous	protein	levels.		
The	limitations	of	this	study	included	the	use	of	only	single	cell	clones,	i.e.	only	one	 of	 each	 NRas,	 KRas	 and	 HRas	 cell	 line	 clone	 with	 G12V	 mutation	 was	compared.	The	lack	of	comparison	of	cell	lines	derived	from	other	clones	of	the	parental	SW48	cell	line	raises	the	possibility	of	unnoticed	clonal	artefacts,	which	may	have	been	taken	as	true	isoform-specific	responses.	Cells	derived	from	the	parental	 cell	 line	 by	 clonal	 selection	 (limited	 dilution	method	 –	 (Dexter	 et	 al.,	1978))	 can	 show	 different	 phenotypical	 properties,	 such	 as	 doubling	 time,	colony	formation	 in	soft	agar	and	metastatic	potential	(Li	et	al.,	2001,	Ware	et	al.,	 2007).	 Hence,	 it	 is	 important	 to	 compare	 at	 least	 2-3	 different	 clones	 to	assure	the	accuracy	of	the	results.	
Nevertheless,	these	preliminary	results	suggested	marked	differences	between	the	 signalling	 of	 distinct	 Ras	 isoforms	 and	 the	 phenotypic	 changes	 of	 the	isogenic	 cell	 lines.	 G12V	 mutation	 seemed	 to	 decrease	 the	 cell	 growth	 when	present	in	NRas,	but	not	in	other	Ras	isoforms	(Fig.	6.3).	A	previous	study	in	a	colon	 cancer	 mouse	 model	 expressing	 the	 G12D	 mutation	 in	 either	 KRas	 or	NRas	has	shown	that	only	oncogenic	KRas	can	contribute	to	hyperplasia	in	the	colon	(Haigis	et	al.,	2008),	hence,	higher	growth	rate	could	also	be	expected	for	the	SW48	cell	line	with	oncogenic	KRas.	However,	this	does	not	explain	why	the	NRasG12V	cell	 line	 is	 actually	 growing	 slower	 than	all	 remaining	 isogenic	 cell	lines,	 including	 the	 parental.	 Another	 reason	 could	 be	 that	 cells	 with	 mutant	NRas	undergo	differentiation	at	higher	densities	(Fig.	6.3,	day	3)	(Roberts	et	al.,	2006b,	 Zweibaum	 et	 al.,	 1983).	 SW48	 cells	 are	 actually	 poorly	 to	moderately	differentiated	 (Huschtscha	 et	 al.,	 1991,	 MacKay	 et	 al.,	 1995),	 so	 there	 is	 a	possibility	that	under	certain	environmental	or	endogenous	stimuli	 they	could	differentiate	 further	 and,	 hence,	 cease	 proliferating	 (Jogi	 et	 al.,	 2012).	 Yet	
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another	 explanation	 for	 slower	 growth	 rate	 of	 NRasG12V	 cell	 line	 would	 be	induction	 of	 apoptosis.	 Previous	 research	demonstrated	 that	 oncogenic	Ras	 is	capable	 of	 stimulating	 pro-apoptotic	 signals	 via	 RASSF1-mediated	 or	 even	MAPK-mediated	cascades	(Vos	et	al.,	2000,	Cox	and	Der,	2003).	These	findings	pose	 a	 chance	 that	 in	 case	 of	 SW48	 cell	 line	 such	 apoptotic	 event	 would	 be	plausible.	 Either	 way,	 to	 confirm	whether	 differentiation	 or	 programmed	 cell	death	 actually	 occurred,	 further	 experiments	 would	 have	 to	 validate	 the	presence	of	specific	markers	–	e.g.	CDX1	as	a	marker	of	intestinal	differentiation	(Bonner	 et	 al.,	 1995,	 Chan	 et	 al.,	 2009,	 Mallo	 et	 al.,	 1997)	 or	 Bax	 as	 a	 pro-apoptotic	marker	(Paradiso	et	al.,	2001).	What	is	also	interesting	to	note,	G12V	mutation	 did	 not	 accelerate	 proliferation	 of	 SW48	 cell	 line	 when	 present	 in	KRas	or	HRas,	 implying	 that	 these	 isoforms	may	not	 further	 contribute	 to	 the	transforming	potential	of	these	cells.		
Another	 striking	 difference	 between	 Ras	 isogenic	 cell	 lines	 were	 the	 distinct	levels	of	activation	of	downstream	signalling,	as	measured	by	phosphorylation	of	Akt,	MEK	and	ERK	(Fig.	6.5-6.8).	Based	on	Western	blotting,	after	stimulation	with	EGF,	human	HRas	protein	seemed	to	provide	better	pAkt	and	pMEK	signals	than	 other	 Ras	 isoforms.	 Interestingly,	 pERK	 appeared	 to	 be	 less	 affected	 by	activate	 HRas,	 at	 least	when	 compared	with	wild	 type	 protein	 (Fig.	 6.8).	 It	 is	important	 to	 take	 into	account	 the	mutations	already	existing	 in	wt	SW48	cell	line,	which	are	G719S	in	EGFR,	S33Y	in	CTNNB1	and	S668fs*39	(frame	shift)	in	FBXW7	(Forbes	et	al.,	2015,	Ahmed	et	al.,	2013).	The	mutation	present	in	EGFR	is	 hyperactivating	 and	 resutls	 in	 around	 10-fold	more	 active	 protein	 than	wt	(Yun	 et	 al.,	 2007).	Mutations	 in	 EGFR	 are	 generally	 not	 frequent	 in	 colorectal	cancer	(Barber	et	al.,	2004,	Lynch	et	al.,	2004,	Moroni	et	al.,	2005,	Nagahara	et	al.,	 2005,	Yunxia	et	 al.,	 2010,	Oh	et	 al.,	 2011)	and	 their	 significance	 in	disease	prognosis	and	treatment	has	not	been	established.	On	the	other	hand,	mutations	of	the	S33	codon	of	beta-catenin	(CTNNB1	gene)	are	common	in	various	human	cancers,	 including	 hereditary	 non-polyposis	 colorectal	 cancer	 (Akiyama	 et	 al.,	2000,	 Johnson	 et	 al.,	 2005,	 Kim	 et	 al.,	 2003,	 Saegusa	 and	 Okayasu,	 2001).	Mutations	 in	 beta-catenin	 may	 confer	 resistance	 to	 PI3K	 and	 Akt	 inhibitors	(Tenbaum	 et	 al.,	 2012).	 Finally,	 F-box	 and	 WD	 repeat	 domain-containing	 7	
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(FBXW7)	 is	a	part	of	an	E3	ubiquitin	 ligase	complex	and	a	 tumour	suppressor	often	mutated	 in	colorectal	cancer	 (Markowitz	and	Bertagnolli,	2009,	Wang	et	al.,	2012).	Mutations	in	FBXW7	may	also	sensitise	cells	to	treatment	with	mTOR	inhibitors	(Jardim	et	al.,	2014,	Mao	et	al.,	2008,	Wang	et	al.,	2013).				Notably,	 these	 endogenous	 mutations	 in	 SW48	 cell	 line	 could	 affect	 Ras-dependent	 signalling,	 especially	 the	 changes	 in	 upstream	RTK	 receptor	 EGFR.	Although	these	mutations	uniformly	affect	all	Ras	isogenic	cell	lines,	they	could	have	a	greater	impact	on	a	particular	isoform	which	participates	in	a	feedback	loop.	Earlier	 studies	demonstrated	 that	Ras	 is	 involved	 in	a	negative	 feedback	loop	from	MEK	to	upstream	ERBB,	EGFR	or	IGFR	receptors,	which	is	relieved	by	MEK	or	BRAF	inhibition	that	leads	to	activation	of	ERK	or	PI3K	and	Akt	(Ebi	et	al.,	 2011,	 Klinger	 et	 al.,	 2013,	 Lamba	 et	 al.,	 2014,	Misale	 et	 al.,	 2014,	Molina-Arcas	et	al.,	2013,	Prahallad	et	al.,	2012,	Sun	et	al.,	2014,	Turke	et	al.,	2012,	Van	Schaeybroeck	et	al.,	2014).	This	negative	regulation	was	seen	in	studies	focused	on	KRas	signalling	and	whether	this	is	a	generic	or	an	isoform-specific	signalling	mechanism	remains	to	be	revealed.	In	this	context,	the	increased	stimulation	in	PI3K	 and	 MAPK	 pathways	 seen	 in	 the	 HRasG12V	 mutant	 cell	 line	 could	 be	explained	 by	 the	 fact	 that	 HRas	 may	 not	 take	 part	 in	 negative	 feedback	regulation,	as	opposed	to	the	other	Ras	isoforms.	Rather,	KRas	and	NRas	mutant	cell	 lines	 may	 show	 decreased	 levels	 of	 pAkt	 and	 pMEK	 due	 to	 feedback	inhibition	 of	 upstream	 signalling	 receptors.	 Interestingly,	 pERK	 levels	 do	 not	seem	to	be	affected	by	these	feedback	loops,	as	ERK	might	be	the	final	node	in	these	negative	regulation	loops	and	its	high	levels	of	activation	may	aid	in	their	propagation.	
To	 further	 investigate	 the	 differences	 in	 network	 biology	 in	 a	 Ras	 isoform-dependent	background,	each	isogenic	cell	line	was	treated	with	specific	GFs	and	pathway	component	inhibitors	(Fig.	6.9	–	6.16).	The	data	of	this	study	provided	some	preliminary	 results,	which	 can	be	used	 for	 studying	 relative	 coupling	of	isoforms	to	downstream	effectors	and	involvement	in	feedback	loops.	Previous	work	 utilised	 a	 combined	 empirical	 and	 theoretical	 means	 of	 modelling	signalling	networks	in	an	EGFR-dependent	context	(Klinger	et	al.,	2013).	In	that	
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study,	 the	 phosphorylation	 status	 of	 cell	 lines	 prior	 and	 after	 treatment	 was	measured	 using	 multiplex	 proteomics	 and	 the	 data	 was	 examined	 using	 a	modular	 response	 analysis	 (MDA),	 which	 allows	 to	 quantitatively	 measure	negative	and	positive	feedback	loops,	as	well	as	cross	talks	between	pathways.	This	 is	 important	 as	 such	 signal	 transduction	 subtleties	may	 exert	 significant	effects	 on	 the	 pharmacologic	 action	 of	 drugs	 (Cirit	 et	 al.,	 2010,	 Friday	 et	 al.,	2008,	Fritsche-Guenther	et	al.,	2011,	Sturm	et	al.,	2010).	This	chapter	aimed	to	optimise	 the	 necessary	 reagents,	 both	 receptor	 agonists	 (GFs)	 and	 inhibitors,	for	the	experimental	part	of	such	network	biology	approach.	The	data	obtained	for	saturating	and	sub-saturating	levels	of	these	reagents	will	be	used	in	future	work,	 which	 combines	 inhibition	 and	 stimulation	 to	 delineate	 differences	 in	phosphorylation	 status	 and,	 hence	 variations	 in	 the	 regulation	 of	 signalling	networks.	
The	 results	 of	 this	 chapter	 suggest	 that	 stimulation	 with	 EGF	 exerts	 a	differential	effect	on	Ras	isoform	signal	propagation	(Fig.	6.9).	Highest	levels	of	phosphorylated	 EGFR	 were	 present	 in	 KRasG12V	 cell	 line,	 followed	 by	HRasG12V,	however,	 total	 receptor	 levels	were	higher	 in	 the	 latter	 (Fig.	6.12).		Activation	of	EGFR	requires	dimerisation,	which	can	be	driven	by	either	ligand-binding	 or	 increased	 receptor	 expression	 (Yarden	 and	 Schlessinger,	 1987a,	Yarden	and	Schlessinger,	1987b).	A	crucial	step	in	EGFR	activation	is	the	release	of	 the	 intrinsic	 autoinhibition	 of	 its	 kinase	 domain	 by	 the	 formation	 of	 an	asymmetric	dimer	between	 the	kinase	domains	of	 the	 receptor	 (Kovacs	 et	 al.,	2015,	 Zhang	 et	 al.,	 2006).	 The	 C	 lobe	 of	 one	 kinase	 domain	 (activator)	allosterically	 binds	 to	 the	 N	 lobe	 of	 the	 other	 kinase	 domain	 (receiver)	 and	switches	 it	 on.	 Such	 asymmetry	 of	 EGFR	 dimer	 may	 lead	 to	 different	phosphorylation	 of	 the	 activator	 and	 receiver	 tyrosine	 residues	 in	 the	intracellular	tail	(Kovacs	et	al.,	2015).	
The	 observed	 increase	 in	RTK	 abundance	 in	 the	 study	 of	 this	 thesis	might	 be	linked	with	a	positive	 feedback	 loop	 in	HRasG12V	mutant	 cell	 line,	 e.g.	due	 to	increased	 transcription	 of	 EGFR	 downstream	 of	 Ras.	 Egfr	 gene	 expression	 is	regulated	by	Sp1,	ETF	and	c-jun	transcription	 factors	(Kageyama	et	al.,	1988a,	Kageyama	 et	 al.,	 1988b,	Mialon	 et	 al.,	 2005),	 whereas	 Ras	 signalling	 affects	 a	
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myriad	 of	 downstream	 TFs,	 including	 c-jun	 (Chang	 et	 al.,	 2003,	 Chen	 et	 al.,	2001).	Hence,	 it	 is	possible	that	Ras	also	regulates	Egfr	transcription	via	c-jun.	On	 the	other	hand,	 receptor	abundance	on	 the	cell	membrane	depends	on	 the	subtle	equilibrium	between	receptor	degradation	and	recycling	(Chi	et	al.,	2011,	Doherty	and	McMahon,	2009,	 Jones	et	 al.,	 2006,	Maxfield	and	McGraw,	2004).	Thus,	 such	 increase	 in	 EGFR	 levels	 may	 be	 a	 result	 of	 either	 a	 decrease	 in	protein	 degradation	 due	 to	 reduction	 in	 receptor	 phosphorylation	 and	subsequent	ubiquitination	(Roepstorff	et	al.,	2009),	or	an	elevated	recycling	of	the	 receptor	 back	 to	 the	 cell	 membrane,	 which	 could	 be	 especially	 affecting	HRasG12V	 cell	 line.	 To	 examine	 whether	 EGFR	 protein	 levels	 increased	 as	 a	result	of	one	of	these	mechanisms,	transcript	levels	could	be	measured	by	qPCR	and	ubiquitination	status	checked	by	pull	down	assay.	Also,	EGFR	 levels	could	be	quantified	after	shorter	stimulation	times	with	EGF,	e.g.	after	5	min	instead	of	20	min,	 which	would	 allow	 for	 looking	 at	 the	 receptor	 before	 internalisation	(Henriksen	et	al.,	2013).		
On	 the	 other	 hand,	 Met	 receptor	 abundance	 was	 observed	 to	 be	 highest	 in	KRasG12V	cell	line,	whereas	the	remaining	cell	lines	did	not	seem	to	have	any	of	the	 receptor	expressed	 (Fig.	6.10	and	6.12).	This	 is	particularly	 interesting,	as	increased	Met	 abundance	was	 observed	 before	 in	 SW48	 cell	 line	 bearing	G12	codon	mutations	(including	G12V)	in	KRas,	but	not	G13D	mutation	or	parental	cell	 line	 (Hammond	 et	 al.,	 2015).	 This	 increased	 receptor	 abundance	 was	correlated	 with	 increased	 levels	 of	 doublecortin-like	 kinase-1	 (DCLK1),	 A-kinase	anchor	protein	12	(AKAP12)	and	Caveolin-1.	 In	contrary,	 tight	 junction	protein	 ZO-2	 and	 the	 aldehyde	 dehydrogenase	 ALDH3A1	 showed	 concerted	decrease	 in	 protein	 abundance	 in	 KRasG12V	 cell	 line,	 compared	 to	 parental.	Remarkably,	 caveolin-1	 has	 been	 shown	 to	 be	 regulated	 by	 KRas	 in	 colon	tumourigenesis	(Basu	Roy	et	al.,	2013),	whereas	DCLK1	has	been	shown	to	be	an	 intestinal	 tumour	stem	cell-specific	marker	(Nakanishi	et	al.,	2013).	DCLK1	protein	expression	pattern	correlates	well	with	Met	expression	in	KRas	mutant	SW48	 cell	 lines,	 suggesting	 regulatory	 mechanism	 for	 gene	 expression	(Hammond	et	 al.,	 2015).	 It	would	be	useful	 to	 examine	whether	DCLK1	 levels	
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also	correspond	to	Met	abundance	in	the	remaining	Ras	isogenic	cell	lines	using	Western	blotting	or	proteomics.	
Finally,	 IGF1Rβ	 stimulation	 with	 IGF	 revealed	 that	 KRasG12V	 cell	 line	 had	relatively	 highest	 phosphorylation	 status	 of	 this	 RTK,	 although	 total	 receptor	levels	were	lowest,	as	compared	to	other	isogenic	cell	lines	(Fig.	6.11	and	6.12).	This	 preliminary	 data	 suggests	 that	 oncogenic	 KRas	 may	 mediate	 a	 positive	feedback	 loop	 back	 to	 IGF1Rβ,	 which	 finally	 may	 lead	 to	 downregulation	 of	receptor	 abundance.	 This,	 however,	 will	 require	 further	 confirmation.	 In	conclusion,	 the	RTKs	examined	 in	 this	study	 in	context	of	Ras	signalling	 imply	tangible	differences	between	Ras	isoforms	and	should	be	studied	further	using	more	biological	replicates.	Similarly	 to	 stimulation	 data	 shown	 in	 this	 chapter,	 experiments	 involving	inhibition	 of	 Ras	 pathway	 components	 were	 briefly	 examined	 using	 single	biological	 replicates	 and,	 hence,	 provide	 initial	 optimisations	 for	 the	 drugs	chosen	 (Fig.	 6.13-6.16).	While	 PI3K	 inhibitor	 LY94002	 and	MEK1/2	 inhibitor	AZD6244	 seem	 to	 potently	 inhibit	 their	 targets	 in	 all	 isogenic	 cell	 lines	 (Fig.	6.13-6.14),	 mTOR	 inhibitor	 rapamycin	 appears	 to	 only	 suppress	 signalling	 in	the	HRasG12V	cell	 line	(Fig.	6.15).	Both	NRasG12V	and	parental	cell	 lines	may	not	have	any	basal	phosphorylated	p70S6K,	which	may	mean	that	their	mTOR	signalling	to	downstream	effectors	is	somehow	suppressed.	This	may	be	further	reflected	by	the	fact	that	SW48	cells	with	HRasG12V	mutation	appear	to	be	the	largest	when	 grown	 in	 normal	 or	 starved	 culture	media	 (Fig.	 6.19),	 as	mTOR	signalling,	which	 is	 potently	 active	 in	 this	 cell	 line,	 is	 associated	with	 protein	synthesis	 and	 cell	 growth	via	 its	downstream	substrate	p70S6K	 (Fingar	 et	 al.,	2004,	Laplante	and	Sabatini,	2009).	Moreover,	rapamycin	 inhibits	signalling	 in	KRasG12V	 cell	 line	 only	 at	 lower	 drug	 concentrations	 and	 further	 titration	reverses	this	inhibitory	effect.	It	seems	that	there	might	be	a	negative	feedback	loop	in	KRasG12V	cell	line,	which	might	be	relieved	upon	mTOR	inhibition.	This	assumption	 could	 be	 tested	 using	 the	 network	 biology	 approach	 described	above	(Klinger	et	al.,	2013).			
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Conclusions	and	Perspectives		The	three	founding	members	of	Ras	superfamily,	HRas,	KRas	(KRasA	and	KRasB	splice	 variants)	 and	 NRas,	 are	 the	 key	 signalling	 molecules	 involved	 in	 a	multitude	of	cellular	processes	and	are	some	of	the	most	common	human	proto-oncogenes.	 These	 highly	 homologous	 GTPases,	 however,	 exhibit	 isoform-specific	 coupling	 to	 different	 human	 cancers	 (Cox	 et	 al.,	 2014,	 Forbes	 et	 al.,	2015,	 Prior	 et	 al.,	 2012)	 and	 the	KRasB	 isoform	alone	 is	 sufficient	 for	 normal	mouse	 development	 (Koera	 et	 al.,	 1997,	 Johnson	 et	 al.,	 1997,	 Plowman	 et	 al.,	2003,	Umanoff	et	al.,	1995,	Esteban	et	al.,	2001).	These	discrepancies	may	be	the	result	of	Ras	isoform-specific	expression	across	tissues	and	during	development	and	the	differences	in	coupling	and	activation	of	Ras	downstream	effectors.		The	first	part	of	this	thesis	provided	the	first	measurement	of	the	absolute	copy	number	of	Ras	isoform	transcript	levels,	as	well	as	the	first	comprehensive	map	of	spatiotemporal	expression	of	Ras	across	all	four	isoforms	in	mouse	ESC	line	and	in	a	panel	of	mouse	tissues	throughout	development.	This	study	optimised	a	quantitative	method	based	on	real	time	RT-PCR,	which	allowed	estimating	Ras	isoform	transcript	 in	copy	number.	The	average	amount	of	 total	Ras	 (panRas)	was	around	5	copies/pg	RNA	in	ESCs	and	around	26	copies/pg	RNA	in	mouse	tissues.	 Mass	 spectrometry	 analysis	 provided	 the	 preliminary	 results	 on	 Ras	isoform	expression	at	protein	level,	with	an	estimated	44-770	ng	of	panRas/mg	of	total	protein.				At	 the	 transcript	 level,	 KRasB	was	 the	most	 abundant	 isoform,	whereas	HRas	was	 always	 lowly	 expressed.	 The	 expression	 of	 the	 ESC-specific	 Ras	 isoform	ERas	was	high	 in	undifferentiated	cells,	but	was	steadily	decreasing	over	 time	during	 cellular	 differentiation.	 In	 mouse	 tissues,	 KRasA	 was	 the	 most	dynamically	 regulated	 isoform,	 with	 increasing	 expression	 in	 the	 stomach,	intestine,	 kidney	 and	 liver	 over	 time	 during	 embryonic	 development.	Interestingly,	 KRasA	 was	 shown	 for	 the	 first	 time	 to	 be	 expressed	 in	 the	
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embryonic	 heart.	 At	 the	 protein	 level,	 the	 expression	 of	 KRasB	 and	 HRas	 in	murine	tissues	was	by	and	large	similar	and	it	did	not	parallel	transcript	levels.	However,	 these	proteomic	data	were	only	preliminary	 and	 represented	 single	biological	repeats.	Moreover,	the	protein	levels	of	NRas	could	not	be	measured	due	 to	 a	 technical	 error.	Therefore,	 future	work	 is	 necessary	 to	provide	more	biological	 replicates	 and	 to	 include	 the	 expression	 of	 the	 remaining	 Ras	isoforms.			Together,	 the	 expression	 studies	 reported	 in	 this	 thesis	 provide	 the	 most	comprehensive	and	quantitative	approach	for	studying	Ras	isoform	expression	to	date,	at	least	at	the	transcript	level.	Knowing	the	basal	expression	of	Ras	in	a	normal	 endogenous	 context	 provides	 the	 first	 insights	 into	understanding	 the	extent	of	Ras	isoform	functional	overlap	in	comparative	models.	The	differences	in	transcript	versus	protein	levels	obtained	in	this	study	may	be	explained	by	a	recent	 work,	 which	 showed	 that	 KRAS,	 as	 compared	 to	 HRAS,	 is	 poorly	translated	due	to	the	presence	of	rare	codons	in	its	genomic	sequence	(Lampson	et	 al.,	 2013).	 The	 study	 also	 argues	 that	 rare	 codons	 make	 KRas	 a	 weaker	oncogene	 than	 HRas.	 However,	 low	 protein	 levels	 of	 KRas	 may	 prompt	tumourigenesis,	 as	 high	 expression	 of	 the	 mutated	 protein	 may	 lead	 to	oncogenic	 stress	 and	 cellular	 senescence.	 The	 study	 of	 this	 thesis	 contradicts	this	model,	as	KRasB	protein	expression,	although	proportionally	lower	than	at	the	transcript	level,	is	similar	to	the	other	Ras	isoforms.		Finally,	the	first	hypothesis	of	this	thesis	(section	1.3)	can	be	rejected:	
	Hypothesis	 1:	 The	 expression	 levels	 can	 explain	 Ras	 isoform	 functional	 non-redundancy	during	development.	
	Expression	 levels	 do	 not	 justify	 the	 developmental	 requirement	 of	 KRasB	(Koera	 et	 al.,	 1997,	 Johnson	 et	 al.,	 1997,	 Plowman	et	 al.,	 2003,	Umanoff	 et	 al.,	1995,	 Esteban	 et	 al.,	 2001).	 Although	 KRasB	 is	 the	 major	 Ras	 isoform	 at	transcript	level,	 its	protein	expression	is	similar	to	the	levels	of	HRas,	which	is	dispensable	 for	 normal	 mouse	 development.	 Table	 7.1	 summarises	 the	
	 186	
milestones	 of	 this	 thesis	 that	 help	 us	 better	 understand	 the	 functional	differences	between	the	four	main	Ras	isoforms.		
























Highly	abundant;	 Similar	levels	to	HRas	 	 	Transcript	vs	proteins	levels	do	not	correlate	
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Date:	 	 	 23/05/2012		
Constructed	by:	 Anna	Newlaczyl	




Fig.	 A3.1	 pCR4-TOPO-mHRas	 plasmid.	A	schematic	 representation	of	pCR4-TOPO	 plasmid	 with	 the	 mouse	 HRas	 fragment	 insert	 with	 annotation	 and	comments.	
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Date:	 	 	 26/01/2012	
Constructed	by:	 Anna	Newlaczyl	





Fig.	 A3.2	 pCR4-TOPO-mNRas	 plasmid.	 A	 schematic	 representation	of	pCR4-TOPO	 plasmid	 with	 the	 mouse	 NRas	 fragment	 insert	 with	 annotation	 and	comments.	
	
	 236	
ERas			 	 	 	 							HRas	
		
KRasA		 	 	 	 								KRasB	
		
NRas		 	 	 									 									POL2RE	
	
	
Plasmid	 Standard	curve	equation	 R2	 %E	ERas	 -2.661x+39.599	 0.99867	 83.00	HRas	 -2.5432x+38.549	 0.99851	 88.20	KRasA	 -2.4254x+37.152	 0.9994	 94.07	KRasB	 -2.5863x+39.671	 0.99549	 86.22	NRas	 -2.5293+38.202	 0.99836	 88.85	POL2RE	 -2.7848+43.324	 0.9905	 78.15	
	
Fig.	 A4.1	 Plasmid	 standard	 curves	 used	 in	 qRT-PCR	 for	 endoderm	 and	














































































































ERas			 	 	 	 							HRas	
		
KRasA		 	 	 	 								KRasB	
		
NRas		 	 	 									 									POL2RE	
	
	
Plasmid	 Standard	curve	equation	 R2	 %E	ERas	 -2.697x+42.129	 0.99672	 81.53	HRas	 -3.0946x+48.056	 0.98534	 68.14	KRasA	 -2.6449+43.885	 0.99843	 83.68	KRasB	 -3.0387x+45.065	 0.99659	 69.76	NRas	 -3.0288x+46.943	 0.99582	 70.05	POL2RE	 -2.8045x+42.673	 0.99448	 77.43	
	






























































































HRas	 	 	 	 	 						KRasA	
		






	HRas	 -2.6679x+40.941	 0.99387	 82.81	KRasA	 -2.6092x+40.035	 0.99855	 85.30	KRasB	 -2.4924x+42.473	 0.99236	 90.74	NRas	 -2.4942+41.662	 0.99113	 90.65	
	
Fig.	 A5.1	 Ras	 isoform	 standard	 curves	 used	 for	 the	 qRT-PCR	 data	 from	































































Table	 A5.1	 Ras	 isoform	 protein	 abundance	 in	 adult	 mouse	 tissues.	 Ras	isoform	ng	protein	per	mg	of	total	protein	was	estimated	using	standard-based	mass	spectrometry.			
	
Ras	ng	protein/mg	total	protein	
Mouse tissue	 HRas	 KRasB	 KRasA+NRas	 panRas	brain	 424.00	 263.55	 83.07	 770.61	lung	 52.05	 65.28	 12.04	 129.37	intestine	 26.10	 37.39	 29.21	 92.70	liver	 13.79	 0.00	 58.64	 72.43	pancreas	 17.38	 3.47	 23.83	 44.67			
